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“Considerando in retrospettiva il mio lungo percorso, quello di coetanei e 
colleghi e delle giovani reclute che si sono affiancate a noi, credo di poter 
affermare che nella ricerca scientifica, né il grado di intelligenza né la 
capacità di eseguire e portare a termine il compito intrapreso, siano i fattori 
essenziali per la riuscita e la soddisfazione personale. Nell’una e nell’altra 
contano maggiormente la totale dedizione e il chiudere gli occhi davanti alle 
difficoltà: in tal modo possiamo affrontare problemi che altri, più critici e più 
acuti, non affronterebbero”. 
Rita Levi-Montalcini, Elogio dell’imperfezione (1987).
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1.1 STRUCTURE AND FUNCTIONS OF THE SKIN
 The skin is the largest organ of the body, extending to an area of approximately 2 m2 in 
adults [1]. Anatomically, the skin can be divided in three layers (Figure 1):
 -  Epidermis: a stratified, non-vascularized epithelium, with a thickness of 75-150 µm 
except on palms and soles where it can be up to 600 µm thick [1]. The epidermis 
consists primarily of keratinocytes (90-95%) [2], which proliferate as columnar-shaped 
cells from the innermost, single-cell layer called stratum basale or germinativum [1, 3]. 
Keratinocytes migrate towards the upper part of the epidermis undergoing a process 
of differentiation, in which they change their morphology and cell content, and express 
epidermal differentiation proteins (keratins) [1, 3, 4]. In this process, keratinocytes are 
first part of the stratum spinosum (8-10 cell layers), in which they appear as poligonal-
shaped cells, and subsequently of the stratum granulosum (3–5 cell layers), in which 
they appear as granule-rich flatter cells where the nucleus and other organelles begin 
to degenerate [1, 3]. The final product of this process is the stratum corneum (15-30 
cell layers), composed of non-viable but biochemically active, keratin-filled cells called 
corneocytes [1]. Corneocytes are eventually shed from the skin surface, a process called 
desquamation [4]. In normal skin, the journey from the basal layer to the shedding of 
corneocytes takes approximately 30 days to complete [1].
 -  Dermis: a connective tissue, usually less than 2 mm thick, separated from the 
epidermis by a basement membrane [1]. The main cell type is the fibroblast [1], 
which produces the principal structural components of the dermis: collagen fibers, 
which confer strength and support to the skin, and elastin fibers, which contribute 
to elasticity and resilience [2]. The dermis houses also appendages (including sweat 
glands, eccrine glands and pilosebaceous units), blood vessels, and nerves [1]. 
 -  Sub-cutis or hypodermis: a fatty connective tissue that connects the dermis to 
underlying skeletal components [1].
 The major function of the skin is to form a barrier between the internal milieu and the 
hostile external environment [5], protecting against physical, chemical and microbial insults, 
as well as against the loss of water and electrolytes [1, 5]. This barrier function has been 
termed “la raison d’être of the epidermis” [6]. 
However, the skin is far beyond a mere physical barrier, since it displays additional features 
such as immune-competence, psycho-emotion reactivity, ultraviolet (UV) radiation sensing 
and endocrine functions [2]. For these reasons, the skin has also been termed “a brain on the 
outside” [1, 2].
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Figure 1. Hematoxylin and eosin staining of normal skin.
1.1.1 Barrier function: la raison d’être of the epidermis
 The barrier function of the skin localizes primarily to the stratum corneum [2, 5, 7]. Its 
structure can be described as a “brick and mortar” model, in which corneocytes (bricks) are 
embedded in a lipid matrix (mortar) [1, 2, 7]. The latter is essential in providing the permeability 
barrier and is composed of ceramides (50%), cholesterol (25%), and free fatty acids (10-
20%), with very little phospholipid [1, 2, 5, 7]. Lipids are delivered in the extracellular spaces 
of the stratum corneum at the level of the stratum granulosum by organelles contained in 
keratinocytes, called lamellar bodies [5]. In the matrix, lipids are organized in bilayers (lamellae) 
between the corneocytes, while within the lamellae they can be packed in three phases, as 
schematically shown in Figure 2. Different models have been proposed for the organization 
of lipids in the matrix [8], and evidence is increasing about the involvement of an altered 
composition as well as organization of lipids in skin diseases characterized by an impaired 
skin barrier function [4]. The multiple layers of corneocytes contribute to a tough and resilient 
framework for the lipid matrix [6]. The corneocytes are surrounded by a cornified envelope 
consisting of a densely cross-linked layer of proteins such as filaggrin, loricrin and involucrin 
[4]. On the exterior surface of the cornified envelope is a covalently bound layer of lipids, the 
lipid envelope [6]. The cornified and lipid envelopes minimize the uptake of most substances 
into the corneocytes and allow the proper formation of the lipid matrix. Indeed, a deficient lipid 
envelope results in an irregular lipid matrix and in a defective skin permeability function [4]. 
The corneocytes are filled with keratins and with a mixture of highly hygroscopic substances 
known as natural moisturizing factor (NMF) [6, 9]. NMF is mainly composed of amminoacids 
deriving from proteolysis of filaggrin, but it also comprises sweat-derived components [9]. The 
water-binding property of NMF contributes to the hydration of the stratum corneum, which is 
necessary for hydrolytic enzymatic processes, required for normal desquamation, to take place [6]. 
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 Of note, the barrier function of the skin is not absolute, but it allows a physiological 
movement of water through the stratum corneum and into the atmoshere [6]. This process is 
known as transepidermal water loss (TEWL). 
Figure 2. Schematic representation of the skin barrier. 1) The skin barrier localizes primarily to the 
stratum corneum, a layer of dead cells (corneocytes) embedded in a lipid matrix. 2) This structure is also 
referred to as the “brick” (corneocytes) and “mortar” (lipids) model. 3) The intercellular lipids are arranged 
in layers (lamellae), with either a long or short repeat distance (d), referred to as the long periodicity 
phase (LPP,  ̴13 nm) and short periodicity phase (SPP,  ̴6 nm), respectively. The lateral organization is 
the plane perpendicular to the direction of the lamellar organization. Lipids can be arranged in three 
ways: a very dense, ordered orthorhombic organization; a less dense, ordered hexagonal organization; 
a disordered liquid organization. In normal skin, lipids are mainly organized in the orthorhombic phase. 
Reprinted from “The important role of stratum corneum lipids for the cutaneous barrier function”, Biochim Biophys Acta 
vol. 1841 issue 3, van Smeden J et al., p. 295-313, Copyright (2014), with permission from Elsevier. 
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1.1.2 Neuro-immune-endocrine function: a brain on the outside
 The skin is a potent immune-competent tissue [2, 7]. In the last few years it has become 
clear that practically all cell types residing in and transiting through the skin can exhibit 
immune functionality [1]. 
Among the better characterized cellular components are keratinocytes and mast cells [1, 
10]. Keratinocytes produce and secrete reactive oxygen species (ROS), antimicrobial peptides 
(AMPs), cytokines and chemokines [10]. Mediators are released upon keratinocyte activation 
due to an inflammatory stimulus, but can also be produced under normal conditions in order 
to maintain tissue homeostasis [10]. Mast cells, normally residing in the dermis, release upon 
activation a battery of bioactive mediators of both immune and neuroendocrine responses, 
among which histamine and tryptase [1]. 
 The epidermis can be considered a true sensory tissue [11] and keratinocytes may be at 
the forefront of the sensory system [12]. 
It had long been considered that only free nerve terminals in the epidermis played a role in 
skin surface perception [12]. However, keratinocytes have been shown to express sensory 
proteins activated by various environmental factors including temperature, mechanical stress, 
osmotic pressure, and chemical stimuli. These sensory proteins allow transduction of stimuli 
in intracellular biochemical messages [11]. The transient receptor potential (TRP) and the 
purinergic families are among the most important sensory proteins [11, 12]. It is therefore 
speculated that stimuli are sensed by keratinocytes, then processed and transferred to the 
free nerve terminals [12]. However, the mechanism involved in signal transduction from 
keratinocytes to free nerve terminals remains to be explored [11, 12].  
 The skin is capable to act as a neuroendocrine organ in the periphery [1], and has a 
remarkable stress-sensing capacity [2].
The skin and its appendages have been identified as both a source and target of neuro-
transmitters, neuro-hormones and neuro–peptides, thought previously to be the domain of the 
central nervous system [1, 13]. An example is constituted by the perception of stress: upon the 
occurrence of psychological stress, the central nervous system activates the hypothalamic–
pituitary–adrenal axis (HPA), with subsequent upregulation of key stress hormones believed to 
have an effect on the skin by triggering or aggravating inflammatory skin diseases. Evidence 
has shown that a peripheral equivalent of the HPA axis is present in the skin, since, upon 
environmental stressors such as heat, cold and UV radiation, the same key stress hormones, 
locally-produced, are released. The skin stress response may be signaled to the brain, where 
it affects behaviour and leads to an increased vulnerability to additional stress perception [13]. 
In addition, the skin has receptors for several sex steroid hormones, including oestrogen, 
androgen and progesterone, and is capable of steroidogenesis [1, 14]. 
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 The skin neuro-, immune- and endocrine functions are not disjoint but intermingled 
through interaction with multiple pro- and anti-inflammatory neuropeptides, cytokines and 
hormones [14]. 
Figure 3. Principle of iontophoresis using an Ag/AgCl electrode system. An iontophoretic system 
consists of a source of electric current, an electrode containing a reservoir and an indifferent electrode. 
The formulation containing the ionized molecule of interest (e.g. D+A-) and saline (NaCl) is placed in the 
reservoir of the electrode bearing the same charge. Upon application of an eletric current, the ionized 
molecules are forced into the skin by electrorepulsion (electromigration). To maintain electroneutrality, a 
ionix flux in the anode-to-cathode direction is set in motion in the skin, which acts as a negatively charged 
membrane at physiological pH (electroosmosis). This flux, responsible for carrying uncharged molecules 
(D0, A0) and high-molecular-weight  cations, is generated primarily by endogenous Na+ and Cl-, being saline 
the principal extracellular electrolyte. Electron fluxes are transformed into ionic fluxes via electrochemical 
reactions at the electrodes. The electrochemistry occurring at the Ag anode requires the presence of Cl- 
ions in the reservoir: this is usually obtained by adding saline or, when available, by using a hydrochloride 
salt in the formulation. The reduction occurring at the cathode by the arrival of electrons from the power 
supply releases Cl- ions; for electroneutrality, this must be compensated for by the arrival of cations from 
the skin or by the loss of anions. The arrows indicate the contribution of each transport mechanism to the 
iontophoretic flux: electromigration, electroosmosis, and passive diffusion. When small and hydrophilic ions 
are used, the efficiency of electromigration is much higher than that of electroosmosis and passive diffusion. 
Modified from “Iontophoretic drug delivery”, Adv Drug Deliv Rev vol. 56 issue 5, Kalia YN et al., p. 619-658, Copyright (2004), 
with permission from Elsevier, and from “Diagnostic and therapeutic applications of iontophoresis”, J Drug Target vol. 17 
issue 9, Sieg A et al., p. 690-700, Copyright (2009), with permission from Taylor & Francis Group (www.tandfonline.com).
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1.2 IN VIVO SKIN MODELS 
 Given the complexity of skin structure and functions, studying the mechanisms regulating 
skin homeostasis and underlying skin diseases can be challeging. In order to investigate one 
specific process or cell type, in vivo skin models can be used. These constist in the infliction of 
a minimally-invasive and standardized challenge to the skin, and in the evaluation of cutaneous 
growth, differentiation and inflammation at one or several points in time. While in vivo models 
provide a simplification of a complex situation, they allow to retain the interplays and cross-
talks among the different cells and mediators in the skin. In this thesis, we focused on two such 
in vivo models: tape stripping and histamine iontophoresis. 
1.2.1 Tape stripping
 Tape stripping consists in the repetitive application of adhesive tape to remove 
corneocytes from the stratum corneum. This procedure is used to abrogate, totally or partially, 
the barrier function of the skin without inducing cytopathic effects on the underlying epidermal 
keratinocytes [15]. Total abrogation can be assessed clinically with the appearance of a red and 
homogeneously glistening surface characterizing the viable epidermis. Since its introduction 
in the 1950s [16], tape stripping has become an established model of acute as well as chronic 
barrier disruption to investigate homeostatic repair responses [15, 17-19]. 
 Although this method appears simple and easy to perform, several parameters have 
been shown to influence the outcome, including the type of tape and its rapid or slow removal, 
the pressure, the duration of pressure application, the anatomical site, and the condition of 
the skin before stripping [20, 21]. It is therefore important to standardize the procedure and 
to specify these parameters in order to obtain results which are reproducible and comparable 
between studies [20, 21].  
1.2.2 Histamine iontophoresis
 Iontophoresis is a technique which uses a small and defined electric current to 
facilitate the transport of charged and uncharged molecules across the skin [22]. Charged 
molecules are driven into the skin under the direct influence of an electric field, a process 
called electromigration [22-24]. Uncharged molecules are carried by the electroosmotic flow 
generated by the movement of cations in the anode-to-cathode direction across the skin [22-
24]. The contribution of electromigration and electroosmosis to the total iontophoretic flux 
depends on the physicochemical properties of the molecules being transported [22, 23], the 
former prevailing for small ions, the second for uncharged molecules and high-molecular-
weight cations. Although iontophoresis cannot entirely avoid variability in passive diffusion, 
the delivery of molecules is less dependent on the condition of the skin [22]. The principle of 
iontophoresis is described in detail in Figure 3. 
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 Histamine is a well-known pruritogen and vasoactive substance [25]. The delivery of 
histamine in salt form (e.g. histamine dihydrochloride) to the skin via iontophoresis has been 
extensively performed in the last decades. Histamine iontophoresis is considered to be a 
quantifiable model for the study of inflammatory skin responses and microcirculation [24, 26], 
and it has been used to study differences in itch perception and vascular response between 
subjects with inflammatory skin diseases and controls [27, 28], the effects of treatments to 
relieve itch [29, 30] and the effects of psychological conditions on itch perception [31, 32]. 
1.3 INVASIVE AND NON-INVASIVE SKIN ASSESSMENTS IN 
DERMATOLOGY AND IN COSMETIC SCIENCES 
 In dermatology, the gold standard to analyse skin physiology and pathology is the 
histological and immunohistochemical analysis of biopsies. This procedure involves surgical 
removal of a skin sample following local anesthesia. After undergoing a preparatory processing, 
the specimens are stained with dyes to label specific cells, cellular components or structures. 
In histochemistry, for example, labeling is achieved by a chemical reaction between chemicals 
in the dye and components in the tissue, as in the hematoxylin and eosin (HE) staining (Figure 
1). In immunohistochemistry, labeling is obtained by the binding of antibodies in the dye 
with antigens in the tissue. Examination is carried out by microcopic analysis. While offering 
unrivalled sensitive and specific analysis of cells and tissue morphology, taking biopsies is 
invasive and patients may experience discomfort during the procedure.
 Another widely used method to analyze skin status in dermatology is visual assessment. 
Being easily accessible, dermatologists can rely on their visual grading of clinical signs to 
evaluate the type and severity of skin diseases as well as the efficacy of treatments. This has 
led to the definition of several scores for the severity of skin diseases based on visual grading 
of clinical signs such as erythema, dryness and swelling. Examples include the Psoriasis Area 
and Severity Index (PASI) and the Scoring Atopic Dermatitis Index (SCORAD) [33, 34]. Despite 
their reliability when performed by trained physicians, justifying their use in clinical trials, 
visual assessments remain subjective and, most importantly, cannot appreciate the processes 
unfolding below the surface of the skin. 
 Over the last four decades, much (cosmetic) research has focused on the development 
of a third approach to assess skin status, represented by bioengineering techniques [35, 36]. 
These techniques provide objective and non-invasive biophysical or optical measurements of 
skin properties. For example, an indirect estimate of the hydration of the stratum corneum 
can be obtained by measurements of conductance or capacitance on the skin surface [37]. 
The integrity of the barrier function can be indirectly evaluated by measurement of TEWL, 
with higher TEWL indicating an impaired skin barrier [37]. Other techniques are based on 
the interaction of light with various skin structures and on the subsequent measurement 
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of the exiting photons. Raman microspectroscopy, for instance, exploits inelastic scattering 
to measure the biochemical composition of the skin [37]. Reflectance confocal microscopy 
(RCM) uses the different refractive indexes between the cell structures and the surrounding 
tissue to provide images with morphological information at a resolution comparable to that 
of conventional light microscopy [38, 39]. Within bioengineering techniques it is possible to 
include also digital image processing of high-resolution skin photographs, used to enhance, 
segment and quantify specific features [40]. A selection of bioengineering techniques releveant 
for this thesis is reported in Table 1, and illustrations are shown in Figure 4. A more exhaustive 
list of bioengineering techniques can be found in dedicated books [41]. 
Figure 4. Bioengineering techniques for in vivo and non-invasive skin assessments. a) Aquaflux AF200 (Biox, 
UK) for measurement of TEWL; b) Spectrophotometer 2600d (Konica Minolta, Japan) for measurement of 
skin color; c) Corneometer CM825 (Courage + Khazaka, Germany) for indirect measurement of stratum 
corneum hydration; d) gen2 Skin Composition Analyzer (RiverD International B.V., the Netherlands) for 
direct measurement of stratum corneum biochemical composition based on the principle of confocal 
Raman microspectroscopy; e) VivaScope 1500 (Lucid Inc., USA) for imaging of skin morphology based on 
the principle of reflectance confocal microscopy.
Given their non-invasiveness, bioengineering techniques are invaluable in cosmetic sciences, 
where the development of new products requires tests on human volunteers [35, 42]. This is 
even more so since the entry into force of the new European Cosmetics Regulation (1223/2009) 
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in 2013, which banned animal testing (art. 18) and introduced more stringent requirements 
for substantiation of claims about the efficacy and effects of cosmetics (art. 20) [35, 42]. On 
the other hand, bioengineering techniques have not had a great impact in dermatological 
practice yet [36], with an exception for RCM, on its way towards implementation in clinical 
practice [43], and dermoscopy, which continues to gain appreciation in general dermatology 
[44]. The late Professor Albert M. Kligman, one of the greatest exponents of experimental 
dermatology, was among the first and major advocates of the use of bioengineering techniques 
in dermatological practice [36]. He warned against relying solely on visual assessment, since 
even clinically normal-appearing skin could hide abnormal changes, a phenomenon he called 
“invisible dermatoses” [45]. Unfortunately, bioengineering techniques have their limitations. 
In addition to their cost, which in the case of top-notch techniques can be extremely high, 
they can measure only one or a few parameters in the very complex environment which is the 
skin, and some of them are strongly influenced by external factors such as temperature and 
humidity [36, 37, 42]. As a consequence, it is frequently necessary to combine more than one 
method to obtain an overall clinical picture [42] and to follow guidelines to obtain reliable and 
reproducible measurements [46-50]. Besides careful measurements, attention must be paid 
to other aspects of the experiment, from the design of the study protocol, to the selection of 
volunteers and to the analysis and interpretation of the results, as all these aspects might 
hamper the meaningfulness of the study [35]. Professor Kligman was well aware of these 
aspects; as he notably remarked, “a fool with a tool is still a fool” [36]. 
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1.4 SENSITIVE SKIN 
 Sensitive skin (SS) has gained increasing attention in the cosmetic sciences and 
dermatology, as demonstrated by the number of publications in scientific journals emerged 
in the last decades (Figure 5). However, despite extensive research, the understanding of this 
phenomenon remains elusive. The currently accepted definition of SS is a condition of subjective 
cutaneous hyper-reactivity to various factors which are not commonly considered irritants 
[60]. Sensory reactions experienced by subjects characterizing their skin as sensitive include 
itching, stinging, burning, and pricking; at the same time, objective signs of skin irritation such 
as redness and dryiness are often absent [60-63]. Factors triggering SS are diverse; they range 
from contact exposure to chemicals (e.g. soaps, parfumes, household cleansers, cosmetics) 
to environmental insults (e.g. wind, cold, heat, UV radiation, temperature changes, pollution) 
and endogenous insults (e.g. stress, hormonal fluctuations) [60, 63, 64]. The frequent lack of 
objective signs of skin irritation and the heterogeneity in symptoms and triggers are the factors 
which contributed to the difficulty in fully understanding SS [60-64]. 
 Much of the knowledge on symptoms and triggers of SS has been gained from survey-
based epidemiological studies in various industrialized countries (Table 2). In these studies, 
classification of self-reported SS was mainly made via a four-point scale [65-75], in which the 
classes, albeit not universally defined, can be distinguished in: 
(I)  Very sensitive skin, strongly sensitive skin or “I strongly agree with having a sensitive 
skin”; 
(II)  Sensitive skin, moderately sensitive skin, rather sensitive skin or “I somewhat agree 
with having a sensitive skin”; 
(III)  Not very sensitive, slightly sensitive, somewhat sensitive skin or “I somewhat disagree 
with having a sensitive skin”; 
(IV)  Not sensitive at all, not sensitive or “I strongly disagree with having a sensitive skin”. 
Remarkably, a high prevalence of self-assessed SS across different countries emerged, with 
approximately 50-60% of women and 30-40% of men declaring to have this condition. For 
this reason, SS has been indicated as a global challenge [76]. In Table 2 it can be observed 
that female gender, fair skin phototype, dry skin type, presence of skin diseases and atopic 
diathesis are most frequently associated with the likelihood of reporting SS. Most studies found 
that responders claiming their skin as sensitive experience cutaneous reactions to several 
triggering factors, contrary to responders defining their skin as non-sensitive (NSS). It is 
recognized that cultural factors and advertisement of products for SS play likely a role in the 
propensity to report this condition, which could partly explain differences in prevalence among 
different countries [70, 71]. For example, the lower prevalence found in China was attributed 
to the low familiarity with or a different interpretation of the term “sensitive skin” [70, 77]. 
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Nevertheless, the overall similarities in prevalence, symptoms and triggers across countries 
indicate that SS is a true dermatological condition [62]. 
 Besides epidemiological studies, clinical studies have been widely performed with the 
aim to link self-assessed SS to underlying pathomechanisms. In these studies, quantitative 
sensory testing methods are generally used to identify subjects with SS [60, 61]. These tests 
consist in the application of chemicals or other provocative agents to the skin in order to elicit 
specific cutaneous reactions (e.g. itching, stinging, vasodilation); cutaneous reactions are then 
assessed subjectively by the test subjects and, possibly, objectively by bioengineering techniques 
[60, 61]. The underlying hypothesis of these methods is that the pathomechanisms of SS might 
imply an impaired skin barrier function, leading to increased penetration of chemicals, and 
an increased reactivity of the cutaneous nervous system [60, 63, 64]. To date, however, no 
quantitative sensory test has emerged to identify subjects with self-assessed SS with sufficient 
sensitivity and specificity [60, 61, 63]. It has been found that susceptibility to one provocative 
agent does not predict susceptibility to another [78]; in addition, also subjects describing 
themselves as having NSS can develop objective signs of skin irritation. As a consequence, 
evidence from clinical studies has been largely inconclusive, hampering a universal agreement 
on the definition and pathomechanisms of SS [62]. Authors have emphasized the need to 
establish more rigorous methodologies for estimating the pathomechanisms of SS [62], and 
to develop cost-effective, reproducible and minimally invasive metodologies to clarify the 
correlation between subjective perceptions and objective indications of cutaneous irritation 
[61]. 
 An  attemp in this direction has been recently proposed by Richters and coworkers. 
 As a first step, the authors performed a systematic review of the available literature 
on SS [79]. To be included, articles had to contain information about subjective perceptions of 
cutaneous irritation. The aims of the review were to:
(I) Overview the pathomechanisms possibly involved in SS;
(II)  Critically appraise the quality and reliability of diagnostic tests for SS;
(III)  Identify key reasons causing ambiguity around the SS phenomenon;
(IV) Formulate recommendations for future research.
The authors found that impaired skin barrier function, sensory hyper-reactivity, vascular 
responsiveness and atopic predisposition were the pathomechanisms most often associated 
with SS. They also confirmed that selection by means of sensory testing rarely led to significant 
differences between subjects with SS and NSS, as measured by established bioengineering 
techniques. Key reasons causing ambiguity in the understanding of SS were the high 
heterogeneity in the selection methods of study participants and in the provocations used to elicit 
skin reactions. In addition, many studies did not consider the possible confounder represented 
by the concomitant inclusion of healthy subjects and subjects with atopic diathesis or skin 
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diseases. For future research, the authors proposed that a better selection might be achieved 
by multifactorial questionnaires spanning a range of provocations of chemical, mechanical and 
environmental origin, since, in epidemiological studies, several factors have been reported to 
trigger SS. The combination of clinical, histological and top-notch biophysical measurements 
was also proposed for a breakthrough in the understanding of the SS phenomenon. 
 As a second step, Richters and coworkers performed a survey-based epidemiological 
study on a Dutch sample population to define symptoms and triggers which could discriminate 
subjects with self-assessed SS from NSS subjects [74]. Triggers of different origin (i.e. toiletries, 
emotions, heat) and both subjective and objective symptoms of skin irritation (i.e. discomfort, 
stinging, dryness and erythema) were found to contribute to the discriminatory capacity of the 
model. Importantly, the same discriminative factors were found excluding responders with 
concomitant skin diseases, implying that SS is not defined by concomitant skin diseases only. 
The authors recommended therefore the exclusion of subjects with concomitant skin diseases 
from future studies, as symptoms inherent to these diseases overlap with the symptoms of SS 
and would therefore confound the outcomes.  
 In the third step, Richters and coworkers implemented the recommendations of the 
literature review in clinical studies, in which in vivo skin models were used to elicit a cutaneous 
inflammatory response [80-82]. Selection of participants with self-assessed SS and NSS, 
without concomitant skin diseases, was based on a multifactorial questionnaire designed 
from the model derived in the survey-based epidemiological study. Differences between the 
groups could be found at the clinical, immunohistochemical and biophysical level, indicating 
the discriminative power of the multifactorial questionnaire as a selection tool. These results 
show that novel insights into the pahtomechanisms of SS could be gained through a rigorous 
methodology, driven by a thorough knowledge of findings and gaps from previous relevant 
literature. 
 As a concluding remark, it is important to address the possible confusion arising when 
referring to the terms “sensitive skin” and “skin irritation”. SS is, in fact, sometimes referred 
to as “irritable skin” [64], whereas the term “subjective irritation” has been used to describe 
the occurrence of cutaneous perceptions in the absence of clinical signs of irritation [62]. It 
is difficult to distinguish the two terms, as experiencing cutaneous perceptions or redness 
following external insults can be considered as having an irritable skin. However, it is also 
true that skin irritation can be experienced by subjects not defining their skin as sensitive, 
and that not every study on skin irritation focuses on SS [83]. For example, in vivo skin models 
can be used to irritate the skin by disruption of the epidermal barrier or by application of 
a surfactant, in order to study the cutaneous inflammatory processes (chapter 1.2). Studies 
using surfactants are especially widespread to identify individuals at risk of irritant contact 
dermatitis in occupational medicine [84]. In the following of this thesis, for clarity purposes, 
we will refer to “sensitive skin” when this is the self-reported assessment of an individual, 
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whereas we will refer to “skin irritation” when in vivo models are used to elicit cutaneous 
inflammatory reactions.  
Figure 5. Publications in PubMed in which the term “sensitive skin” appears in the title or abstract.
1.5 PHOTOBIOMODULATION 
 Light-based therapies are widely used in dermatology and in cosmetic sciences [87]. 
Photobiomodulation is one such therapy based on the absorbance of non-ionizing light by 
endogenous photoreceptors to elicit non-thermal, biological reactions through photochemical 
events [88]. This process is reported to result in beneficial therapeutic outcomes including 
the alleviation of pain, immunomodulation, and promotion of wound healing and tissue 
regeneration [88, 89]. However, despite its reported beneficial therapeutic outcomes, two 
major challenges remain before photobiomodulation can find its way into the mainstream of 
medicine and dermatology [88-90]. The first challenge concerns the fact that the molecular 
mechanisms responsible for transducing light into clinical effects have not been established 
yet. At the present day, several photoreceptors have been discovered in the skin, including 
cytochtome c oxidase, flavin-containing cryptochromes, and opsins [91-93]. A generally 
accepted mechanism is that absorption of light by cytochtome c oxidase, an enzime located 
in the mitochondrial respiratory chain, would trigger the release of mediators, including 
nitric oxide (NO), adenosine triphosphate (ATP) and ROS, which in turn would activate gene 
transcription resulting in cellular processes such as proliferation and differentiation [89, 91]. 
However, the multiplicity of putative photoreceptors and effector pathways suggests that 
additional mechanisms or a combination thereof likely contribute to mediating light effects [92]. 
The second challenge pertains to the high number of light parameters which can determine a 
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1
biological response. Wavelength is the most relevant, as without absorption of the right 
wavelength by the corresponding photoreceptor, there can be no photochemistry. The delivered 
dose (J/cm2), consisting in the product between irradiance (mW/cm2) and irradiation time (s), 
plays also a pivotal role. It has been established that cells follow a biphasic dose response, 
according to which only a narrow window of dose triggers activation, while lower or higher 
doses lead to no activation or even inhibition, respectively [89, 90]. The dose must also be 
delivered at the depth at which the photoreceptors are located: attention must be paid to tune 
the light power at the surface in order to reach a suitable density of photons inside the skin, 
while ensuring that skin temperature does not increase significantly [94]. This is true especially 
for shorter wavelengths, as they have a shallower penetration depth in the skin [89]. As a 
result of this complexity, several inconclusive in vitro and in vivo studies have been published 
in literature, often with lack or poor reporting of the rationale for the choice of the optical 
parameters [92]. A more rigorous approach in selecting the optical parameters, together with 
the pursuit of fundamental research on the identification of photoreceptors and molecular 
pathways, is expected to overcome the controversies and ultimately bring phototherapy to the 
mainstream of therapies [92, 94]. 
 Photobiomodulation with light in the blue spectral range (400-495 nm) is heading 
toward this direction. Recently, light emitting diodes (LEDs) with well-characterized optical 
parameters and quasimonochromatic output have been used to irradiate human skin cells in 
order to distinguish the biological effects of different wavelengths [95, 96]. Blue light at 453 
nm emerged for its anti-proliferative and anti-inflammatory effects [95, 97]. Promising results 
were found also in clinical studies in which blue light at 453 nm was used in the treatment 
of psoriasis and atopic dermatitis (AD), two common skin diseases characterized by hyper-
proliferation of keratinocytes from the basal layer and by an inflammatory infiltrate in the 
epidermis and dermis [98-100]. The absence of side effects reported in these studies would 
represent an advantage of blue light compared with UV radiation, whose beneficial effects in 
the treatment of these dermatoses come at the expense of an increased risk of skin cancer 
and photoaging [98-100]. Another inflammatory skin disease where beneficial effects of blue 
light have been widely reported is acne, and expectations are high also for applications in 
skin rejuvenation and wound healing [94, 101]. Taken together, the current evidence indicates 
that photobiomodulation with blue light does have biological effects, and might represent a 
therapeutic paradigm shift from UV irradiation in the treatment of inflammatory dermatoses.  
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1.6 OBJECTIVES AND THESIS OUTLINE 
 This thesis focused on the non-invasive, objective and in vivo evaluation of skin barrier 
properties and cutaneous inflammation in healthy volunteers. This evaluation was applied in 
two research areas: sensitive skin and skin irritation. 
Sensitive skin
Rationale
 Historically, clinical studies aimed at investigating the pathomechanisms involved in 
sensitive skin (SS) through linking of subjective perceptions to objective measurements of skin 
properties by bioengineering techniques have been rather unsuccessful, leading to inclusive 
results about this condition. In a recent systematic literature review, Richters and coworkers 
identified impaired skin barrier function, sensory hyper-reactivity and vascular responsiveness 
as pathomechanisms most often associated with SS [79]. Furthermore, the authors proposed 
a novel perception-based questionnaire spanning a range of provocations of different origin 
to select participants with self-assessed SS in clinical studies, and recommended to exclude 
participants with concomitant atopic diathesis and skin diseases, as these conditions likely 
represent a confounder [74].
Objective
 The first objective of this thesis was to investigate three possible pathomechanisms 
of SS, namely impairment of the skin barrier and enhanced vascular and sensory reactivities, 
following the recommendations of Richters and coworkers and their multifactorial questionnaire 
as selection tool. 
 -  Barrier impairment: the possible impairment of the skin barrier function was 
analyzed, for the first time, using confocal Raman microspectroscopy (CRS), a top-
notch technique for the assessment of skin biochemical composition (chapter 2.2). 
Measurements with established biophysical methods were added for comparison. In 
this respect, a systematic literature review was also conducted in which the advantages 
and disadvantages of each technique were highlighted, and an association between 
the skin barrier assessments performed with CRS and with established biophysical 
methods was sought (chapter 2.1). 
 -  Vascular and sensory reactivities: the possible enhanced vascular and sensory 
reactivities were addressed by histamine iontophoresis, a well-known in vivo model 
eliciting itch and a wheal-and-flare response (chapter 3.1). Established biophysical 
methods, together with digital image processing of skin photographs, were used for 
the assessment of skin reactions. Immunohistochemistry was additionally employed 
to provide an in-depth evaluation of the effects of the histamine iontophoresis model 
on the skin. 
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1As shown in Table 2 in chapter 1.4, epidemiological studies frequently reported a remarkably 
high percentage of women defining their skin as sensitive. To further characterize SS in women, 
a cross-sectional digital survey about the perceived influence of fluctuating hormone levels 
on self-assessed SS was carried out (chapter 4.1). Albeit fluctuations in female hormones 
occurring during the menstrual cycle and menopause have already been suggested among the 
triggers of SS, data on the prevalence of women perceiving their influence as well as on the 
associated symptoms and stimuli are lacking. From the same cross-sectional digital survey, 
risk factors increasing the likelihood of reporting SS were also identified (chapter 4.2). 
Skin irritation
Rationale
 When the skin is perturbed, for example by disruption of the stratum corneum or 
by penetration of a chemical irritant, a release of molecular markers such as cytokines, 
chemokines and AMPs occurs, orchestrating the inflammatory response and ultimately leading 
to the restoration of skin homeostasis. Bioengineering techniques can assess the inflammatory 
response at the macroscopic level, for example by measuring the extent of barrier disruption 
by TEWL or the intensity of erythema; however, they do not provide information about which 
molecular markers are involved in inflammation. As a result, in vivo data on the dynamics of 
molecular markers of cutaneous inflammation are scarce. 
Objective
 The second objective of this thesis was to provide novel insights into the non-invasive 
and in vivo evaluation of skin irritation at the molecular level. 
 -  In the first step, a systematic literature review was conducted to provide an overview 
of the existing methods to sample in a minimally-invasive fashion molecular markers 
of inflammation from human skin (chapter 5.1). 
 -  In the second step, one of these methods (transdermal analyses patch – TAP) was 
employed to characterize the dynamics of molecular markers following two in vivo 
models of skin irritation, namely tape stripping and histamine iontophoresis (chapter 
5.2). 
 -  In the third step, these in vivo models of skin irritation and the measurement of 
molecular makers with TAP were employed in the evaluation of the conditioning 
effects of photobiomodulation with blue light at 453 nm (chapter 5.3). Evidence from 
in vitro and clinical studies suggests that blue light at 453 nm has anti-inflammatory 
effects in the skin [95, 96, 98-100], whereas in vivo data on its biological effects on 
irritated healthy skin in humans are still lacking. 
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From these studies, the comparison between the assessment of skin irritation at the molecular 
level and at the macroscopic level by means of bioengineering techniques was evaluated. 
Chapter 6 provides a summary and discussion of the results obtained in this thesis, together 
with future perspectives offered by bioengineering techniques in dermatology and in cosmetic 
sciences. Chapter 7 presents the Dutch summary of the results and discussion, while the last 
chapter (chapter 8) contains a short summary of the findings of this thesis, the research data 
management, and information about the author.
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ABSTRACT
Skin barrier function, confined to the stratum corneum, is traditionally evaluated using 
established, non-invasive biophysical methods like transepidermal water loss, capacitance, and 
conductance. However, these methods neither measure skin molecular composition, nor its 
structure, hindering the actual causes of skin barrier change or impairment. At the same time, 
confocal Raman microspectroscopy (CRS) can directly measure skin molecular composition 
and structure and has proven itself to be a powerful technique for biomolecular analysis. The 
aims of this literature review were to evaluate non-invasive biophysical methods in view of CRS 
and to outline a direction towards more specific and informative skin measurement methods. 
We address this by investigating, for the first time, the relation between in vivo assessment 
of the skin barrier using indirect biophysical methods and the actual skin composition and 
structure as given by CRS and emphasize the high potential of CRS for dermatology and 
cosmetic sciences. CRS acceptance in these fields will require close collaboration between 
dermatologists, skin scientists, and spectroscopy experts towards simplifying the technology 
and creating robust, rapid, easy-to-use, and less expensive CRS applications.
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INTRODUCTION
 The major function of the skin is to provide a barrier between the body and the 
environment, protecting the organism from external injurious agents and pathogens and from 
the loss of water and electrolytes [1]. The barrier function of the skin is fulfilled primarily by the 
stratum corneum (SC), a thin layer of tightly stacked corneocytes embedded in a lipid matrix [2] 
The SC is 10-20 µm thick in most body sites except the palms of the hands and the soles of the 
feet, where it is one order of magnitude thicker [3]. Corneocytes are terminally differentiated 
keratinocytes containing different types of keratins, water and natural moisturizing factor 
(NMF), a hygroscopic mixture of amino acids and other components mainly derived from 
degradation of the epidermal protein filaggrin (FLG) [4]. The lipid matrix is composed of a 
mixture of ceramides, cholesterol and fatty acids arranged in parallel layers (lamellae) between 
the corneocytes; within the lamellae, lipids are present in three different lateral organizations, 
ranging from a very dense to a disordered, liquid phase [2]. Keratinocytes are the major cell 
type in the epidermis and proliferate from the basal layer, situated at the boundary with the 
dermis. During their migration towards the skin surface they differentiate to corneocytes, 
expressing different types of structural proteins, flattening out and losing their nucleus; in 
addition, keratinocytes deliver lipids to the SC by exocytosis of organelles (lamellar bodies) at 
the boundary between SC and viable epidermis [1]. The SC is also punctuated by appendages 
(including hair follicles, sebaceous and sweat glands), which add further structural and 
molecular elaboration [5]. The skin barrier is thus a complex structure whose integrity depends 
on the interplay of several factors, including the processes of proliferation and differentiation of 
keratinocytes, the release of lipids from lamellar bodies, the cohesion of corneocytes and the 
organization of lipids between them. 
 The understanding of the skin barrier is of central importance in several fields 
including dermatology, skin pharmacology, and personal care. In particular, in dermatology, 
an impairment of the skin barrier is associated with different dermatological diseases and has 
been suggested in sensitive skin, which nowadays is a widely accepted clinical state [6-8]. In 
skin pharmacology, new transdermal drug delivery methods have to overcome the skin barrier 
while maintaining its integrity [9]. In personal care, skin treatments need to be effective yet mild 
on the SC barrier in order to prevent excessive discomfort and skin irritation. As an example, 
recent fractional non-ablative skin rejuvenation devices for both professional and home use [10] 
aim at sparing the skin barrier function to a much higher degree than ablative approaches [11]. 
It is clear that, in order to understand the mechanisms contributing to SC barrier homeostasis 
as well as the mechanisms leading to SC impairment, the direct measurement of its molecular 
components would be required, possibly in vivo and non-invasively. 
 Over the last three decades, SC barrier function and hydration have been extensively 
evaluated by means of transepidermal water loss (TEWL) and electrical methods like 
capacitance and conductance, respectively [12, 13]. These established and easy-to-use 
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biophysical techniques consist of hand-held probes placed in contact with the skin allowing 
rapid, in vivo, and non-invasive measurements. The principle of each technique is schematically 
shown in Figure 1. The major limitation of TEWL and electrical techniques is that they are 
indirect methods, not measuring directly the SC molecular composition. In particular, in the 
case of the electrical techniques, substances or treatments that interact with the keratin-
water network of the SC can change the electrical properties of the skin without actually 
altering the water content [14]. A second limitation is that they are influenced not only by 
intrinsic factors, such as anatomical site, which are naturally expected to impact the outcome 
of the measurement, but also by extrinsic factors like ambient temperature and humidity [15]. 
Moreover, the skin appendages have a biasing effect on measurements through the influence 
of sweat gland activity, presence of hair follicles and secretion of sebum from the sebaceous 
gland along the hair shaft. Guidelines have been defined in order to standardize measurement 
procedures and minimize the influence of these factors [14, 16]. 
 Besides the indirect, probe-based biophysical instruments, optical methods based 
on light absorption or scattering, like optical coherence tomography (OCT), near-infrared 
spectroscopy (NIR) and Raman microspectroscopy (RS), have also been reported in the in vivo 
and non-invasive assessment of skin properties [17-19]. Among these, since the pioneering 
studies of Caspers et al. [20-22] in 2000, confocal Raman microspectroscopy (CRS) has emerged 
for the evaluation of SC barrier function and hydration at high spatial and temporal resolution. 
CRS allows the direct measurement of the SC molecular composition and distribution by 
combining the principle of confocal signal acquisition with inelastic (Raman) photon scattering: 
the signal, coming from a small and spatially defined volume of tissue, can be defined as 
an “optical sectioning” of the skin.  The principle is schematically shown in Figure 2. This 
methodology has been recognized and widely accepted by scientists working on the frontier of 
skin research, as well as single cell research, including stem cell characterization [23-25]. 
 It would therefore be of importance to investigate the relation between the composition 
and distribution of SC molecular components measured by CRS, assumed as the “gold 
standard” for in vivo analysis of molecular composition at high resolution, and the indirect 
biophysical measurements. For this purpose, we systematically reviewed in vivo studies on 
humans in which both CRS and at least one biophysical parameter between TEWL, capacitance, 
and conductance were measured. 
 We are of the opinion that such analysis will help both dermatologists and skin scientists 
to (i) improve their critical appraise of the values given by indirect biophysical techniques and (ii) 
understand the advantages offered by CRS in the evaluation of healthy skin and in the diagnosis 
and treatment of diseased skin. 
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Figure 1. Principle of measurement of indirect biophysical techniques. a) Transepidermal water loss 
(TEWL). TEWL is defi ned as the fl ux density of condensed water diffusing from inside the body to the 
surface. It is measured in grams of water per square meter per hour (g/m2h). Condensed water fl ows 
through a tortuous path via the intercellular lipids in which corneocytes are embedded. The variable 
measured by all TEWL instruments is actually the fl ux density of water evaporating from the surface, 
corresponding to the fl ux density of condensed water when no other sources of water are present (e.g. 
perspiration, wet skin surface). Instruments feature a chamber equipped with sensors of temperature 
and humidity; one extremity is open and placed in contact with the skin, while the other extremity can be 
open or closed. Sensor readings are used to calculate the fl ux density of water vapour by measurement of 
the humidity gradient between the extremities of the chamber or by measurement of the linear increase 
of humidity inside the chamber. b) Electrical method based on the conductance principle (Skicon 200EX). 
The probe head (area: 28 mm2) features two concentric interdigital electrodes of 75-µm width and 200-
µm distance. Upon contact with the skin, an oscillating electric current (frequency: 3.5 MHz) of a few 
micro Amperes (µA) fl ows between the electrodes. The conductance of the electric current is measured 
in micro Siemens (µS) and it is used to indicate stratum corneum hydration. The measurement depth of 
the instrument is suggested to be very superfi cial within the stratum corneum. Instrument readings can 
be infl uenced by perspiration, sebum and hair. c) Electrical method based on the capacitance principle 
(Corneometer CM825). The probe head (area: 49 mm2) features a gold grid covered by a glass lamina. 
An oscillating electric fi eld (frequency: 0.9-1.2 MHz) is developed between the tracks of the grid and 
penetrates into the skin upon contact with the probe. The capacitance of the system changes according to 
the moisture content of the superfi cial skin layers: the changes are then converted in arbitrary units and 
used to indicate stratum corneum hydration. There is uncertainty over the exact measurement depth of the 
instrument, with some sources indicating that it might include the upper epidermis. Instrument readings 
can be infl uenced by perspiration, sebum and hair.
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Figure 2. Principle of measurement of confocal Raman microspectroscopy. a) Monochromatic laser light 
is focused in the stratum corneum in a volume of about 5-µm length (axial resolution) and 1-µm width 
(dimension of the laser spot). Photons interact with the molecules, releasing some of their energy. Of the 
photons that exit the skin, only the ones coming from the focus region are detected thanks to the presence 
of a confocal pinhole. b) The photons which underwent frequency shifts due to the release of energy to 
molecules during the interaction are used to obtain Raman spectra. The position and intensity of each 
peak are representative of the different molecules and their amounts, respectively. Raman spectra can be 
obtained in a low (fingerprint) as well as a high energetic region: each region contains different information 
about the molecular composition and structure of the stratum corneum.
METHODS
 An extensive literature search was performed in November 2014 in four computerized 
bibliographical databases: PubMed, EMBASE, Web of Science and the Cochrane Library. 
Medical subject heading and free text searches embracing the following terms were used: 
“Raman”, “skin”, “human”, including all possible synonyms. The complete search strategy is 
shown in supplementary Table S1. The literature search had no date nor language restrictions. 
 After the initial search, titles and abstracts were reviewed for relevance by two 
independent reviewers (DF and GRdAS) taking into account the inclusion and exclusion criteria. 
Inclusion criteria were full text papers in English in which CRS and at least one biophysical 
measurement were performed in vivo on human volunteers. Biophysical measurements 
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corresponded to TEWL, capacitance, and conductance. Exclusion criteria were review articles 
and articles published only in abstract form. Once the relevant studies were identified, full 
publications were retrieved and independently reviewed for inclusion by the two reviewers. The 
reference lists of the included articles were additionally screened to ensure that all relevant 
studies were included. Consensus on inclusion was reached by discussion in all phases. 
 Methodological quality of the included studies was assessed by the STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) criteria: each study received, 
independently by the two reviewers, a score ranging from 0 to 22, which was then expressed 
as a percentage of the maximum score [26]. Depending of the level of fulfillment of the criteria 
stated in STROBE, articles were categorized as A (>80%), B (60%-80%) or C (<60%). When 
scores differed by more than 1.5, consensus was reached by discussion. 
RESULTS
Article selection and quality
 The article selection process is shown in Figure 3. A total of 33 articles were selected 
for full-text evaluation. For 15 articles, the inclusion criteria were not applicable following 
full-text evaluation and were therefore excluded from further analysis. Two articles for which 
the inclusion criteria applied were excluded because of the impossibility to compare CRS and 
biophysical measurements given that these measurements were performed in unrelated 
experiments. Since 15 out of 16 included articles used the confocal Raman spectrometer and 
data processing method introduced by Caspers et al. [21], the reference list of this article was 
manually screened, in addition to the reference lists of the articles that fulfilled the inclusion 
criteria. Manual screening resulted in the inclusion of five more articles.  
 Article quality was, on average, good: four articles were classified as a category C 
(score <60%), 14 articles were classified as a category B (score 60-80%) and the remaining 
three articles were classified as a category A (score >80%). Shortcomings were mainly related 
to no reference to bias and limitations of the study and lack of indication of the number of 
participants included at each stage.
 Results will be discussed for each biophysical technique in the following paragraphs. A 
detailed summary of each study included in this review can be requested from the first author. 
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Duplicate articles excluded: 
n = 606 
Total citations identified: 
PubMed (514) 
EMBASE (611) 
Web of Science (537) 
Cochrane Library (33) 
n = 1695 
 
Citations for first 
screening: 
n = 1089 
 
Excluded after screening 
titles and abstracts: 
n = 1056 
Full text articles for 
detailed evaluation: 
n = 33 
Included after screening 
references from full texts 
and from Caspers et al. 
[21]: 
n = 5 
 
Excluded after full text 
examination: 
n = 17 
-      Ex vivo (3) 
-      In vivo, but no CRS nor    
      biophysical measurements (4) 
-     In vivo + CRS, but no  
      biophysical measurements (6) 
-     In vivo + biophysical  
      measurements, but no CRS (2) 
-      In vivo + CRS + biophysical  
      measurements, but   
      comparison not possible (2) 
 
 
Articles included in the 
review: 
n = 21 
 
Figure 3. Article selection process.
TEWL
 TEWL is widely recognized as an indicator of the SC barrier function and corresponds 
to the fl ux density of water diffusing from the inner tissues to the body surface [27]. Under 
the simplifying assumption of steady-state diffusion in an homogeneous membrane, the fl ux 
density can be modeled with the one-dimensional Fick’s fi rst law of diffusion [27]:   
J = D
∆c
∆z
where J = fl ux density (Kg m-2 s-1); D = diffusion coeffi cient (m2 s-1);  ∆c = positive concentration 
difference across the membrane (Kg m-3); ∆z = membrane thickness (m). According to this 
model, TEWL depends thus on the diffusion coeffi cient D, on the positive concentration 
difference across the membrane ∆c and on SC thickness. Because the predominant pathway 
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for water loss through the skin is considered to be the intercellular route, i.e. through the lipids 
in which corneocytes are embedded, major contributors to the diffusion coefficient D are the 
lipids (specifically their amount, relative proportion and lateral organization), as well as the 
tortuous path created by the stacked packing of corneocytes [28-30]. 
 As to SC thickness, a weak correlation (r = -0.35) with TEWL was found in a study by 
Bielfeldt et al. [31]. SC thickness was estimated indirectly from the water profile, measured 
on the forearm of healthy volunteers, after fitting with a mathematical model derived from 
Fick’s first law of diffusion. This law was also used to calculate the diffusion coefficient D, 
which correlated strongly with TEWL (r = 0.92). Authors concluded that the physicochemical 
properties of the SC (like the physical constraint of corneocytes and the chemical constraint 
of lipids) are mainly responsible for the quality of the barrier in the protection from water loss. 
Indeed, it is known that the intercellular lipids in the SC play an essential role in preventing 
loss of water and other electrolytes [1]. Accordingly, in the studies included in this review, 
CRS measurements of lipids correlated with TEWL. A study by Janssens et al. [32] focused 
on the lipid/protein ratio, measured as the ratio of the integrated signal intensity from 2866 
to 2900 cm-1 (CH2 asymmetric stretching of lipids) and from 2910 to 2966 cm
-1 (CH3 symmetric 
stretching of proteins): decreasing values were reported from healthy controls to non-lesional 
and to lesional forearm skin of atopic dermatitis (AD) patients, with a strong correlation with 
1/TEWL (r = 0.86). In agreement with Bielfeldt et al. [31], authors concluded that lipid/protein 
ratio plays a more important role in the impairment of the skin barrier in AD than SC thickness. 
Janssens et al. [33] reported high TEWL in conjunction with impaired lipid composition and 
organization with techniques other than CRS. The importance of lipids in the skin barrier 
was demonstrated in another study on AD patients by Simpson et al. [34]: TEWL decreased 
following a four-week application of a moisturizer containing niacinamide and a ceramide 
precursor, along with increased ceramides levels. Niacinamide, a compound of vitamin B3 
which has been shown to increase the levels of SC ceramides [35], was tested also on healthy 
skin, resulting in lower increase of TEWL following tape stripping [36]. On the other hand, a 
study by Boireau-Adamezyk et al. [37] showed that the relationship between lipids and TEWL is 
not straightforward in the facial area, characterized by higher levels of ceramides, cholesterol 
and lipid/protein ratio,  as well as hydration, and yet by poor barrier function indicated by high 
TEWL. Smaller, immature corneocytes and thinner SC, driven by faster proliferation, have also 
been reported in literature for facial skin [38, 39]: these factors, leading to a shorter diffusion 
path length through the corneocytes [40], play most probably the major role for the increase 
of TEWL. The weak influence of SC thickness on TEWL found by Bielfeldt et al. [31] might thus 
hold primarily for body parts other than the facial area. 
 Besides lipids and corneocytes, also NMF plays a role in the water-retaining capability 
of the SC [30]. Following the discovery that mutations in the gene encoding for FLG are a major 
predisposing factor for AD [41], a number of studies have investigated whether the levels of 
NMF measured with CRS could be used as markers of FLG genotype. TEWL measurements 
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were used in these investigations as well. All studies included in this review reported that NMF 
levels were significantly decreased in carriers compared with non-carriers of FLG mutations. 
On the other hand, inconsistent results were shown for TEWL, which was significantly increased 
in AD patients carrying FLG mutations compared to AD patients without FLG mutations when 
clinically assessed disease severity was higher in the former group [42, 43] and it showed 
no differences when disease severity was similar between the two groups [33, 44, 45]. In 
agreement with our findings, the inclusion of different disease severities has been indicated 
in a recent work as the reason for the discrepancies in TEWL found in past studies [46]. These 
results suggest that lower NMF levels due to the presence of FLG mutations do not necessarily 
result in increased barrier impairment, as assessed by TEWL. Inconsistencies between FLG 
genotype and TEWL have emerged in other studies in literature [47-49]. It has been suggested 
that increased TEWL in patients with moderate-to-severe AD is independent of FLG genotype 
[45]; accordingly, the studies of Janssens et al. [32, 33] on the impaired skin barrier in AD did 
not find an effect of FLG genotype either on the lipid/protein ratio or on the composition and 
organization of lipids. 
 In terms of SC water content, higher TEWL was found by Nikolovski et al. [50] and 
Boireau-Adamezyk et al. [37] in conjunction with high SC water content in infant (3-12 months 
old) forearm skin and in adult facial skin, respectively. However, increased TEWL was also 
reported by Fluhr et al. [51] in conjunction with decreased SC water content following tissue 
tolerable plasma (TTP) application, a new approach for topical microbial disinfection of the 
skin surface employed in wound therapy. Trends of increased TEWL and decreased SC water 
content were shown also in a study by Mlitz et al. [43] comparing mild-to-moderate AD patients 
to healthy controls [43]. It is thus necessary to emphasize that SC water content and water flux 
are two separate variables [16] and that increased TEWL may reflect a decreased as well as an 
increased level of hydration [52]. 
Electrical methods
 Hydration measured with electrical methods is not always representative of the SC 
water content, as measured with CRS in the studies included in this review. In the same 
study cited for TEWL, Bielfeldt et al. [31] calculated water content in and below the SC by 
integrating the water profiles from the surface to the SC thickness and from the SC thickness 
to 20 µm deeper, respectively. The results showed a mild negative correlation with the SC 
water content and with SC thickness (r = -0.45 and r = -0.49, respectively), a mild positive 
correlation with the water content below the SC (r = 0.55) and a clear correlation with the SC 
water gradient (r = 0.62) [31]. Another study calculated the water content at 3 µm and at 15 
µm through integration of the water profiles, reporting mild squared correlation coefficients 
with conductance at baseline and following a water patch test (baseline: R2 =  0.11 at 3 µm, 
R2 = 0.31 at 15 µm; water patch test: R2 = 0.36 at 3 µm, R2 = 0.33 at 15 µm) [53]. Fluhr et 
al. [54] found that capacitance was higher in infant skin (5-7 months old) than in adult skin; 
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unfortunately, no SC water content was calculated from the water profile for comparison. In 
a study on skin seasonal changes, Egawa and Tagami [55] reported that capacitance and the 
sweat components lactic acid and urea increased in summer, while water profiles showed no 
changes. Of note, the humidity of the experimental room was higher in summer despite the air 
conditioning; a possible explanation for the higher hydration measured by capacitance could 
be the presence of sweating, since its influence on electrical methods is known [14]. In another 
pilot study, Egawa et al. [56] reported lower capacitance and conductance and a trend to lower 
mean amount of water in the upper SC of psoriatic lesional skin compared to non-lesional 
skin; however, a proper comparison between electrical methods and SC water content is not 
feasible since the mean water amounts were measured along different depths in lesional and 
non-lesional skin. 
 Despite no direct comparison between conductance and capacitance is possible, 
we found more agreement with the SC water content for the former. Boncheva et al. [57] 
demonstrated that conductance measured across the SC with repetitive tape stripping changed 
linearly with the water depth profile up to 37 mass percentage (where mass percentage, or 
mass%, indicates the grams of water per 100 grams of protein), corresponding to a rather 
superficial depth in the SC. For higher mass%, the relationship of SC water with conductance 
became exponential, probably due to the different influence of “free” water in the deeper SC 
with respect to “bound” water closer to the skin surface. In the study by Boireau-Adamezyk 
et al. [37], conductance and SC water content were both higher on the face, but while the 
former was different between outer and inner arms, the latter showed no differences. It has 
already been suggested that conductance correlates with the water content of the superficial 
portion of the SC as well as with that of the whole SC [58]. Accordingly, one in vitro study 
demonstrated that the measurement depth of the conductance instrument covers less than 
15 µm, thus reasonably within the SC, while the measurement depth of capacitance is up 
to 45 µm, corresponding to the viable epidermis; this value is in contrast with the 10-20 µm 
indicated by the manufacturer [59]. In that study, plastic foils were inserted between the probes 
and a filter pad saturated with ultrapure distilled water; subsequently, the signal reduction 
obtained by increasing the number of plastic foils was calculated and used to estimate the 
measuring depth of each instrument. The correlations calculated by Bielfeldt et al. [31] add to 
the uncertainties as to where in the skin the capacitance signal is coming from and suggest 
an influence of SC water gradient. In addition, previous studies have stated that capacitance is 
more sensitive for dry to very dry skin, while conductance is more sensitive for highly hydrated 
skin [14, 60, 61]. The comparisons described in this review tend to confirm those results. In fact, 
low capacitance was in agreement with reduced SC water content following TTP application in 
the study by Fluhr et al. [51]. Moreover, in the study by Mlitz et al. on mild-to-moderate AD and 
in several others in literature [49, 62, 63], capacitance correlated with clinical assessment of 
disease severity in AD, a condition in which dry skin is one of the major hallmarks. Conductance 
correlated with the SC water content in facial skin, characterized by high hydration [37]. 
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 A number of studies investigated the effects of long term use (14 to 27 days) of 
moisturizers. Crowther et al. [35] measured the SC water content through integration of the 
water profiles from the skin surface to the SC thickness and found a significant increase at 
two weeks of treatment and at one-week regression of a moisturizer containing glycerol and 
niacinamide. Two other products containing only glycerol had no significant effects on the SC 
water content. These results did not correlate with capacitance, which was increased for each 
moisturizer throughout all time points of the study; authors attributed this outcome to the 
high dielectric constant of glycerol. Another study did not show full agreement between the 
two techniques in a one-volunteer experiment [64]. In the study on the moisturizer containing 
niacinamide and a ceramide precursor, Simpson et al. [34] showed that capacitance was 
increased by 118% with respect to baseline, while only a trend to higher SC water content was 
found. On the other hand, increased capacitance was in agreement with an improved clinical 
dryness assessment. These outcomes reveal that values given by capacitance and conductance 
should be interpreted with caution, as incorrect estimation of the true SC water content might 
derive from the influence of the electric properties of the products applied rather than from the 
skin. The performance of capacitance and conductance has been questioned also in terms of 
the ability to discriminate mild changes in skin moisturization following a comparison with NIR 
spectroscopy, another optical method to directly measure skin water content [65]. 
DISCUSSION
 In this review we evaluated the outcomes of indirect biophysical measurements in 
relation to the SC molecular composition and distribution measured by CRS. We found that 
increased TEWL, indicator of skin barrier impairment, can underlie different amounts of lipids, 
water and NMF, depending on body site and disease state. The “integral” nature of TEWL 
measurement (both in the axial and in the lateral dimensions) cannot detect differences at 
the structural or molecular level if these result in a similar barrier impairment, as found in 
studies over AD and FLG genotype. It is clear that the advantage of CRS of knowing, in vivo 
and non-invasively, “which” SC components are mostly affected, rather than “if” the SC in 
its whole is affected, would provide a much more specific and complete understanding of the 
skin barrier. Applications of CRS to the assessment of the skin barrier could include a more 
focused diagnosis and rational treatment of skin diseases, a detailed evaluation of the recovery 
of biochemical components following stimulations of different nature [66], and a deeper insight 
into the barrier function involvement in sensitive skin. A step towards personalized medicine 
and personal care would thus be possible. 
 We confirm that electrical methods are limited by the influence of external factors (e.g. 
sweat) and by uncertainties over the exact measurement depth of the instruments. Their use 
in the evaluation of moisturizers should always be accompanied by measurements with other 
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techniques and investigations of different aspects of hydration changes (such as water binding and 
retention) in order to avoid incorrect conclusions due to the influence of the electric properties of 
the moisturizer [67]. CRS can help to gain a better understanding of moisturizer mechanism within 
the skin through the direct measurement of water content, distribution, and SC swelling [35]. In 
addition, it has recently been demonstrated that CRS can differentiate between different water 
binding states, including unbound, partially bound and primary bound water [68, 69]. The water 
content in each binding state has been found to vary differently in function of external stimuli like 
humidity and mechanical stress and, remarkably, correlations with structural and organizational 
changes in lipids and proteins were highlighted [68, 70]. This demonstrates the potential of CRS to 
study the correlation of skin barrier and hydration status in function of stimuli of different nature. It 
has been reported that nearly all major cosmetic companies have now employed CRS to understand 
mechanisms of skin hydration and that claims made from the findings of such investigations will 
continue to emerge [71].
 In terms of future perspectives on non-invasive skin measurements, we believe that 
indirect biophysical techniques will continue to be used due to their capability to provide objective 
information on healthy and diseased skin in a rapid and relatively inexpensive way. However, the 
specificity and richness of additional information provided by a new class of measurement like CRS 
cannot be underestimated. Besides characterizing the SC molecular composition and structure, 
CRS can track the in vivo penetration of actives and drugs within the SC, together with the effect 
of penetration enhancers, provided the substances under investigation have a Raman signal and 
the amount applied is sufficient to be detected by currently available devices [72]. Carotenoids, 
retinol, petrolatum oil and ibuprofen are among the substances successfully measured in vivo using 
CRS [73-76]. Such measurements are obtained in a non-destructive, immediate and labeling-free 
fashion, representing an advantage compared to other techniques used to track the penetration of 
substances in the skin, like tape stripping and multiphoton microscopy: the first requires a layer-by-
layer removal of SC by adhesive tape followed by extraction and quantification by high performance 
liquid chromatography, while the second requires, for most procedures, labeling of the substances 
under investigation with fluorescent dyes, possibly affecting the penetration within the skin [18]. 
Furthermore, in contrast to infrared spectroscopy, also used to track the penetration of substances 
in the skin, CRS has a higher spatial resolution and is not affected by interference from water [18]. In 
addition to the analysis of the skin barrier, RS has proven useful in other dermatological applications. 
In the oncological field, ample proof-of-concept of Raman-based spectral discrimination between 
normal and neoplastic skin tissue has been reported: it is suggested that potential in vivo, real-
time Raman applications could range from cancer diagnosis to tumor-margin detection during 
surgical resection [77]. Successful attempts at combining RS with imaging methods like OCT and 
reflectance confocal microscopy (RCM) have been described, allowing concomitant morphological 
and biochemical characterization of the skin [78-80].
 On the other hand, it is important to note that CRS has some inherent limitations. 
As only one out of 107 photons undergoes Raman scattering, the technology requires very 
54
CHAPTER 2.1
sensitive detectors [18] and can be used for the measurement of molecules present in sufficient 
concentrations. Moreover, during skin measurements, the detection limit is often hindered 
by tissue autofluorescence, which gives rise to a high signal background, thereby significantly 
decreasing the signal-to-noise ratio of the Raman spectra. The effects of tissue autofluorescence 
are usually minimized with a baseline removal in the spectrum post-processing [21, 22, 69], while 
fewer approaches focus on reducing autofluorescence prior to the collection of spectra, for example 
by photobleaching [81, 82]. As any optical measurement, Raman signals undergo attenuation at 
deeper skin layers, requiring normalization by a skin-derived Raman peak, for example keratin [21], 
or correction by a mathematical algorithm [83], to allow a reliable definition of the concentration 
profiles. Further challenges inherent to in vivo CRS applications are minimization of body movement, 
for which an inverted set-up is usually used [21, 22], and of laser heating effects, which have to 
comply with the maximum permissible exposure (MPE) limits defined internationally [84]. It follows 
that CRS applications are characterized by high performance requirements in terms of hardware 
(e.g. lasers, detectors, confocal optics) to obtain high quality spectra, as well as by specific software 
“know-how” to process and extract the information of interest [84] (e.g. deconvoluton methods in 
case of overlapping spectral bands [22, 68]). As a consequence, current state-of-the-art in vivo 
Raman applications are complex, expensive, and relatively bulky, needing trained personnel for 
their use and not yet allowing measurements on recessed body parts [24, 84, 85]. An approach that 
would reduce the size, cost, and complexity required for acceptance in mainstream clinical and 
dermatocosmetic practices would be to develop dedicated Raman devices for specific applications 
in which, instead of conventional optical components, integrated optics technology is used, the 
components of which are miniaturized and mass-produced [85]. Such dedicated applications can 
be developed thanks to the fact that relevant diagnostic information is often contained in a limited 
number of spectral regions, and that statistical analysis methods could be effectively used to extract 
this information from the Raman spectra [69, 86]. From the end users point of view (dermatologists 
and skin scientists), the question is to determine how to include the information provided by the 
Raman instrumentation in routine clinical or product testing protocols and how it could affect 
the decision making processes [87]. In order to answer these questions and to widen the use 
of CRS, we recommend performing clinical trials in which a close collaboration is established 
between spectroscopists, dermatologists, and skin biology scientists. We hope the endpoint of 
such collaborations to be robust, rapid, easy-to-use, and less expensive CRS applications allowing 
a deepening of our understanding of the skin and its barrier function. Meanwhile, we strongly 
encourage performing clinical investigations to gain further insights into the relationship between 
indirect biophysical techniques and the skin molecular composition measured by current state-of-
the-art CRS applications to create clear rules both for applicability of indirect methods and their 
limitations. The outcome of such studies will improve the critical appraisal of the measurements 
performed with indirect, macroscopic biophysical techniques, helping to bridge the gap between 
the current non-invasive evaluation of the barrier function and future assessments performed by 
promising techniques like CRS. 
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CONFOCAL RAMAN MICROSPECTROSCOPY VS. MACROSCOPIC BIOPHYSICAL SKIN MEASUREMENTS
ABBREVIATIONS 
AD Atopic dermatitis
AR Allergic rhinoconjunctivitis
a.u. arbitrary units
AUC Area under the curve
CRS Confocal Raman microspectroscopy
FLG Filaggrin
NMF  Natural moisturizing factor 
NSS Non-sensitive skin
SC Stratum corneum
SS Sensitive skin
TEWL Transepidermal water loss
TIS score Three item severity score
TRP Transient reception potential
2.2
Sensitive skin: 
assessment of the skin barrier using confocal 
Raman microspectroscopy
Richters RJ1
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ABSTRACT
Background/aims: Sensitive skin (SS), a frequently reported condition in the Western world, 
has been suggested to be underlined by an impaired skin barrier. The aim of this study was 
to investigate the skin barrier molecular composition in SS subjects using confocal Raman 
microspectroscopy (CRS) and to compare it with that of subjects with non-sensitive skin (NSS), 
atopic dermatitis (AD) and allergic rhinoconjunctivitis (AR), who frequently report SS.  
Methods: Subjects with SS (n=29), NSS (n=30), AD (n=11) and AR (n=27) were included. Stratum 
corneum (SC) thickness, water, ceramides/fatty acids, and natural moisturizing factor (NMF) 
were measured by CRS along with transepidermal water loss and capacitance on the ventral 
forearm, thenar, and cheek. Sebum levels were additionally measured on the forearm and 
cheek. 
Results: No differences between SS and NSS subjects were found regarding SC thickness, 
water and NMF content, yet a trend towards lower ceramides/fatty acids was observed in 
the cheek. Compared with AD subjects, the SS group showed higher ceramides/fatty acids 
content in the forearm, whereas no differences emerged with AR subjects. The correlation of 
macroscopic biophysical techniques and CRS was weak, yet CRS confirmed the well-known 
lower content of NMF and water, and thinner SC in subjects with filaggrin mutations. 
Conclusion: The skin barrier in SS is not impaired in terms of SC thickness, water, NMF and 
ceramides/fatty acids content. The failure of biophysical techniques to follow alterations in 
the molecular composition of the skin barrier revealed by CRS emphasizes a strong need in 
sensitive and specific tools for in vivo skin barrier analysis.
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INTRODUCTION
 The skin protects our internal milieu from the external environment due to its low 
permeability, which is mainly established by specific properties of the stratum corneum (SC) [1]. 
The cells of the SC are the result of epidermal differentiation, a gradual maturation process of 
the basal keratinocytes ascending to the cornified layer of the squamous epithelium, functioning 
as corneocytes [1-4]. Next to a tough and resilient organization of the flattened corneocytes, 
the envelope of proteins and lipids surrounding each corneocyte also plays a crucial role in 
preventing penetration and diffusion of foreign substances through the skin and loss of internal 
water. The currently accepted model of the SC, although subject to change [5-7], also contains 
the intercellular lipid lamellae, a product originating from the lamellar bodies of the stratum 
granulosum, and consisting of ceramides, fatty acids, and cholesterol. Located between the 
corneocytes, it contributes to the overall skin barrier function [3, 8-12]. Furthermore, water 
soluble intracorneocyte substances, collectively known as natural moisturizing factor (NMF), 
contribute to the overall skin barrier function by binding water and limiting water loss from the 
skin [1]. Impairment of the skin barrier may result in penetration of allergens and pathogens 
contributing to skin diseases, such as atopic dermatitis (AD), and allergic and irritant contact 
dermatitis.
 Sensitive skin (SS) is a condition characterized by perception of skin discomfort 
following mild stimuli, frequently without objective signs of skin irritation [13-18]. This skin 
condition has been shown to be highly prevalent in the Western world but, despite extensive 
research in the past years, no consensus on its definition and pathomechanisms has been 
reached [19]. Impaired skin barrier function has been suggested to underlie SS [13, 20, 21], 
leading to proposals of an association of SS with atopic conditions [22-24]. The assessment of 
the skin barrier has been traditionally performed by means of indirect macroscopic biophysical 
techniques such as transepidermal water loss (TEWL). The hydration of the SC, indirectly 
measured based on capacitance, has been proposed to be lower in facial areas of SS subjects 
[25] and of subjects perceiving stinging responses following application of lactic acid on the 
nasolabial folds [20]. However, other studies which used macroscopic biophysical techniques 
did not find such differences between a SS and a non-sensitive skin (NSS) group [14, 18, 20, 
26, 27]. This inconsistency between outcomes could be, on the one hand, due to the fact that 
subjects were included in tests using different criteria, since a definition of SS is still lacking. It 
might also be possible that indirect assessments of barrier function and hydration by means of 
TEWL and capacitance lack sensitivity and specificity if the barrier function impairment in SS 
is only subtle.
 Over recent years, confocal Raman microspectroscopy (CRS) has emerged as a 
powerful tool for the direct and non-invasive assessment of the molecular components of 
the skin at high spatial and temporal resolution. CRS is an optical technique based on the 
principle of inelastic (Raman) scattering: when a monochromatic laser beam is focused in 
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the skin, incident photons interact with the vibrational levels of the molecules, transferring to 
them a part of their energy. The exact amount of energy required to excite a vibrational mode 
is dependent on the masses of the atoms involved in the vibration and on the chemical bonds 
between them. The resulting Raman spectra are thus molecule-specific and contain detailed 
information on their type and amounts [28]. In addition, by using the principle of confocal 
detection, only the light scattered from the laser focus is detected, providing spatially resolved 
information, which approaches a subcellular resolution [29]. Raman spectroscopy has already 
established a strong position in non-invasive skin analysis for many applications, ranging from 
detection of non-melanoma skin cancer [30] to evaluation of skin barrier composition in AD [31, 
32]. As CRS is able to detect differences at the molecular level and at high spatial resolution, it 
could provide a breakthrough in the evaluation of barrier function involvement in SS, which so far 
is not possible with macroscopic biophysical techniques [33].
 The primary objective of this study was to evaluate the SC molecular composition using 
CRS in subjects with SS and to compare the results with those measured on subjects with NSS, 
AD, and allergic rhinoconjunctivitis (AR). The underlying hypothesis was that the mechanism 
of SS could be based on aberrant properties of the SC and could share interface with atopic 
conditions. The second objective was to perform a comparative study of the penetration kinetics 
of a solution of glycerol (1%) in water in SS and NSS subjects in order to establish whether faster 
penetration of topicals due to an impaired skin barrier might occur in SS. Glycerol is a widely 
used humectant in dermatologic and cosmetic formulations [34]. In this study, it was chosen 
as a model for substance penetration for its low toxicity, known diffusivity in the SC allowing 
measurement with CRS, hydrophilic nature, and undisruptive effect on the intercellular lipid 
lamellae [34]. The penetration of a lipophilic substance might be heavily influenced by its affinity 
with the lipid compartment of the skin barrier, which is possibly different between SS and 
NSS. Meanwhile, the lack of a disruptive effect on the intercellular lipid lamellae implies that 
different penetration kinetics of glycerol could be attributed to the properties of the skin barrier 
rather than to an active effect of glycerol on the barrier. The knowledge gained should be of 
high value for clinicians and the cosmetic and pharmaceutical industry involved in developing 
solutions for individuals with SS.
PATIENTS AND METHODS
Subject selection
 The inclusion criteria for this study were an age between 18 and 65 years and skin type 
II or III (Fitzpatrick scale). Subjects could not use immunosuppressive drugs during the study 
period. Starting from two days before the test, subjects were advised not to use toiletries (e.g. 
personal care and cosmetic products) in the areas to be investigated and not to excessively 
expose these areas to sunlight or use artificial tanning methods. Four groups of subjects 
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were included. Subjects with SS and subjects with NSS were selected based on a perception-
based questionnaire, as previously described [21, 35, 36]. Briefly, potential participants filled in 
questions on self-assessed skin sensitivity and on skin perceptions (i.e. discomfort, stinging, 
redness, dryness) following exogenous and endogenous triggers (i.e. toiletries, shaving, heat, 
cold, clothes, emotions). The severity of reactions to each trigger and the correspondent 
duration were scored on a visual analogue scale and on an ordinal scale (no reaction, seconds, 
minutes, less than one hour, hour(s), day(s)), respectively. The scores of each trigger were 
summed, and the final score was compared to an upper and lower quartile determined in 
advance by distributing the questionnaire to a large study cohort [37]. If the final score was 
above the upper quartile and the subject reported SS, he/she was included in the group with 
SS. If the final score was below the lower quartile and the subject reported NSS, he/she was 
included in the group with NSS. In addition, subjects in both the SS and NSS groups did not 
have a specific history of skin diseases or other concomitant diseases, including AD, asthma 
and AR in particular. The other two groups included in the study were subjects with AR using 
oral histamine antagonists when experiencing symptoms and without a history of asthma, 
urticaria, AD or other (skin) diseases; and subjects with moderate to severe AD (three item 
severity score - TIS - ≥3) currently using no therapy or using solely topical corticosteroids and 
without a history of asthma, urticaria, AR or other (skin) diseases. Subjects with AR and AD did 
not fill in the full-length questionnaire, but were asked if they perceived their skin as sensitive 
or non-sensitive. The study was conducted in accordance with the Declaration of Helsinki 
principles and was approved by the local ethics committee. Experiments were performed 
at the dermatology department of the Radboud University Medical Center in Nijmegen, the 
Netherlands, between January and March 2015. 
Instrumentation
 Three body sites were measured: (i) the mid-ventral forearm, (ii) the lateral side of the 
thenar eminence of the arm, and (iii) the malar eminence of the right cheek on the 90-degree 
angle crosspoint of the ala of the nose and the lateral canthus of the eye. Forearm and thenar 
measurements were performed in the non-dominant arm (supplementary Figure S1). AD 
subjects did not have active lesions on these body sites. Subjects were acclimatized for 20 
minutes in a temperature- and relative humidity-controlled room (temperature 21 ± 1 °C, 
relative humidity 50 ± 10%). 
 In vivo CRS measurements were performed using the gen2-SCA performance model 
of RiverD International B.V. (Rotterdam, the Netherlands). The device has an axial resolution 
of 5 µm and is equipped with a 785-nm laser source for measurements in the 400-1800 cm-1 
spectral region (NMF, ceramides and glycerol) and a 671-nm laser source for measurements 
in the 2400-4000 cm-1 spectral region (water). The laser power complies with the maximum 
permissible levels for skin as defined by the international laser safety standard (IEC 60285-
1:2007; <30mW for 785 nm, and <20mW for 671 nm). In the 400-1800 cm-1 region, spectra of 
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the cheek and forearm were acquired at 4-µm increments in the axial direction up to a depth of 
28 µm using a 5-s acquisition time per point, whereas the spectra of the thenar were acquired 
at 15-µm increments up to a depth of 180 µm using a 5-s acquisition time until 100 µm and 
a 7-s acquisition time until 180 µm. In the 2400-4000 cm-1 region, spectra of the cheek and 
forearm were acquired at 4-µm increments up to a depth of 40 µm using a 2-s acquisition time 
per point, whereas spectra of the thenar were acquired at 15-µm increments up to a depth of 
180 µm using a 2-s acquisition time until 100 µm and a 5-s acquisition time until 180 µm. Ten 
measurements per body site were performed in each spectral region.
 The macroscopic biophysical techniques employed included: (i) capacitance for the indirect 
measurement of SC hydration (Corneometer CM825, Courage + Khazaka, Germany); (ii) TEWL 
for the indirect assessment of skin barrier (Aquaflux AF200, Biox, UK); and (iii) sebumeter for the 
indirect measurement of sebum level at the skin surface (Sebumeter SM815, Courage + Khazaka, 
Germany). Three measurements per body site were performed, except for the SC hydration of the 
cheek which was measured five times. The sebum measurements were performed on the side 
contra lateral to the one in which CRS was applied and were not performed on the thenar.
Penetration kinetics of glycerol
 A solution of glycerol (1%) in demineralised water (200 µl) was applied to the non-
dominant volar forearm for one minute. A 13-mm-diameter plastic ring was used to prevent 
the spreading of the substance over the skin surface. After wiping off the solution with a tissue, 
CRS measurements in the 400-1800 cm-1 spectral region were performed every 60 s during the 
subsequent 15 minutes using axial steps of 4 µm and up to a depth of 28 µm.
Calculation of parameters from CRS measurements
 Concentration profiles of SC molecular components relative to keratin were obtained 
using the software SkinTools 2.0 (RiverD International B.V.) using a previously reported fitting 
algorithm [28]. Briefly, the algorithm consists of a least square fitting of the Raman spectra 
obtained in vivo to a library of Raman spectra of SC molecular components obtained in vitro, 
resulting in a set of fit coefficients for the SC constituent spectra. The fit coefficients are 
subsequently normalized to the fit coefficient of the keratin spectrum in order to compensate 
for the loss of signal intensity at increasing skin depths [28]. For the measurement of 
concentration profiles of glycerol, the Raman spectrum of the solution of glycerol (1%) in water 
was obtained in vitro and subsequently added to the library of Raman spectra. Obvious outliers 
in the concentration profiles (due for example to presence of cosmic rays or high background 
fluorescence in the corresponding Raman spectra) were removed. 
 The average thickness of the SC was calculated from the water concentration profiles 
using an implementation in Matlab (version R2013a, The MathWorks Inc., USA) of the method 
of Bielfeldt et al. [38], in which the SC thickness was defined as the intercept of two straight 
lines delineating the boundary between the SC and the epidermis. The average water content 
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in the SC was expressed as area under the curve (AUC) of the water profiles from 4-µm depth 
to the SC thickness in the cheek and forearm, and from 10-µm depth to the SC thickness 
in the thenar. The average levels of ceramides/fatty acids (grouped by SkinTools in a single 
variable, ”ceramides”) and of NMF between a depth of 4 and 12 µm in the forearm, 4 and 8 
µm in the cheek and 10 and 50 µm in the thenar were calculated from the corresponding 
average concentration profiles. These intervals were chosen in order to avoid influences from 
skin surface contamination (e.g. sebum) and from washout/desquamation effects at the skin 
surface, as well as to avoid Raman signals from the viable epidermis [39]. The presence of 
filaggrin (FLG) mutations was established according to the method of O’Regan et al. [32], in 
which the cut-off point of 1.07 arbitrary units (a.u.) used for FLG mutations (either FLG-/- or 
FLG+/-) versus no FLG mutation (FLG+/+) was derived from the mean NMF level between a depth 
of 30 and 50 µm measured in the thenar. The presence of exogenous glycerol after topical 
application was verified by calculating the difference spectrum, obtained by subtraction of 
the average Raman spectrum where the glycerol signal was not detectable from the average 
Raman spectrum where glycerol was detected using SkinTools 2.0. If the peaks of the Raman 
spectrum of glycerol were clearly visible in the difference spectrum, presence of exogenous 
glycerol was confirmed. If some peaks were missing or were not convincingly above the noise 
level, the presence of exogenous glycerol was not confirmed.
Statistical analysis
 The results are presented as number (percentage) or as median (minimum-maximum). 
Differences between the groups (SS, NSS, AR and AD) were analyzed using the Mann-Whitney 
exact test for non-parametric independent values. Correlations were investigated using the 
Spearman’s rho. Statistical analyses were performed with SPSS Statistics version 20 for 
Windows (IBM SPSS Inc., USA). A p value ≤0.05 was considered statistically significant. Missing 
values were excluded from the analyses. No corrections for multiple comparisons were applied.
RESULTS
Group characteristics
 In total, 29 subjects were included in the SS group, 30 in the NSS group, 27 in the AR 
group and 11 in the AD group. The group characteristics are presented in Table 1. There were 
no significant differences with respect to age, gender, Fitzpatrick skin type and presence of 
FLG mutations between the groups. Self-assessed facial and body skin differed between SS 
and NSS subjects, with the former reporting more frequently dry or combined (concomitant 
presence of dry and oily parts) skin, and the latter reporting more frequently normal skin 
(p=0.007 and p=0.000, respectively). Self-assessed SS was reported by two-thirds of AR subjects 
and by all AD subjects. The measurements of four subjects in the volar forearm, of one subject 
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in the cheek and of two subjects in the thenar were excluded, because of artefacts found in the 
Raman spectra most probably caused by exogenous agents on the skin. 
Table 1. Population characteristics.
NSS 
n (%) or 
median (range)
SS
n (%) or 
median (range)
AR 
n (%) or 
median (range)
AD 
n (%) or 
median (range)
Self-assessed sensitive skin 30 (100.0) 29 (100.0) 27 (100.0) 11 (100.0)
   SS 
   NSS
0 
30
(0.0)  
(100.0)
29 
0
(100.0) 
(0.0)
18 
9
(66.7) 
(33.3)
11 
0
(100.0) 
(0.0)
Gender 
    Male 
    Female
 
14 
16
 
(46.7) 
(53.3)
 
11 
18 
 
(37.9) 
(62.1)
 
11 
16 
 
(40.7)
(59.3)
 
5 
6 
 
(45.5)
(54.5)
Age (years) 21.5 (18-28) 21.0 (18-32) 23.0 (19-29) 23.0 (20-27)
Skin type (Fitzpatrick) 
    Skin type II 
    Skin type III 
 
22 
8 
 
(73.3) 
(26.7)
 
21 
8 
 
(72.4) 
(27.6)
 
19 
8 
 
(70.4) 
(29.6)
 
8 
3 
 
(72.7) 
27.3)
FLG mutations 
    FLG-/- or FLG+/-  
    FLG+/+ 
    missing 
 
Facial skin dryness 
    Normal 
    Dry 
    Oily 
    Combined (dry and oily)
 
3 
26 
1
 
17 
4 
1 
8
 
(10.0) 
(86.7) 
(3.3)
 
(56.7) 
(13.3) 
(3.3) 
(26.7)
 
3 
25 
1
 
6 
9 
2 
12
 
(10.3) 
(86.2) 
(3.4)
 
(20.7) 
(31.0) 
(6.9) 
(41.4)
 
1 
26 
0
 
(3.7) 
(96.3) 
(0.0)
 
n.a.
 
3 
8 
0
 
(27.3) 
(72.7) 
(0.0)
 
n.a.
Body skin dryness 
    Normal 
    Dry 
    Oily 
    Combined (dry and oily)
 
25 
4 
0 
1
 
(83.3) 
(13.3) 
(0.0) 
(3.3)
 
9 
15 
0 
5
 
(31.0) 
(51.7) 
(0.0) 
(17.2)
          n.a. n.a.
Questionnaire score  29.5 (0.0-62.0) 157.8 (70.3-287.0)           n.a. n.a.
SS: sensitive skin; NSS: non-sensitive skin; AR: allergic rhinoconjunctivitis; AD: atopic dermatitis; FLG-/-: 
homozygous filaggrin mutation; FLG+/-: heterozygous filaggrin mutation; FLG+/+: no filaggrin mutation; 
n.a.: questions about facial and body skin dryness and the questionnaire to determine skin sensitivity were 
not asked/distributed to the AR and AD groups.
Macroscopic biophysical measurements
 Macroscopic biophysical measurements of the forearm, cheek and thenar are reported 
in Tables 2-4. In the forearm, SS and AR had lower TEWL compared with NSS and AD (SS vs. 
NSS: p=0.076, SS vs. AD: p=0.082, AR vs. NSS: p=0.038, AR vs. AD: p=0.044). Similar findings were 
found in the thenar (SS vs. NSS: p=0.016, SS vs. AD: p=0.058, AR vs. NSS: p=0.050, AR vs. AD: 
p=0.071). No further difference between the groups was found with respect to TEWL measured 
on the cheek and with respect to SC hydration and sebum level measured on either body site. 
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Molecular composition measured by CRS
 The average concentration profiles of water, NMF, and ceramides in the forearm and 
cheek for all groups are shown in Figure 1. The SC thickness, SC water content, and average 
NMF and ceramides levels in the forearm, cheek, and thenar are reported in Tables 2-4. 
Numerical values of water, NMF and ceramides at each depth and body site are shown in 
supplementary Tables S1-S3. 
 No significant differences in SC thickness and SC water content were found between 
the groups in either body site. 
 With respect to the average NMF at 4-12 µm measured in the forearm, no significant 
differences emerged between the groups, yet it is possible to observe a trend towards lower 
levels in the AD subjects compared to the other subjects (Figure 1). Similarly, in the cheek, AD 
subjects showed a trend to lower average NMF at 4-8 µm compared to NSS subjects (p=0.091). 
AR subjects tended to have higher average NMF in the thenar at 10-50 µm compared to NSS 
subjects (p=0.076).
 With respect to the average ceramides/fatty acids at 4-12 µm measured in the forearm, 
SS subjects showed higher levels compared to AD subjects (p=0.007), whereas no differences 
emerged between the other groups. In the cheek, SS subjects tended to have lower average 
ceramides at 4-8 µm compared to NSS subjects, yet these values were again higher than 
in subjects with AD (p=0.097). This trend is more pronounced at the skin surface (Figure 1). 
Ceramides were not detectable in the thenar.
Presence of FLG mutations 
 In total, 10 subjects were found to be carriers of FLG mutations (either FLG-/- or FLG+/; 
Table 1). Differences between subjects with FLG-/- or FLG+/- and subjects with FLG+/+ were 
present in the forearm, with the former having lower NMF levels (p=0.017) and a trend towards 
lower water content and thinner SC (p=0.071 and p=0.058, respectively). Similarly, in the 
thenar, subjects with FLG-/- or FLG+/- had lower NMF levels, lower water content and thinner SC 
(p=0.000) compared to subjects with FLG+/+. The results found in the cheek are consistent with 
these findings, albeit no significant differences were present. Numerical results are shown in 
supplementary Table S4. 
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Figure 1. Average concentration profiles of water (a, d), natural moisturizing factor (b, e) and ceramides/
fatty acids (c, f) at different depths (µm) measured in the volar forearm (a-c) and cheek (d-f). Profiles 
represent medians (range). Red = non-sensitive skin (NSS), blue = sensitive skin (SS), brown = allergic 
rhinoconjunctivitis (AR), green = atopic dermatitis (AD).
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Correlations between macroscopic biophysical measurements and CRS
 A moderate to weak negative correlation was found between TEWL and NMF levels in 
the forearm (rho = -0.220, p=0.034, n=93), in the cheek (rho = -0.408, p=0.000, n=96) and in the 
thenar (rho = -0.208, p=0.044, n=95). In the thenar, TEWL correlated weakly with the SC water 
content (rho = 0.207, p=0.044, n=95) and with the SC thickness (rho = 0.202, p=0.050, n=95). Of 
note, the weak correlation with the SC water content remained also when controlling for the 
corresponding SC thickness. No further correlations were found between TEWL and SC water 
content, SC thickness or ceramides levels measured in the forearm and cheek. 
 SC hydration measured with capacitance was not found to correlate with the SC water 
content in either the forearm, cheek or thenar. In the forearm, on the other hand, capacitance 
correlated weakly with the water content in the middle part of the SC (4-12 µm) and with the 
water content up to the upper epidermis (4-32 µm) (rho = 0.222, p=0.032, and rho = 0.207, 
p=0.046, n=93, respectively). In the cheek, capacitance correlated weakly with the NMF levels 
(rho = 0.223, p=0.029, n=96). 
Penetration kinetics of glycerol
Evidence for the presence of exogenous glycerol was visible only at the skin surface 
(0-4 µm) and in the first three minutes following application, as verified by the difference spectra 
shown in Figure 2. Measured levels of glycerol in subjects with NSS and SS are reported in Table 
5. NSS subjects showed consistently higher values of glycerol than subjects with SS, reaching 
statistical significance at one minute after application (p=0.030). In both groups, glycerol 
levels declined slightly from the first to the third minute after application. Baseline levels of 
endogenous glycerol measured at the skin surface (0-4 µm) were not different between SS and 
NSS subjects and, in both groups, were significantly lower that the levels measured in the first 
three minutes after topical glycerol application (p<0.008). 
Table 5. Levels of glycerol at a depth of 0-4 µm at baseline and after application of a solution of  glycerol 
(1%) in demineralized water on the volar forearm for 1 minute.
NSS
median (range)
SS
median (range)n n
Glycerol content [a.u.]
   Baseline 20 783 (643-1280) 20 816 (656-1008) n.s.
   1 minute 22 1274 (835-2205) 20 1039 (783-1545) 0.030
   2 minutes 21 1243 (808-2259) 20 1038 (646-1962) n.s.
   3 minutes 20 1208 (785-2016) 20 994 (672-1925) n.s.
a.u.: arbitrary units; n.s.: no statistically significant difference; NSS: non-sensitive skin; SS: sensitive skin.
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DISCUSSION
 The main objective of this study was to investigate whether the barrier function 
is aberrant in SS by directly measuring the molecular composition of the SC by means of 
CRS. A comparison with the molecular composition of the SC in subjects with NSS, AD and 
AR was made, together with the indirect assessment of the skin barrier by means of TEWL 
and capacitance. In line with the literature, also in this study SS subjects reported more 
frequently dry facial and body skin compared to subjects with NSS. However, we did not find 
strong evidence to support a hypothesis of an impaired skin barrier in SS in terms of SC water 
and NMF levels in either the forearm, cheek or thenar. SC thickness was also not different 
between the groups, which is in line with our previous findings [21]. It is interesting, however, 
that ceramides/fatty acids showed a trend towards lower levels in the cheek of SS subjects 
compared to the NSS group, whereas non-significant higher values were found in the forearm. 
Several studies have suggested the role of an impaired skin barrier function in SS [13, 20, 21] 
and one in particular demonstrated lower ceramides in the facial skin of subject with SS [27]. 
This hypothesis concerning a weaker SC barrier is also supported by previous clinical studies 
performed by our group, in which the same perception-based questionnaire was used to select 
volunteers with SS and NSS [21, 36]. In those clinical studies, the SC of subjects with SS was 
shown to be more vulnerable to chemical and mechanical stimuli than the SC of subjects 
with NSS, suggesting an impaired barrier. Additional mechanisms to those investigated in 
this study might thus play a major role in the barrier function impairment in SS, including 
reduced intercorneocyte adhesion, different organization of lipids in the intercellular lamellae, 
increased inflammatory reactions, and an altered number of mast cells in response to a range 
of stimuli, as previously reported by our group [21, 35, 36]. 
 In addition to barrier function impairment via alterations in molecular balance of 
NMF, ceramides and water, an involvement of the family of transient receptor potential (TRP) 
channels has been hypothesized to play a role in SS [40]. TRP channels are sensory receptors 
activated by a variety of external stimuli and known to mediate a range of skin sensations 
including pain, itch and burning feeling. Increased levels or an upregulated sensitivity of these 
receptors might account for the previously reported increased perception of SS to a variety of 
stimuli [21, 35, 36]. One could also speculate that the more frequent self-reported perception 
of skin dryness in SS subjects might be primarily mediated by these receptors, because of 
the lack of significant differences in SC water content and NMF levels in SS compared to NSS 
subjects demonstrated here.
 The possible association of SS with atopic conditions, as proposed previously [22-24], 
remains less clear. We did detect lower NMF and water levels and thinner SC in subjects with 
FLG mutations, which is well-documented in literature [31, 32], albeit indirectly using CRS and 
in a small population. However, despite frequently reporting SS, in line with previous findings 
[37], no differences emerged between the AR and NSS and SS subjects, at least with respect 
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to the inspected parameters. This could be partially due to the overlap in the characteristics 
of subjects in the groups with respect to skin sensitivity and symptoms, making it difficult 
to obtain distinct groups since AD and AR subjects frequently report SS [37]. Despite this 
difficulty, differentiating between subjects with atopy and subjects without atopy is important, 
since SS cannot be solely explained by having this condition [19]. In fact, the higher ceramides/
fatty acids levels found in the forearm of SS subjects compared to AD subjects, together with 
the observation that FLG mutations do not seem to be reported more frequently in the SS group 
compared to NSS subjects, do not support the hypothesis of SS being a subclinical form of 
AD [40]. This is also supported by the lack of association between SS and the dysbiosis of the 
cutaneous microbiota found in a previous study, in contrast with AD, known to be characterized 
by overabundance of Straphylococcus aureus [40, 41]. Yet, should the TRP receptor family be 
involved in underlying SS sensations, this could suggest at least one common interface with 
AD, where these receptors were shown to mediate sensory discomfort and inflammation, at 
least in murine model [40, 42-44].
 In our previous clinical studies we showed a reduced number of mast cells and a 
reduced number of tapes required to strip off the total SC in the lower back of SS compared 
to NSS subjects [21, 35, 36].  It could be tempting to speculate that the stronger expression of 
ceramides in the forearm of SS subjects might be due to a compensating mechanism of the 
primary defect in activation of the innate immune system, or to an impaired intercorneocyte 
adhesion [21, 35, 36, 45]. This hypothesis might not be valid for the cheek, which is characterized 
by a higher number of mast cells compared to other body sites, and thus does not need a 
compensatory mechanism [46].
 Despite the different results on ceramides levels between the forearm and cheek, we 
are of the opinion that the response of SS is rather universal. Farage et al. [47] evaluated 
whether people claiming to have SS in general also claimed to have SS at specific body sites. 
Most descriptions of facial and body skin were consistent with the perception of SS in general 
(60.7% and 68.4% of responders, respectively) or varied by one degree out of four with respect 
to severity (36.7% and 31.3% of responders, respectively). Our previous findings also support 
the hypothesis of a generalized SS based on possibly altered immune responses in SS [21]. 
 The second objective of this study was to investigate whether topicals penetrate faster 
through the skin of subjects with SS compared to subjects with NSS as a result of possible 
barrier function impairment. We found consistently higher levels of glycerol in the superficial 
layers of the SC in NSS subjects compared to SS subjects in the first three minutes after 
application. This might imply a faster spreading of glycerol on the superficial skin of SS because 
of barrier function impairment. Our results clearly demonstrate that CRS has the potential 
to detect differences in such assessment provided that a sufficiently long application time is 
chosen for the exogenous substance to be applied [48].
 As a final remark, we confirm the difficulty of finding correspondences between the 
measurements performed with the macroscopic biophysical methods (TEWL and capacitance) 
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and the molecular composition of the SC measured with CRS, as demonstrated by the lack of 
correlations found in this study. In previous studies, the skin barrier function of SS subjects was 
predominantly analyzed at baseline or after stimulation using these macroscopic biophysical 
methods and significant differences between SS and NSS subjects could rarely be detected [13, 
14, 16, 18, 20, 26, 49, 50]. A range of limitations of these easy-to-use, rapid measurements are 
known [33], and our study demonstrates that more sensitive and specific tools for the in vivo 
analysis of the skin barrier in general and in SS in particular are needed.  
 In conclusion, we propose that SS is not a subclinical form of AD and that the skin 
barrier is not impaired in terms of SC thickness and in terms of water, NMF and ceramides 
content. Treatments of SS solely based on hydration and ceramides supplementation do not 
seem to correspond to the identified SC properties, although benefits have been reported. More 
research efforts should be directed at unraveling the role of the cutaneous nervous system, in 
particular the involvement of TRP channels, on the onset of subjective perceptions of sensitive 
and dry skin. Among other mechanisms to be investigated in SS, we would include the role of 
an altered immune response and intercorneocyte adhesion. 
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Table S4. Supplementary table filaggrin mutations.
FLG+/+ 
median (range)
FLG+/- and FLG-/- 
median (range)n n
CRS parameters Forearm
   SC thickness [µm] 82 16.5 (13.5-24.2) 10 15.7 (14.1-17.9) 0.058
   AUC Water 4-SC [a.u.] 82 612.7 (478.6-1010.0) 10 584.4 (505.8-674.9) 0.071
   Average NMF 4-12µm [a.u.] 82 1.0 (0.6-1.8) 10 0.9 (0.5-1.2) 0.017
   Average Cer 4-12µm [a.u.] 82 44.7 (24.6-81.5) 10 44.4 (33.9-56.0) 1
CRS parameters Cheek
   SC thickness [µm] 84 14.1 (10.8-21.5) 10 13.7 (11.6-14.5) n.s.
   AUC Water 4-SC [a.u.] 84 508.9 (393.4-780.4) 10 491.8 (417.7-562.7) n.s.
   Average NMF 4-8µm [a.u.] 84 0.8 (0.4-1.5) 10 0.7 (0.5-1.2) n.s.
   Average Cer 4-8µm [a.u.] 84 74.7 (35.4-155.1) 10 75.7 (45.1-87.2) n.s.
CRS parameters Thenar
   SC thickness [µm] 85 101.9 (40.1-159.6) 10 66.9 (41.4-120.2) 0.000
   AUC Water 10-SC [a.u.] 85 3917.7 (1401.8-6659.5) 10 2500.0 (1447.8-4279.1) 0.000
   Average NMF 10-50µm [a.u.] 85 1.9 (1.1-2.6) 10 0.9 (0.6-1.1) 0.000
a.u.: arbitrary units; AUC: area-under-curve; Cer: ceramides/fatty acids; CRS: confocal Raman 
microspectrosocpy; FLG-/-: homozygous filaggrin mutation; FLG+/-: heterozygous filaggrin mutation; FLG+/+: 
no filaggrin mutation; n.s.: no statistically significant difference; NMF: natural moisturizing factor; SC: 
stratum corneum.
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Figure S1. Body locations where the measurements with confocal Raman microspectroscopy (CRS) were 
performed.

Chapter 3
Vascular and sensory reactivity 
in sensitive skin
ABBREVIATIONS 
a*  CIE spectrum (Commission Internationale de l’Éclairage): a*, b* and L* values
a.u. arbitrary units
BM Basal membrane
BSA Bovine serum albumin
CLAHE Contrast-limited adaptive histogram equalization
CMOS Complementary metal-oxide semiconductor 
CV Coefficient of variation
DAB  3,3’-diaminobenzidine tetrahydrochloride
DAPI Diamidine phenylindole
HE  Hematoxylin and eosin
IFSI  International forum for the study of itch
LED Light emitting diode
LTB4  Leukotriene B4
NSS  Non-sensitive skin
PBS  Phosphate buffered saline
ROI Region of interest
SC  Stratum corneum
SS  Sensitive skin
TEWL  Transepidermal water loss
VAS  Visual analogue scale
3.1
Histamine iontophoresis as in vivo model to study 
human skin inflammation with minimal barrier 
impairment: pilot study results of application of 
the model to a sensitive skin panel
Falcone D1
Uzunbajakava NE2
Richters RJ1
van de Kerkhof PC1
van Erp PE1
Skin Pharmacol Physiol, 2017. 30(5): 246-259.
1 Department of Dermatology, Radboud University Medical Center,  
Nijmegen, the Netherlands.
2 Philips Research, Eindhoven, the Netherlands.
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ABSTRACT
Background/aims: Histamine iontophoresis is known to elicit itch and a wheal-and-flare 
reaction; however, its impact on the skin barrier and underlying compartments has not been 
thoroughly evaluated yet. The primary objective of this study was to characterize that using 
immunohistochemistry, biophysical measurements and image analysis. Secondly, to explore 
whether skin reactions to this model differ in sensitive skin (SS).
Methods: Eighteen healthy subjects, n=9 with SS and n=9 with non-sensitive skin (NSS), were 
included based on a perception-based questionnaire. Histamine iontophoresis was performed 
on the buttock and skin reactions evaluated up to 72 hours after stimulation. 
Results: The wheal-and-flare peaked at 30 minutes; after 8 hours, no clinical signs were 
visible. No signs of disruption of the stratum corneum, as well as no increase in the number 
of Ki67-positive cells emerged, whereas fewer tryptase-positive mast cells and increased 
epidermal thickness were observed at 1 hour and 72 hours, respectively. SS subjects showed 
higher perception of itch compared with NSS subjects. 
Conclusion: Histamine iontophoresis is a well-standardized in vivo model to quantitatively 
study the early stages of cutaneous inflammation with minimal impact on the skin barrier. In 
line with previous studies, it highlighted increased sensory perceptions in SS. 
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3.1
INTRODUCTION
 The barrier function of the skin is fulfilled primarily by the stratum corneum (SC), 
the outermost layer of the epidermis [1]. The integrity of the SC as skin barrier depends on 
the interplay of several factors, including the process of proliferation of keratinocytes from 
the basal layer, and their gradual differentiation to corneocytes across the epidermis. Upon 
disruption of the SC, the release of mediators from keratinocytes, including several interleukins 
and chemokines [2], prompts the onset of an inflammatory response, resulting in a transient 
infiltrate of immune cells in the dermis, and hyperproliferation and abnormal differentiation in 
the epidermis [3]. 
 In order to study the cutaneous inflammatory response in vivo, human skin models 
can be used. These models consist in the application of minimally invasive and standardized 
challenges to the skin, followed by evaluation of skin reactions at one or several points in 
time. Examples include tape stripping, consisting in repeated application of adhesive tape to 
mimic disruption of the skin barrier in disease or following skin-material interactions [3, 4], 
and application of leukotriene B4 (LTB4) to mimic psoriasis-like infiltration of immune cells in 
the epidermis [5]. In this study, we focus on one such in vivo model: histamine iontophoresis. 
Histamine, either exogenously applied or endogenously released from mast cells, is known to 
elicit a triple response [6, 7]: itch, because of excitation of mechano-insensitive C-fibers [8]; 
wheal, due to increased capillary permeability; and flare, induced by the release of vasoactive 
neuropeptides from afferent nerve fibers [7]. Iontophoresis is based on the use of a small 
and defined electric current to facilitate the transport of ionized molecules across the skin 
barrier [9, 10]. In addition, albeit it cannot entirely avoid passive diffusion and variability 
thereof, iontophoresis is less influenced by the condition of the skin at the application site 
than topically applied molecules on the SC [10]. Histamine iontophoresis has been widely 
used as experimental itch model both in healthy and diseased state [6, 7, 11-13] and has been 
described as a quantifiable model for the study of the early stages of cutaneous inflammation 
[14]. However, to our best knowledge, no study thoroughly evaluated the effect of this model on 
the epidermal and dermal compartments. 
 The primary objective of this study was to characterize the effects of histamine 
iontophoresis on the epidermal and dermal compartments using immunohistochemistry and 
non-invasive assessments including biophysical methods and image analysis. In this respect, 
we propose an easy-to-use method to segment the wheal-and-flare reaction using classical 
image processing techniques. We investigated in particular the impact on the skin barrier, the 
underlying hypothesis being that histamine iontophoresis exerts its effects primarily on the 
dermal vasculature and cutaneous sensory system and can thus be used as a model of acute 
and local skin inflammation with minimal barrier impairment, in contrast with other in vivo 
models such as tape stripping and application of LTB4.
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 As a secondary objective, we explored whether skin responses to histamine iontophoresis 
differ significantly between subjects with sensitive skin (SS) and non-sensitive skin (NSS). 
With as much as 50-61% women and 30-44% men reporting SS in the industrialized world, 
and consensus on the definition and pathomechanism remaining elusive despite extensive 
research [15], SS skin has been identified as a global challenge [16]. However, recent clinical 
studies based on the selection of a SS and NSS panel according to a novel perception-based 
questionnaire [17] and on the application of in vivo skin models followed by clinical, biophysical 
and immunohistochemical analysis, have shown that aberrant vascular and inflammatory 
reactions, accompanied by enhanced sensory reactivity, were the hallmarks of SS [18-20]. We 
thus hypothesized that the triple response elicited by histamine iontophoresis might differ 
between SS and NSS subjects. In addition, since histamine has been reported to be normally 
prevented from entering the skin unless the barrier is compromised [6, 21], topical application 
of histamine was added to evaluate whether stronger reactions possibly observed in SS 
subjects might be due to aberrant properties of the SC [15].
PATIENTS AND METHODS
Study participants
 Potential participants were recruited via websites and asked to fill in the novel 
perception-based questionnaire [17], as previously described [18-20]. Briefly, inclusion was 
based on self-assessed skin sensitivity and on a sensitive skin score obtained by rating skin 
perceptions (i.e. discomfort, stinging, redness, dryness) following exogenous and endogenous 
triggers (i.e. toiletries, shaving, heat, cold, clothes, emotions). The score was compared with 
upper and lower quartiles previously determined [17]. If the score was above the upper quartile 
and the subject reported slightly higher or much higher SS compared to others, he/she was 
included in the group with SS. If the score was below the lower quartile and the subject reported 
equal of lower SS compared to others, he/she was included in the group with NSS. Additional 
criteria for inclusion were Fitzpatrick skin type II-III and willingness to give a written informed 
consent. Pregnant or breastfeeding women and volunteers with a history of skin diseases, 
atopic or allergic predisposition (i.e. atopic dermatitis, asthma, allergic rhinoconjuctivitis), 
use of immunosuppressive drugs, compromised skin at the experimental sites (volar forearm 
and lower back) and presence of implanted electrical devices (e.g. cardiac pacemakers) were 
excluded from participation. Volunteers were asked not to apply toiletries on the experimental 
sites from 24 hours before the experiments and not to sunbathe or use a tanning bed from 
two weeks before the experiments. The study was performed in a temperature- and humidity-
controlled room at the dermatology department of the Radboud University Medical Center in 
Nijmegen, the Netherlands, between April and November 2015, and was approved by the ethics 
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committee Regio Arnhem-Nijmegen. Before the start of the study procedures, volunteers were 
left to acclimatize for 15 minutes with the body sites to be assessed uncovered. 
Randomization
 All subjects underwent the same study procedures up to 60 minutes after histamine 
iontophoresis with respect to the non-invasive measurements, whereas they underwent a 
randomization with respect to the skin biopsies taken at 1, 8, 24 and 72 hours after histamine 
iontophoresis: namely, two biopsies at two out of the four possible time points were taken from 
each volunteer. This design was a compromise between getting insights into skin reactions 
to histamine iontophoresis at the immunohistochemical level and reducing the burden of the 
study for the volunteers. The choice of the time points was based on previous studies [18-20].
Histamine iontophoresis 
 Histamine iontophoresis was performed on the buttock (at the level of the upper side 
of the intergluteal cleft) at 0.4 mA for 2.5 minutes using an iontophoresis sytem (Chattanooga 
Group, Hixson, TN, USA) and a pair of silver-silver chloride electrodes with an active area of 
7.2 cm2 (Iomed Iogel Iontophoresis Electrode small; Chattanooga Group, Hixson, TN, USA), as 
previously described [11, 12]. This resulted in a current density of 0.06 mA/cm2. The active area 
was filled with 1.5 mL of a solution of 0.5% histamine dihydrochloride (Allergopharma B.V., Zeist, 
the Netherlands) in 1% hypromellose gel prepared by the local pharmacy. The pH of the solution 
was 4.5-5.0. Prior to stimulation, the skin areas where the electrodes needed to be applied were 
gently rubbed with a 5 cm x 5 cm tissue (Cutisoft, BSN medical GmbH, Hamburg, Germany) 
soaked in 1.5 mL demineralized water in order to remove sebum and other impurities possibly 
causing localized increased resistance to the ionic flux. Every 15 s during iontophoretic histamine 
application, subjects were asked to rate their level of perceived itch on a visual analogue scale 
(VAS) ranging from 0 (no perception) to 10 (strongest possible itch perception), with 3 being the 
threshold for the willingness to scratch the skin [6]. The average itch score and the time to reach 
the scratching threshold were calculated. To avoid evaporative cooling, remaining amounts of gel 
were wiped off immediately after stimulation [14]. The level of perceived itch was asked also at at 
5, 30 and 60 minutes after histamine iontophoresis.
Topical application of histamine
 Between 30 and 60 minutes after stimulation with histamine iontophoresis, the same 
amount of histamine (1.5 mL) was applied topically on the contra lateral side of the buttock 
(10 cm apart) and, subsequently, on the non-dominant mid volar forearm. Histamine was left 
on the skin for 2.5 minutes and wiped off immediately afterwards. The application area of 2 
cm x 3.5 cm was chosen to approximately match the area of the active electrode. Rating of 
itch perception during topical histamine application and at 5 minutes after wiping off [21] were 
performed as for histamine iontophoresis.
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Non-invasive measurements
 Transepidermal water loss (TEWL) (Aquaflux AF200, Biox, UK) and skin redness (a* 
value) (Spectrophotometer 2600d, Konica Minolta, Japan) were measured at baseline on the 
buttock and on the non-dominant volar forearm, and at 5, 30 and 60 minutes after histamine 
iontophoresis. Depending on the randomization performed for skin biopsies, TEWL and a* value 
were measured on the buttock also at 8, 24 and 72 hours after stimulation. Measurements 
were repeated three times on adjacent skin areas and averaged. 
 Skin photographs were taken at 5, 30 and 60 minutes after histamine iontophoresis with a 
single-lens reflex digital camera (D3200, Nikon, Japan), equipped with a a 32-Light emitting diode 
(LED) ring flash (PLMRFN, Polaroid, USA) to provide a shadow-free illumination. An algorithm, 
implemented in Matlab (version R2013a, The MathWorks Inc., USA), was applied to the digital 
images to segment the wheal-and-flare reaction. Briefly, different combinations of histogram-
based contrast enhancement and thresholding were tested and compared to manual erythema 
segmentation. The best combinations resulted to be the linear histogram-based contrast 
enhancement followed by thresholding with the Isodata method [22] for the reaction at 5 and 30 
minutes, and the non-linear histogram-based contrast ehancement with Isodata thresholding 
for the reaction at 60 minutes. The acquisition set-up and the algorithm are described in the 
supplementary material. 
Tissue processing and immunohistochemistry
 Prior to the biopsy procedure, the skin was cleansed with chlorhexidine 0.5% m/v in alcohol 
70% v/v. Punch biopsies (3 mm) were taken under 1% lidocaine chloride. The specific choice of 
the anesthetic not containing adrenalin as a vasoconstrictor was made not to counteract the 
vasodilating effect of histamine. One additional biopsy was taken from non-challenged skin, serving 
as an internal control. In total, three biopsies were taken from each volunteer. All specimens 
were fixed in 10% formalin for subsequent paraffin embedding and sectioned at 6 µm thickness. 
Paraffin-embedded specimens were deparaffinized in histosafe (Adamas Instrumenten B.V., the 
Netherlands) and rehydrated in decreasing concentrations of alcohol (100-50%) and demineralized 
water. For K16 and filaggrin, xylene (Klinipath B.V., the Netherlands) was used for deparaffinization. 
Antigen retrieval was achieved by citrate buffer (pH 6.0, 10 min at 100°C) for Ki67, CD1a, CD31, 
K16 and filaggrin stainings and by EDTA/Tween-20 (10 mM EDTA, + 0.05% Tween-20, pH 8.0, 10 
min at 100°C) for the CD3 staining. The tryptase antibody did not require antibody retrieval steps. 
Endogenous peroxidase activity was blocked by 3% H2O2 in methanol for Ki67, CD1a, CD31, CD3 
and tryptase antibodies. This step was followed by preincubation in 1% bovine serum albumin 
(BSA) (Sanquin Reagents, the Netherlands) in phosphate buffered saline (PBS) for 15 minutes for 
Ki67 and tryptase antibodies, 30 minutes for CD1a and CD3 antibodies and 60 minutes for CD31 
antibody. For K16 and filaggrin, 5% normal goat serum (Vector Laboratories Inc., USA) in PBS 
for 15 minutes was used. Incubation with primary antibodies dissolved in 1% BSA was performed 
overnight at room temperature, except K16 and filaggrin which were incubated for 60 minutes. The 
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following clones and dilutions were used: Ki67 (1:100, clone MIB-1, Dako), tryptase (1:100.000, clone 
AA1, Dako), CD1a (1:200, clone 010, Dako), CD3 (1:100, clone F7.2.38, Abcam), CD31 (1:80, clone 
JC70A, Dako), K16 (1:50, clone LL025, Biotrend), filaggrin (1:100, polyclonal 19058, BioLegend). 
For all stainings exept K16 and filaggrin, amplification was obtained by EnVision anti-mouse 
(Dako, Glostrup, Denmark) for 45 minutes, visualization of the antibody with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) solution (Sigma-Aldrich, St. Louis, MO) for 10 minutes and counterstaining 
with Mayer’s hematoxylin (Sigma-Aldrich, Saint Louis, USA). Lastly, specimens were dehydrated in 
increasing concentrations of alcohol (50-100%) and histosafe and mounted using Permount glue 
(Thermo Fisher Scientific, Waltham, USA). For K16 and filaggrin, visualization of the antibody was 
obtained with Alexa Fluor 488 conjugate (1:200) and Alexa Fluor 647 conjugate (1:200) (Invitrogen, 
USA) in 1% BSA. Counterstaining and mounting were obtained with Fluoromont-G with diamidine 
phenylindole (DAPI, eBioscience, USA). 
Semiquantitative assessment of immunohistochemical markers
 Specimens were imaged using Axiokop 2 MOT microscope at a magnification of ×200, 
Axiocam MRc5 digital camera and AxioVision software (version 4.8, Carl Zeiss, Germany). 
Semiquantitative analysis of immunohistochemical markers was performed using macro colour 
deconvolution and color thresholding in ImageJ (version 1.49, National Institutes of Health, 
USA). The thickness of the SC and of the viable epidermis were measured in hematoxylin and 
eosin (HE)-stained sections by dividing the SC/viable epidermis area by the average length of 
the basal membrane (BM) (computed as Feret’s distance in ImageJ) [18-20]. Ki67-positive cells 
were expressed as number of cells per mm BM length. CD1a-positive cells were measured as 
percentage of the viable epidermal surface where a positive signal was detected. The dermis 
was assessed from the BM down to 350 µm across the specimen. Tryptase-positive cells were 
expressed as number of cells per mm2 dermis. CD31- and CD3-positive cells were expressed 
as percentage of the dermal surface where a positive signal was detected.
 Immunofluorescence images of K16 and filaggrin were obtained using Axio Imager 
M2 microscope at a magnification of ×200, AxioCam 503 Mono digital camera and ZEN 2 pro 
software (version 5.8, Carl Zeiss, Germany) and qualitatively compared. 
Statistical analysis
 Results are presented as median (minimum-maximum). To answer the primary 
objective of the study, differences between values of the same variable measured at baseline 
and after stimulation with histamine iontophoresis were analyzed with the Wilcoxon sign rank 
test for non-parametric repeated measures. Of note, for the immunohistochemical markers 
measured at 1, 8, 24 and 72 hours and for TEWL and a* value measured at 8, 24 and 72 hours 
following histamine iontophoresis, a paired comparison with baseline values was performed, 
i.e. baseline values from volunteers sampled at other time points were not pooled together. To 
answer the secondary objective of the study, differences between SS and NSS subjects were 
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analyzed at baseline and at 5, 30 and 60 minutes after histamine iontophoresis using the Mann-
Whitney exact test for non-parametric independent values. In the comparison between SS and 
NSS subjects, the following variables were considered: TEWL, a* value, wheal-and-flare area, 
average VAS score for itch during histamine iontophoresis and topical histamine application and 
time to reach the scratching threshold during histamine iontophoresis. Correlations were done 
with the Spearman’s rho. Statistical analyses were performed with SPSS Statistics version 20 for 
Windows (IBM SPSS Inc., USA). A p value ≤0.05 was considered statistically significant. Due to the 
exploratory nature of this study, no corrections for multiple comparisons were applied.
RESULTS
Study population
 A total of 106 potential participants received the questionnaire. Fifty questionnaires were 
returned and, of these, 32 had to be excluded because of the score being outside the proper 
range or because of concomitant presence of skin diseases, atopic or allergic predisposition. 
In total, eighteen subjects were eligible for inclusion in the study, n=9 with SS (one male, eight 
females) and n=9 with NSS (two males, seven females). In both groups, median age was 21 
years old (19-36 in the SS group, 20-32 in the NSS group) and, in both groups, three subjects 
had Fitzpatrick skin type II and six subjects had Fitzpatrick skin type III. The number of subjects 
measured at each time point is described in Table 1.
Table 1. Overview of study procedures and measurements including randomization performed for taking 
skin biopsies at 1, 8, 24 and 72 hours after histamine iontophoresis on the buttock.
Baseline During iontophoresis 5min 30min 1h 8h 24h 72h
TEWL
SS n=9 - n=9 n=9 n=9 n=4 n=4 n=4
NSS n=9 - n=9 n=9 n=9 n=4 n=4 n=4
a* value
SS n=9 - n=9 n=9 n=9 n=4 n=4 n=4
NSS n=9 - n=9 n=9 n=9 n=4 n=4 n=4
VAS score for itch
SS n=9 n=9 n=9 n=9 n=9 - - -
NSS n=9 n=9 n=9 n=9 n=9 - - -
Skin photograph
SS - - n=9 n=9 n=9 - - -
NSS - - n=9 n=9 n=9 - - -
Skin biopsy
SS n=9* - - - n=6* n=4* n=4 n=4
NSS n=9* - - - n=6* n=4 n=4 n=4*
NSS: non-sensitive skin; SS: sensitive skin; TEWL: transepidermal water loss; VAS: visual analogue scale
*Biopsies taken from one volunteer with SS at baseline, at 1h and at 8h, as well as biopsies taken from one 
volunteer with NSS at baseline, at 1h and at 72h could not be evaluated due to damage.
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Figure 1. Representative photographs of skin reactions to histamine iontophoresis in two volunteers (a,b,c 
and d,e,f). a,d) At 5 minutes, early onset of edema and erythema in the stimulated site and of flare in the 
surrounding skin were observed. b,e) At 30 minutes, edema increased while the flare reaction was mostly 
unchanged. c,f) At 60 minutes, the edema and the surrounding flare reaction generally decreased, and in 
most volunteers an irregularly dotted erythema pattern appeared in correspondence of the wheal.
Histamine iontophoresis: clinical assessment and non-invasive measurements
 Representative wheal-and-flare reactions at 5, 30 and 60 minutes after histamine 
iontophoresis are shown in Figure 1. At 8, 24 and 72 hours no wheal or flare were longer visible 
in skin photographs.
 The values of TEWL, a* value and wheal-and-flare area measured at baseline and at 
5, 30 and 60 minutes after histamine iontophoresis are shown in Figure 2. In both SS and NSS 
subjects, TEWL increased by approximately 3.5 g/m2h at 5 minutes and started to recover at 30 
minutes, yet at 60 minutes it remained slightly but significantly higher than baseline (p≤0.05). 
In both SS and NSS subjects, the a* value increased by approximately 6 arbitrary units (a.u.) at 
5 minutes and remained significantly higher than baseline up to 60 minutes (p≤0.05). Similarly, 
in both SS and NSS subjects, the wheal-and-flare area at 30 minutes was generally comparable 
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Table 3. Biophysical measurements and (immuno)histochemical markers measured at baseline and at 8, 
24 and 72 hours after histamine iontophoresis.
All (randomized) SS NSS
n med range p value n med range n med range
Biophysical measurements
TEWL [g/m2h]
     Baseline 8h 8 9.6 (8.7-14.0)
n.s.
4 9.4 (8.7-11.5) 4 10.3 (8.8-14.0)
     8h 8 9.8 (9.3-16.3) 4 9.7 (9.4-10.5) 4 10.4 (9.3-16.3)
     Baseline 24h 8 10.9 (8.3-16.8)
n.s.
4 12.3 (10.2-16.8) 4 9.8 (8.3-13.0)
     24h 8 10.8 (6.9-15.7) 4 11.9 (9.4-15.7) 4 9.2 (6.9-15.5)
     Baseline 72hh 8 12.8 (8.7-16.8)
n.s.
4 12.4 (8.7-16.8) 4 13.5 (11.6-14.7)
     72h 8 12.4 (9.2-17.3) 4 12.8 (9.2-17.3) 4 12.2 (10.7-14.9)
a* value [a.u.]
     Baseline 8h 8 4.2 (1.9-6.7)
n.s.
4 5.4 (1.9-6.7) 4 4.0 (3.5-5.3)
     8h 8 5.2 (2.2-7.3) 4 6.7 (2.2-7.3) 4 4.5 (3.5-5.2)
     Baseline 24h 8 4.6 (3.4-6.6)
0.078
4 4.9 (3.6-6.6) 4 3.9 (3.4-5.6)
     24h 8 5.5 (4.0-6.5) 4 5.6 (4.0-6.5) 4 5.1 (4.2-6.1)
     Baseline 72h 8 4.2 (1.9-5.6)
0.023
4 4.1 (1.9-4.8) 4 4.7 (4.0-5.6)
     72h 8 4.4 (2.3-5.9) 4 4.3 (2.3-5.9) 4 5.0 (3.8-7.2)
Epidermal markers
SC thickness [µm]
     Baseline 1h 10 19.3 (16.5-32.5)
n.s.
5 21.3 (17.5-29.6) 5 17.3 (16.5-32.5)
     1h 10 19.5 (15.0-37.2) 5 20.5 (18.9-28.1) 5 18.6 (15.0-37.2)
     Baseline 8h 7 18.2 (15.6-29.6)
n.s.
3 18.5 (18.2-29.6) 4 16.9 (15.6-20.1)
     8h 7 18.6 (16.1-27.1) 3 23.2 (21.0-27.1) 4 18.0 (16.1-18.6)
     Baseline 24h 8 17.9 (11.3-32.5)
n.s.
4 19.9 (11.3-22.7) 4 16.4 (14.0-32.5)
     24h 8 18.3 (11.4-40.3) 4 22.5 (11.4-26.3) 4 16.1 (15.7-40.3)
     Baseline 72h 7 18.2 (11.3-20.1)
n.s.
4 17.9 (11.3-18.4) 3 20.1 (14.0-20.1)
     72h 7 19.3 (13.7-22.5) 4 17.5 (13.7-21.3) 3 20.4 (16.3-22.5)
Epidermis thickness [µm]
     Baseline 1h 10 64.3 (58.8-78.1)
0.065
5 64.8 (61.3-69.2) 5 63.0 (58.8-78.1)
     1h 10 67.5 (61.7-75.5) 5 66.1 (61.7-70.2) 5 69.6 (64.8-75.5)
     Baseline 8h 7 67.7 (63.0-80.9)
n.s.
3 67.7 (64.8-69.2) 4 71.1 (63.0-80.9)
     8h 7 67.8 (56.2-81.5) 3 67.8 (67.2-76.9) 4 73.4 (56.2-81.5)
     Baseline 24h 8 63.9 (58.8-79.4)
0.055
4 65.7 (61.3-79.4) 4 62.7 (58.8-75.5)
     24h 8 70.4 (65.7-82.9) 4 71.3 (65.7-72.8) 4 68.8 (66.4-82.9)
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All (randomized) SS NSS
n med range p value n med range n med range
     Baseline 72h 7 69.2 (65.0-80.9)
0.016
4 69.2 (65.7-79.4) 3 75.5 (65.0-80.9)
     72h 7 80.3 (71.3-86.3) 4 78.4 (72.1-84.6) 3 80.3 (71.3-86.3)
Ki67 (cells/mm BM)
     Baseline 1h 10 40.8 (23.5-50.0)
n.s.
5 44.0 (23.5-50.0) 5 32.8 (26.0-49.3)
     1h 10 30.7 (23.8-52.8) 5 38.6 (26.6-52.8) 5 28.1 (23.8-39.6)
     Baseline 8h 7 39.7 (23.5-59.9)
n.s.
3 28.6 (23.5-29.8) 4 48.4 (29.2-59.9)
     8h 7 47.8 (28.8-50.1) 3 47.8 (46.0-50.1) 4 44.4 (28.8-49.4)
     Baseline 24h 8 46.7 (27.8-50.3)
n.s.
4 47.0 (28.6-50.0) 4 41.0 (27.8-50.3)
     24h 8 43.9 (22.4-53.3) 4 43.3 (34.3-53.3) 4 44.7 (22.4-51.5)
     Baseline 72h 7 39.7 (26.0-59.9)
n.s.
4 43.1 (37.6-50.0) 3 27.8 (26.0-59.9)
     72h 7 39.9 (33.4-85.3) 4 57.1 (33.7-85.3) 3 39.9 (33.4-52.0)
CD1a (% epidermis)
     Baseline 1h 10 4.4 (3.2-6.3)
n.s.
5 3.6 (3.2-5.4) 5 4.5 (4.2-6.3)
     1h 10 4.1 (3.2-6.9) 5 3.9 (3.2-6.9) 5 4.2 (4.0-4.7)
     Baseline 8h 7 4.4 (3.0-6.6)
n.s.
3 3.6 (3.0-5.7) 4 4.4 (3.9-6.6)
     8h 7 4.6 (2.6-7.0) 3 3.6 (3.5-6.1) 4 4.6 (2.6-7.0)
     Baseline 24h 8 4.5 (3.2-5.7)
n.s.
4 3.9 (3.2-5.7) 4 4.5 (3.9-4.9)
     24h 8 4.7 (2.6-5.5) 4 5.0 (3.1-5.5) 4 3.7 (2.6-5.4)
     Baseline 72h 7 4.9 (3.0-6.6)
n.s.
4 4.5 (3.0-5.4) 3 6.3 (4.9-6.6)
     72h 7 4.9 (1.9-6.0) 4 4.3 (1.9-4.9) 3 5.0 (5.0-6.0)
Dermal markers
CD3 (% dermis)
     Baseline 1h 10 0.2 (0.1-0.8)
n.s.
5 0.6 (0.1-0.8) 5 0.2 (0.1-0.2)
     1h 10 0.2 (0.1-0.5) 5 0.3 (0.2-0.5) 5 0.2 (0.1-0.5)
     Baseline 8h 7 0.3 (0.1-0.5)
n.s.
3 0.4 (0.3-0.5) 4 0.3 (0.1-0.4)
     8h 7 0.2 (0.1-0.7) 3 0.2 (0.1-0.3) 4 0.3 (0.2-0.7)
     Baseline 24h 8 0.2 (0.1-0.7)
n.s.
4 0.3 (0.1-0.7) 4 0.2 (0.1-0.6)
     24h 8 0.4 (0.1-1.0) 4 0.4 (0.3-0.5) 4 0.5 (0.1-1.0)
     Baseline 72h 7 0.3 (0.2-0.8)
n.s.
4 0.3 (0.2-0.8) 3 0.4 (0.2-0.6)
     72h 7 0.5 (0.2-0.6) 4 0.4 (0.2-0.5) 3 0.5 (0.5-0.6)
CD31 (% dermis)
     Baseline 1h 10 1.0 (0.4-1.9)
n.s.
5 1.2 (0.7-1.9) 5 0.8 (0.4-1.1)
     1h 10 1.0 (0.8-1.8) 5 1.1 (0.9-1.8) 5 0.9 (0.8-1.4)
     Baseline 8h 7 1.2 (0.4-1.7)
n.s.
3 1.2 (1.2-1.7) 4 1.1 (0.4-1.4)
     8h 7 0.8 (0.7-1.4) 3 1.1 (0.8-1.4) 4 0.7 (0.7-0.8)
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All (randomized) SS NSS
n med range p value n med range n med range
     Baseline 24h 8 1.2 (0.5-1.7)
n.s.
4 1.1 (0.7-1.7) 4 1.2 (0.5-1.7)
     24h 8 1.0 (0.6-1.4) 4 1.2 (0.8-1.4) 4 0.9 (0.6-1.4)
     Baseline 72h 7 1.2 (0.8-1.9)
n.s.
4 1.1 (0.9-1.9) 3 1.2 (0.8-1.7)
     72h 7 1.0 (0.6-1.5) 4 1.1 (0.6-1.4) 3 0.8 (0.7-1.5)
Tryptase (cells/mm2 dermis)
     Baseline 1h 10 117.0 (79.7-129.4)
0.037
5 114.7 (79.7-129.4) 5 118.4 (85.8-126.1)
     1h 10 101.0 (76.0-119.5) 5 104.4 (76.0-112.1) 5 98.0 (79.1-119.5)
     Baseline 8h 7 80.6 (61.1-124.5)
n.s.
3 80.6 (79.7-86.3) 4 96.9 (61.1-124.5)
     8h 7 76.4 (66.4-99.6) 3 67.2 (66.4-76.4) 4 90.6 (66.9-99.6)
     Baseline 24h 8 107.0 (61.1-128.1)
n.s.
4 107.2 (80.6-123.8) 4 112.1 (61.1-128.1)
     24h 8 102.0 (70.1-141.7) 4 96.9 (70.1-122.8) 4 114.6 (74.5-141.7)
     Baseline 72h 7 105.0 (75.3-129.4)
n.s.
4 109.8 (86.3-129.4) 3 85.8 (75.3-128.1)
     72h 7 122.0 (67.3-156.2) 4 129.3 (67.3-147.5) 3 84.0 (71.4-156.2)
BM: basement membrane; med: median; n.s.: no statistically significant difference; NSS: non-sensitive 
skin; SC: stratum corneum; SS: sensitive skin.
p values obtained with Wilcoxon sign rank test for non-parametric repeated measures.
to the area at 5 minutes, whereas it decreased at 60 minutes. No differences between SS and 
NSS subjects emerged for either TEWL, a* value or the wheal-and-flare area. There was no 
correlation between the a* value and the wheal-and-flare area measured at 5 and 30 minutes, 
whereas a weak yet significant correlation was present at 60 minutes (rho = 0.512, p=0.030, 
n=18). The numerical data are reported in Table 2. 
 At 8, 24 and 72 hours, considering both groups together, no differences with respect 
to baseline were present for TEWL, while the a* value was slightly higher at 24 and 72 hours 
(p=0.078 and p=0.023, respectively). The numerical data are reported in Table 3. 
Histamine iontophoresis: VAS score for itch
 The average VAS score for itch measured during stimulation and the time necessary to 
reach the scratching threshold were not different between the groups: average VASSS = 4.3 (1.6-
6.8), average VASNSS = 4.1 (0.6-6.6), time to thresholdSS = 30 s (0 s-120 s), time to thresholdNSS = 
37.5 s (15 s-75 s). One subject with NSS never perceived VAS scores higher than the scratching 
threshold. 
 At 5 minutes after histamine iontophoresis, all subjects except one NSS subject still 
reported some itch. At 30 minutes, remaining perceptions were reported by two subjects with 
NSS and eight with SS. At 60 minutes, this was the case only for three subjects with SS. Values 
are shown in Figure 2 and numerical data are reported in Table 2. 
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Figure 2. The values of TEWL (a), a* value (b), wheal-and-flare area (c) and average VAS score for itch (d) 
measured at baseline and after histamine iontophoresis in volunteers with sensitive skin (SS, n=9) and 
non-sensitive skin (NSS, n=9). Values at baseline and up to 60 minutes after histamine iontophoresis were 
measured in all volunteers (n=18). Values at 8, 24 and 72 hours were measured in a subgroup of volunteers 
according to the randomization described in the Materials and Methods. Graphs represent median and 
range (minimum-maximum).
Histamine iontophoresis: histological and immunohistochemical markers
 The HE staining revealed no effects of histamine iontophoresis on the SC in terms of 
change of thickness or presence of parakeratosis. On the other hand, the living epidermis 
showed a trend to increased thickness at 1 and 24 hours after histamine iontophoresis (p=0.065 
and p=0.055, respectively) and was significantly thicker at 72 hours (p=0.016). No inflammatory 
infiltrates in the epidermis or dermis were observed. Representative HE images are shown in 
Figure 3. 
 In the epidermal compartment, immunohistochemical stainings neither showed 
changes in the number of CD1a-positive cells nor in the number of Ki67-positive cells. Of 
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note, a slight increase of the latter was present only in two SS subjects at 72 hours. In the 
dermal compartment, no influx of CD3-positive cells or changes in the area covered by CD31-
positive cells were visible. A significant decrease in the number of tryptase-positive mast cells 
was observed at 1 hour after histamine iontophoresis (p=0.037). Representative images of the 
immonohistochemical stainings are shown in Figure 4, whereas the numerical data for each 
marker are reported in Table 3. 
 Qualitative assessment of the immunofluorescence staining revealed no presence of 
increased expression of K16 at any time point, whereas a slight increase in the intensity of the 
filaggrin signal could be detected at 24 and 72 hours in about half of the volunteers assessed 
at these time points. Representative images are shown in Figure 5. 
Figure 3. Representative HE photographs of skin reactions to histamine iontophoresis in two volunteers 
(a,b,c, and d,e,f). a,d) Control skin. b) At 1 hour, spongiosis is present in the epidermis. No changes in the 
stratum corneum are visible. c) At 8 hours, no changes compared to control skin are visible. e,f) At 24 and 
72 hours, a slight increase in the epidermal thickness is visible. No atypia is observed, albeit the higher 
intercellular spaces in the upper stratum spinosum and in the stratum granulosum indicate spongiosis 
(more pronounced at 72 hours). No changes in the stratum corneum nor influx of inflammatory infiltrates 
in either the epidermis and dermis are visible.
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Figure 4. Representative photographs of immunohistochemical data. Tryptase-positive mast cells 
decreased significantly at 1 hour after histamine iontophoresis (b) compared to control skin (a). Ki67-
positive nuclei, CD1a-positive cells, CD3-positive cells and CD31-positive cells showed no change at 72 
hours after histamine iontophoresis (d,f,h,l, respectively) compared to control skin (c,e,g,i, respectively).
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Figure 5. Representative immunofluorescence photographs of expression of K16 (green) and filaggrin 
(red) in two volunteers (a-f and g-n, respectively) at baseline (a,b,c and g,h,i) and at 72 hours after 
histamine iontophoresis (d,e,f and l,m,n). Diamidine phenylindole was used as counterstaining (blue). In 
both volunteers, no expression of K16 can be detected at baseline (b,h) or at 72 hours after histamine 
iontophoresis (e,m), whereas a slightly increased intensity in the filaggrin signal is visible at 72 hours (f,n) 
compared to control skin (c,i). The last row (o,p,q) shows an example of psoriatic skin, used as positive 
control for the increased suprabasal expression of K16 (p) and as negative control for the absence of 
filaggrin expression (q) compared to normal skin.
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Topical application of histamine
 In the buttock, during topical histamine application, five subjects with NSS and four 
with SS did not perceive any sensation. The remaining volunteers had only transient and 
subthreshold perceptions, with no differences between SS and NSS subjects except one subject 
with SS who reported itch values above the scratching threshold: average VASSS = 0.5 (0.0-4.1), 
average VASNSS = 0.0 (0.0-0.8). At 5 minutes, two subjects with SS had remaining perceptions 
(VAS score of 1 and 5). One subject with NSS and one with SS developed a slight erythema, 
while edema was not visible in any volunteer. 
 In the non-domintant mid volar forearm, baseline TEWL values were higher in subjects 
with SS: TEWLss = 12.0 g/m2h (8.6-16.9), TEWLNSS = 10.6 g/m
2h (6.6-14.3) (p=0.031), whereas a* 
values were not different: a* valuess = 6.2 a.u. (3.1-8.3), a* valueNSS = 6.2 a.u. (3.4-8.1). During 
topical histamine application, seven subjects with NSS and four with SS did not perceive any 
sensation. The remaining volunteers had only transient and subthreshold perceptions, with no 
differences between SS and NSS subjects except one subject with SS who reported itch values 
above the scratching threshold: average VASSS = 0.5 (0.0-4.6), average VASNSS = 0.0 (0.0-0.5) 
(p=0.063). At 5 minutes, two subjects with SS had remaining perceptions (VAS score of 2). One 
subject with SS developed a slight erythema, while edema was not visible in any volunteer. 
DISCUSSION
 The primary objective of this study was to characterize the effects of histamine 
iontophoresis on the epidermal and dermal compartments combining invasive 
(immunohistochemistry) and non-invasive assessments. 
 We confirm that histamine iontophoresis is a quantifiable model for the study of the 
early stages of cutaneous inflammation [14], as indicated by the fast onset of the wheal-and-
flare reaction at 5 minutes. This acute reaction was mirrored by presence of spongiosis in the 
epidermis (Figure 3), possibly due to the underlying increased capillary permeability, and by 
the decrease of tryptase-positive mast cells, possibly indicative of degranulation induced by 
the vasoactive peptides released by histamine [23]. No clinical signs of irritation were visible 
at time points later than 1 hour. On the other hand, the lack of activation of Langerhans cells 
in the epidermis and of influx of T-cells in the dermis, evidenced by the unchanged numbers 
of CD1a- and CD3-positive cells, respectively, confirms that this model (at least with the 
parametrs chosen in this study) is not suitable for studying key mediators of adaptive immunity 
activated by sustained inflammation. For studying these mediators other in vivo models such 
as tape stripping and application of LTB4 would be more appropriate [3-5].
 We confirm our hypothesis that histamine iontophoresis causes local and acute 
cutaneous inflammation with minimal barrier impairment. The minimal barrier impairment 
was demonstrated by the minor increase and fast recovery of TEWL and by the absence of an 
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increased proliferative response [24]. Previous works already suggested that the effects of 
iontophoresis at modest current densities (<0.5 mA/cm2) on TEWL are largely accounted for by 
hydration induced throught the contact with the solution to be administered [25], albeit possible 
disorganization of the lipid bilayers in the SC cannot be ruled out [26]. On the other hand, 
histology showed that this model had secondary effects in the epidermal compartment, since a 
slight yet significant increase in epidermal thickness was present at 72 hours. In absence of an 
increased proliferative response, the thicker epidermis might be partly attributed to an effect 
on late-differentiation markers like filaggrin. Iontophoresis was previously shown to induce the 
loss of the epidermal calcium gradient, and in turn the loss of the epidermal calcium gradient 
has been shown to decrease differentiation-specific markers [27, 28]. In in vitro experiments on 
human keratinocytes it was observed that the addition of histamine reduced the expression of 
differentiation-specific proteins [29]. The slightly higher expression of filaggrin observed at 24 
and 72 hours might thus be a reaction to a transient decrease caused by either iontophoresis or 
histamine or by the two combined. Another possible explanation might be that the spongiosis 
elicited by the acute histamine reaction, together with an intact skin barrier limiting free 
movement of water, could have induced an unbalance in the water transport at the interface 
between the living epidermis and the SC; hence the higher intercellular spaces visible in the 
HE images (Figure 3). The increase in epidermal thickness at 24 and 72 hours might in turn be 
responsible for the change in the a* value measured at these time points.  
 The secondary objective of this study was to explore whether skin responses to 
histamine iontophoresis differ significantly between SS and NSS subjects. The only significant 
difference was a higher VAS score for itch at 30 minutes after stimulation. The occurrence of 
increased sensory perceptions in SS is in agreement with the results reported by previous 
clinical studies [18-20], and it has been recognized by the International Forum for the Study of 
Itch (IFSI), which has recently initiated a special interest group on SS [30]. On the other hand, in 
contrast to the aberrant vascular reactions in SS reported previously [20], we could not detect 
differences in skin redness measured by the a* value or in the extent of the wheal-and-flare 
reaction measured by image analysis. One reason could be due to the low number of volunteers 
included in each group, preventing to identify subtle differences between SS and NSS subjects. 
Another reason could be due to insufficient sensitivity and specificity of the measurements 
used. The a* value is of difficult interpretation in this model, since it is known to be influenced 
by several factors among which edema [31], blood volume, and vasodilation [32], all variables 
affected by histamine. To get more insights into the vascular reactions, additional parameters 
could be evaluated, for example the reflectance spectra from the skin [32], the extent and 
topographical map of the wheal [33], and the changes in concentration/velocity of erythrocytes 
[34]. The lack of differences in VAS score for itch during topical histamine application on the 
buttock and on the volar forearm do not support a major impairment of the skin barrier in SS, 
contrary to other conditions (e.g. atopic dermatitis, dandruff) in which topical histamine was 
shown to elicit an itchy response [7, 21]. However, the higher baseline TEWL and the trend to 
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higher VAS score reported by SS subjects during topical histamine application on the volar 
forearm suggest subtle aberrant properties of the SC, which should be evaluated with more 
sensitive and specific approaches [35]. 
 In conclusion, we propose that histamine iontophoresis can be used as in vivo model to 
elicit local and acute skin inflammation with minimal impact on the skin barrier, in contrast to 
tape stripping and topical application of irritants in which the skin barrier is disrupted either 
mechanically or chemically. In particular, this model could be applied to skin disorders in which 
aberrant cutaneous mast cells and their mediators play a role; for example, to investigate 
the still poorly-defined pathomechanisms underlying chronic spontaneous urticaria [36], or to 
help the diagnosis of different variants of mastocytosis [37]. The effect of the model on mast 
cells dynamics could be analyzed directly in skin biopsies; otherwise, mast cell degranulation 
could be indirectly assessed by microdialysis and subsequent histamine measurement [38]. 
Concomitant biophysical measurements can be added to assess the effects of the model at 
the (sub)clinical scale. Of note, the status of the barrier function should be assessed before 
application of the model, to control whether abnormal skin reactions should be related to 
aberrant barrier properties rather than to a different mast cells dynamics [7]. Should differential 
responses compared to controls emerge, further clinical trials could employ the histamine 
iontophoresis model also to monitor disease activity and the response to treatments. With 
respect to the evaluation of aberrant vascular reactions in SS, future studies using histamine 
iontophoresis should include a higher number of volunteers and evaluate the wheal-and-flare 
reaction with sensitive and specific approaches [32-34]. 
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SUPPLEMENTARY MATERIAL
MATERIALS AND METHODS
Acquisition set-up
 Skin photographs were acquired using a commercially available single-lens reflex digital 
camera (D3200, Nikon, Japan), equipped with a complementary metal-oxide semiconductor 
(CMOS) sensor (23.2 mm x 15.4 mm, 24.2 megapixels) and with a 18-55 mm zoom lens. 
To provide a shadow-free illumination, a 32-white light LED ring flash (PLMRFN, Polaroid, 
USA) with a color temperature of 5500 K was mounted on the camera. All experiments were 
performed under the same ambient light conditions (neon-lighting from the ceiling, curtains 
closed to avoid daylight). A circular sticker of known area was attached to the skin and used to 
estimate the area of the wheal-and-flare (in cm2) by a mathematical proportion between the 
pixels belonging to the sticker and to the erythema [1]:
Areaerythema=
(Pixelsticker *Pixelerythema)
Areasticker 
Skin photographs were taken while holding manually the camera perpendicular to the skin and 
the sticker, at a distant sufficient to image the wheal-and-flare reaction and the sticker. The 
following settings were used to take photographs:
 -  Manual focus and mode (M) – aperture and shutting speed adjusted to match optimal 
exposure;
 -  Focal length 55 mm; 
 -  ISO 200;
 -  Image quality “FINE” – corresponding to JPEG images with a low (1:4) compression 
ratio;
 -  Color space sRGB;
 -  Ring flash in continuous (“Light”) mode;
 -  Preset manual white balance – obtained by acquiring an image of a white A4-sized 
sheet in the experimental conditions (ambient lighting and ring flash in continuous 
mode).
Contrast enhancement: histogram stretching and equalization 
 The histogram of a grey-level image X represents the number of pixels nm for each 
grey level m=0,1,...,L–1 belonging to the image. In histogram equalization, the histogram is 
flattened across the dynamic range  [0, L–1] so that the cumulative histogram, or cumulative 
(1)
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density function, approximates a linear ramp. Each pixel of the contrast-enhanced image Y can 
be expressed with the following formula:
Yi=floor[(L-1)
Xi
m=0
P(Xm)]Σ
Where n represents the total number of pixels in the image, P(Xm)= 
nm
n  is the normalized 
histogram and floor [ ] rounds down to the nearest integer. 
In histogram stretching, the histogram is stretched between a minimum and maximum grey 
level, mostly the dynamic range [0, 255]. Each pixel of the contrast-enhanced image Y can be 
expressed with the following formula:
Yi= 255 *
[Xi – min(X)]
γ
[max(X) – min(X)]
Where min(X) and max(X) represent the maximum and minimum grey level in X, respectively. 
If γ = 1 the histogram is linearly stretched across the predefined dynamic range, while if γ > 1 
the histogram is non-linearly stretched with greater emphasis on enhancing contrast of high 
grey levels.
Thresholding: Otzu’s method and Isodata algorithm
 Thresholding is the process of reducing a grey-level image into a binary image by 
selecting a grey level M so that all pixels with grey level m ≥ M are classified as belonging to 
the object of interest and all pixels with grey level  m < M are classified as belonging to the 
background. The selection of the most suitable threshold M can be improved by increasing the 
separation between peaks in histogram stretching or equalization. Two widely used approaches 
for thresholding are the Otzu’s method and the Isodata algorithm. In Otzu’s method [2], the 
threshold M is chosen by maximizing the variance (distance) between the object and the 
background. In the Isodata method [3], the threshold M is iteratively computed as the average 
between the average grey level of the background and of the object. The algorithm stops when 
the absolute difference between the thresholds M obtained in iterations k and k –1 is lower 
than a predefined value . 
Algorithm for segmentation of histamine-induced wheal-and-flare 
 The algorithm for erythema segmentation is based on the use of built-in functions 
implemented in Matlab (version R2013a, The MathWorks Inc., USA). The first step consists 
in manually choosing a rectangular Region of Interest (ROI) containing the wheal-and-flare 
reaction. The ROI is converted from the RGB to the CIE Lab color space, in which color is 
expressed as a three-dimensional quantity defined by an L*-axis (brightness), a*-axis (red-
(2)
(3)
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green chromaticity) and b*-axis (yellow-blue chromaticity) [4, 5]. All subsequent steps are 
performed on the ROI representing a*, since erythema induces a significant increase in this 
component making it particularly suited for its evaluation [4-6]. The white point corresponding 
to the CIE standard illuminant “d55” is used in the conversion between RGB and CIE Lab [6]. 
As a pre-processing step, contrast-limited adaptive histogram equalization (CLAHE) is applied 
on small ROI regions (10 x 10 pixels) in order to decrease the occurence of inhomogeneities in 
the background of the ROI. Subsequently, global contrast enhancement in the range 0-225 and 
thresholding are performed. Six segmented binary images are obtained by combining the three 
histogram-based contrast enhancement techniques (histogram equalization and histogram 
stretching with γ = 1 and γ = 2) with the two thresholding methods (Otzu’s and Isodata). The aim 
was to compare these combinations to find the most suitable for segmenting the histamine-
induced wheal-and-flare. As a fourth step, post-processing on the binary images is performed: 
firstly, a median filter of dimension 10 x 10 pixels is applied to eliminate spurious pixels and 
smoothen the boundary of the segmented wheal-and-flare; secondly, empty regions inside the 
segmented erythema are “filled”, to include pixels belonging to the centrally-developed edema 
to the total area affected by the histamine reaction. Because this segmentation approach is 
based only on the pixel intensities and is independent of the shape and configuration of the 
object of interest, pixels belonging to the borders or to outer regions of the wheal-and-flare 
could be segmented as well. This issue is solved in the last step by automatically selecting 
the biggest segmented area in the ROI, which corresponds to the total area affected by the 
histamine reaction. 
 In addition to manually select the ROI containing the histamine-induced wheal-and-
flare, the user is asked to manually select another ROI containing the sticker. The segmentation 
of the sticker is performed to calculate the pixels belonging to it in order to apply (1) to the 
segmented wheal-and-flare. The steps of the algorithm are summarized in Figure S1. 
 Of note, the application of the algorithm is suitable when the flare surrounds the wheal 
in the characteristic wheal-and-flare reaction. In our experiments we noticed, however, that 
when the histamine reaction decreased (usually starting between 30 and 60 minutes after 
application), the flare decreased in extent and intensity, not necessarily symmetrically around 
the wheal. In addition, in most volunteers an irregularly dotted erythema pattern appeared 
in correspondence of the wheal. We propose therefore a variant of the algorithm in which no 
application of CLAHE in the pre-processing step nor filling and selection of the biggest area in 
the post-processing step are performed, the reasons being the irregularity in shape and the 
limited extention of the flare in later time points, not involving background inhomogeneities 
in skin color. Although the lack of selection of the biggest segmented area may result in the 
possible inclusion of spurious pixels belonging to outer regions, we noticed that the selection 
of a small ROI close to the flare could partially overcome this issue resulting in satisfactory 
results.  
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Figure S1. Algorithm for histamine-induced wheal-and-flare segmentation consisting in histogram-
based contrast enhancement and thresholding. All steps are implemented in Matlab (version R2013a, The 
MathWorks Inc., USA).
Data analysis
 The algorithm was used to segment the wheal-and-flare reaction at 5 and 30 minutes 
after histamine iontophoresis. Since in most volunteers a clear decrease in the reaction was 
visible at 60 minutes after histamine iontophoresis, the variant of the algorithm was applied at 
this time point. 
 In order to test the accuracy of the algorithm, the wheal-and-flare reaction on the 
original ROI was segmented manually by pointing as many points as needed on its border 
[7]. The area of this polygon was calculated using (1) and used as reference to evaluate the 
accuracy using a border detection error coefficient, or XOR [8]:
XOR=
(Pixelmanual Pixelerythema)
Pixelmanual
Where  is the exclusive-OR operation giving the pixels for which the semiautomatically and 
manually segmented areas disagree. To test reproducibility, the algorithm and the manual 
selection were repeated three times for each image and the coefficient of variation (CV) was 
computed. Results are presented as mean ± SD.
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Also the variant of the algorithm was tested three times on each image and the CV was 
computed. In this case, no manual segmentation was performed and results are qualitatively 
presented.
RESULTS
 The algorithm was tested on all 18 volunteers at 5 and 30 minutes after histamine 
iontophoresis. The area, CV and XOR obtained with the six combinations are presented in Table 
S1. 
 The method based on histogram equalization (“Histeq”) provided satisfactory results 
but was in general slightly conservative (i.e. it tended to segment a smaller area belonging to 
the wheal-and-flare reaction compared to the manual segmentation). In addition, at 5 minutes 
and in three volunteers, one to two repetitions of the algorithm provided a poor segmentation 
(i.e. the area belonging to the wheal-and-flare reaction was only partially segmented). At 30 
minutes the performance of the algorithm improved, since the poor segmentation occurred in 
two volunteers and for just one repetition. The thresholding with Otsu’s and Isodata methods 
yielded the same outcome. The method based on linear histogram stretching (“Imadjustγ=1”) 
provided the best results in terms of accuracy (hence the lowest XOR). However, at 5 minutes 
after stimulus, two to three repetitions in three volunteers for the Otsu’s method and in one 
volunteer for the Isodata method erroneously segmented a part of the background of the ROI 
due to strong skin color differences between the sun exposed and non-exposed areas. At 30 
minutes, this was the case in the same volunteers but occurred only in one to two repetitions. 
The method based on non-linear histogram stretching (“Imadjustγ=2”) yielded the worst 
performance at 5 minutes, in which poor segmentation occurred in five (Otsu’s method) and 
three (Isodata method) volunteers (hence the highest XOR). The method improved at 30 minutes 
but, especially using Otsu’s thresholding, it remained conservative and poor segmentation 
occurred in two volunteers. Representative segmentation results are shown in Figure S2. 
 The variant of the algorithm was tested on all 18 volunteers at 60 minutes after histamine 
iontophoresis. The area and CV obtained with the six combinations are presented in Table S2. 
 The method based on histogram equalization was the least robust to low-contrast 
erythema borders and tended to include spurious pixels belonging to the background, whereas 
the method based on non-linear histogram stretching was the most conservative and the 
most reproducible as demonstrated by the lowest CV. The method based on linear contrast 
enhancement had an intermediate behaviour. Thresholding with Otsu’s or Isodata methods 
yielded equal results for the histogram equalization and similar results for the linear histogram 
stretching approaches, while for the non-linear histogram stretching approach, Otsu’s method 
was more conservative than the Isodata. Representative segmentation results are shown in 
Figure S3. 
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Table S1. Results of the algorithm for segmentation of histamine-induced wheal-and-flare at 5 minutes 
(n=18) and 30 minutes (n=18) after histamine iontophoresis.
Method Area  
T5min [cm
2]
CV  
T5min [%]
XOR  
T5min [%]
Area  
T30min [cm
2]
CV  
T30min [%]
XOR  
T30min [%]
Manual 23.7 ± 5.7 3.5 ± 1.7 - 22.3 ± 5.1 4.5 ± 1.6 -
Histeq Totsu 21.9 ± 5.5 7.0 ± 6.9 24.1 ± 8.5 20.3 ± 4.4 6.1 ± 3.2 21.3 ± 5.4
Histeq Tiso 21.9 ± 5.5 7.0 ± 6.9 24.1 ± 8.5 20.3 ± 4.4 6.1 ± 3.2 21.3 ± 5.4
Imadjustγ=1 Totsu 25.3 ± 6.9 4.5 ± 3.8 21.6 ± 4.7 23.7 ± 6.4 3.5 ± 3.4 20.2 ± 5.0
Imadjustγ=1 Tiso 24.0 ± 6.3 3.3 ± 3.0 20.8 ± 5.5 22.8 ± 5.9 3.6 ± 2.5 19.2 ± 4.0
Imadjustγ=2 Totsu 20.1 ± 6.3 5.5 ± 5.2 28.0 ± 11.5 20.8 ± 6.0 5.2 ± 6.2 21.9 ± 7.3
Imadjustγ=2 Tiso 21.1 ± 6.4 4.7 ± 4.1 26.4 ± 10.8 20.6 ± 5.0 4.2 ± 3.5 20.3 ± 5.3
CV: coefficient of variation; Histeq: histogram equalization; Imadjust: histogram stretching; Iso: Isodata 
method; Otsu: Otsu’s method.
Table S2. Results of the variant of the algorithm for segmentation of histamine-induced wheal-and-flare 
at 60 minutes (n=18) after histamine iontophoresis.
Method Area  
T60min [cm
2]
CV  
T60min [%]
Histeq Totsu 9.9 ± 4.3 10.4 ± 9.6
Histeq Tiso 9.9 ± 4.3 10.4 ± 9.6
Imadjustγ=1 Totsu 9.0 ± 5.4 8.8 ± 10.1
Imadjustγ=1 Tiso 9.3 ± 4.7 8.3 ± 8.0
Imadjustγ=2 Totsu 7.1 ± 5.1 4.7 ± 6.3
Imadjustγ=2 Tiso 8.0 ± 4.8 5.0 ± 7.5
CV: coefficient of variation; Histeq: histogram equalization; Imadjust: histogram stretching; Iso: Isodata 
method; Otsu: Otsu’s method.
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Figure S2. Representative results of the algorithm for histamine-induced wheal-and-flare segmentation 
obtained in images taken on the buttock of three volunteers (a-c) after histamine iontophoresis. a) Good 
segmentation results obtained in all six combinations of histogram-based contrast enhancement and 
thresholding. b) The linear histogram stretching methods erroneously selected an area belonging to the 
background because of strong inhomogeneity in skin color. c) Poor segmentation results obtained by the 
non-linear histogram stretching method with Otsu’s thresholding.
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Figure S3. Representative results of the variant of the algorithm for histamine-induced wheal-and-flare 
segmentation obtained in images taken on the buttock at 60 minutes after histamine iontophoresis. The 
surrounding flare has faded and there is the appearance of an irregularly dotted erythema pattern in 
correspondence of the wheal. The non-linear histogram streatching methods show the most conservatory 
results with least influence of spurious pixels belonging to the background.
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ABSTRACT
Background: Sensitive skin is a widespread condition, which is most frequently reported by 
women. Changing hormone levels during the menstrual cycle and menopause have been 
suggested among the stimuli triggering sensitive skin. 
Objectives: To investigate the perceived influence of fluctuating hormone levels on self-
assessed sensitive skin, including symptoms and stimuli linked to skin sensitivity, as well as 
potential changes in facial and body skin and sensitive body parts, depending on hormonal 
status. 
Patients and methods: A digital questionnaire was distributed to a population of women aged 
20-65 years old. 
Results: A total of 278 women were included in the analysis. About 42% premenopausal women 
declared a perception of (increased) skin sensitivity just before and during the menstrual cycle, 
while this was reported by almost 32% of peri- and postmenopausal women following the 
menopause. The majority of reported symptoms included the presence of bumps/pimples, 
dryness, itching, and redness, and the majority of reported stimuli were shaving, weather, 
toiletries, and emotions. No differences emerged regarding characteristics of facial and 
body skin across different hormonal status. Significant differences in sensitivity of body parts 
emerged for the face and feet, reported by a larger percentage of premenopausal women and 
peri- and  postmenopausal women, respectively. 
Conclusion: The prevalence of the perceived effects of fluctuating hormone levels on self-
assessed sensitive skin in women is high. These effects should be taken into consideration 
in skin testing and dermatological practice, and support the need for selecting personal care 
routine or treatment during the menstrual cycle and menopause.
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INTRODUCTION
 As much as 50% to 61% of women in the industrialized world describe their skin as 
sensitive [1]. Sensitive skin (SS), usually defined as a subjective cutaneous hyper-reactivity to 
various stimuli [2], has been widely investigated in recent years, but a clear characterization 
of this condition is still lacking due to the frequent absence of objective signs of skin irritation 
and the variability of symptoms and severity [3]. Previous work from our group has shown 
that insights into the pathomechanisms of SS could be gained by selecting volunteers via a 
perception-based questionnaire, in which a range of eliciting factors of different nature are 
considered, among which figure toiletries, heat, cold, and emotions [4, 5]. Fluctuations in 
female hormone levels during the menstrual cycle and menopause have also been suggested 
among the eliciting factors of SS symptoms in the literature [2, 6]. This hypothesis is supported 
by the presence of oestrogen receptors (ERs), and, to a lesser extent, progesterone and 
testosterone receptors, both in the dermis and in the epidermis [7]. Two oestrogen regulatory 
mechanisms have been described so far, involving a genomic pathway (in which oestrogen 
binds to intracellular ERs) and a non-genomic pathway (in which oestrogen binds to cell 
membrane ERs) [8]. Levels of oestrogen and progesterone decline in the late luteal phase, 
and remain low during the menstrual and early follicular phases [7]. Both hormones fall to 
low levels also in the menopause, a process leading to the loss of ovarian cyclic activity [7, 8]. 
Oestrogen decline in menopausal women has been linked to the exacerbation of aging effects, 
such as skin dryness and wrinkling [8], possibly via influence on dermal collagen content. From 
observations of menopausal women taking exogenous oestrogen for menopausal symptom 
relief (hormone replacement therapy – HRT) and those not taking HRT, it was reported that 
menopausal women on HRT had better lipid coverage of corneocytes in the stratum corneum 
(SC), better lipid lamellar organization, and improved water-holding capacity in the SC 
compared to menopausal women who did not take HRT [9-11]. From studies on premenopausal 
women, a trend towards decreased SC hydration and a weakened skin barrier, measured by 
transepidermal water loss (TEWL), emerged in correspondence with the perimenstrual phase, 
in which oestrogen levels are at their lowest [12, 13]. These results suggest that decreased 
oestrogen levels during menopause and the perimenstrual phase could contribute to the onset 
or exacerbation of SS through an effect on the skin barrier function. In this respect, the effects 
of progesterone are more limited and less studied [7]. Furthermore, female hormones could 
exert an inflammatory and immunological effect via an influence on mast cell behaviour [14], a 
mechanism which might explain the variability in skin prick tests and allergy patch tests across 
the menstrual cycle reported in previous studies [15, 16]. 
 The primary objective of this study was therefore to further characterise SS in women by 
investigating the perceived influence of fluctuating hormone levels during the menstrual cycle 
and menopause on self-assessed SS. For this purpose, we designed a digital questionnaire to 
be distributed to a population of women of variable age and hormonal status. Several factors 
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possibly influencing the effect of hormone levels on SS were evaluated; these included: age, 
use of exogenous hormones as contraceptives or HRT, self-assessed SS, intensity of menstrual 
or menopausal symptoms, presence of atopic predisposition or skin diseases, and body mass 
index (BMI). Questions on stimuli and symptoms which make women aware of the fact that 
their skin may become (more) sensitive due to the menstrual cycle or menopause were also 
added. As a second objective, we investigated whether self-assessed characteristics of facial 
and body skin, as well as sensitive body parts, differ as hormonal status changes. 
 Given the high prevalence of SS among women, we believe that obtaining deeper 
insights into the role of fluctuating hormone levels could be of relevance in the evaluation 
of patients’ symptoms in clinical practice, in the assessment of skin responses to dermato-
cosmetic treatments, as well as in the selection of personal care routine.
PATIENTS AND METHODS
Participants and recruiting procedure
 The digital questionnaire was distributed, in December 2014, to women aged between 
20 and 65 years old and registered in the database of a recruiting agency. The database 
consists of people from several provinces across the Netherlands. A quota of a minimum of 300 
respondents was set, i.e. respondents could still submit the questionnaire even if the quota had 
been reached while completing it. General information about the study and the questionnaire 
was provided. If willing to participate, respondents had to provide informed consent by agreeing 
to the statement: “I have read the survey information and agree that the information I provide 
will be used for the stated purpose”. To ensure anonymity, participants were not asked personal 
information. Pregnant and breast-feeding women were asked to refrain from participation. 
The study was approved by the Internal Committee Biomedical Experiments (ICBE) of Philips 
Research and by the local ethics committee.
Questionnaire
 The questionnaire was created using a web-based survey tool (EFM version 8.1, 
Verint Systems Inc., USA). Sociodemographic characteristics included age group (20-35 
years, 36-45 years, 46-55 years, and 56-65 years), Fitzpatrick skin type, height, and weight. 
Atopic predisposition was defined as a history of asthma, atopic dermatitis, or hay fever. 
Hormonal status was defined as: premenopausal (a regular menstrual cycle circa every 
month), perimenopausal (clear changes in terms of menstrual cycle length and intensity, 
or no menstrual cycle for up to 12 months), postmenopausal (no menstrual cycle for more 
than 12 months) [17]. Intensity of perimenstrual and menopausal symptoms could be rated 
as absent, mild, moderate, or severe. For association analyses, absent and mild responses 
were categorised as “low” symptom intensities, and moderate and severe responses as “high” 
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symptom intensities. Self-assessed SS was defined according to the question: “Do you think 
that your skin is more sensitive with respect to the skin of others?”. Women who assessed their 
skin as much more or slightly more sensitive compared to others, were categorised in the SS 
group, while women who rated their skin as equally or less sensitive compared to others, were 
categorised in the non-sensitive skin (NSS) group [4, 5]. The perceived effect of the menstrual 
cycle on SS was assessed with the question: “Do you notice that your skin becomes sensitive 
or more sensitive during certain phases of the menstrual cycle?”. For association analyses, 
responses “No” and “Yes, rarely” were categorized as “No or rare effect of menstrual cycle 
on SS”, while responses “Yes, sometimes” and “Yes, often” were categorised as “Effect of 
menstrual cycle on SS”. For these analyses, only premenopausal women were included. The 
perceived effect of the menopause on SS was assessed with the question: “Do you notice that 
your skin has become sensitive or more sensitive since the menopause?”. For association 
analyses, responses “No, my skin has become less sensitive since the menopause” and “No, 
my skin sensitivity has not changed” were categorized as “No increased SS after menopause”, 
while response “Yes” was defined as “Increased SS after menopause”. For these analyses, only 
peri- and postmenopausal women were included. For the analysis of stimuli and symptoms, 
which make women aware of the fact that their skin may become (more) sensitive due to the 
menstrual cycle or menopause, only women who reported an effect of the menstrual cycle or 
menopause on SS were included.
Statistical analysis
 Fisher’s exact test was used to study associations between categorical variables. 
Kruskal-Wallis and Mann-Whitney tests were used to evaluate differences between means 
of BMI. For all comparisons, the significance values (p value) are presented. The level of 
significance was set at 0.05. Statistical analyses were performed using SPSS Statistics version 
20 for Windows (IBM SPSS Inc., USA). No corrections for multiple comparisons were applied.
RESULTS
Characteristics of the study population
 A total of 301 women responded to the questionnaire. Women who did not specify 
their age group or hormonal status were excluded from the analysis (n=23). In total, 278 
women were included in this study. Sociodemographic characteristics, presence of atopic 
predisposition, skin diseases, and self-assessed SS for each hormonal status are shown in 
Table 1. Skin diseases were less prevalent in perimenopausal women (p=0.011), while the BMI 
was lower in premenopausal women (p=0.015). The most frequently reported skin diseases 
were psoriasis (n=10), contact dermatitis (n=8), and acne (n=7). For atopic predisposition, 
the majority of women had hay fever (n=76), followed by asthma (n=38) and atopic dermatitis 
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(n=30). These percentages are in line with the prevalence of skin diseases and atopic conditions 
in the Netherlands1. Of note, when women with skin diseases were excluded from the analysis, 
the percentage of SS in the perimenopausal group was slightly higher than in the other groups 
(premenopausal: 45.1%; perimenopausal: 51.0%; and postmenopausal: 42.5%). The difference, 
however, was not significant (p=0.643). 
Table 1. Characteristics of the study participants according to hormonal status (n=278). 
Premenopausal Perimenopausal Postmenopausal
n n % n % n % p value
278 121 43.5 55 19.8 102 36.7
Age group (years) n.a.
          20 - 35 62 59 48.8 3 5.5 0 0.0
          36 - 45 59 49 40.5 9 16.4 1 1.0
          46 - 55 96 13 10.7 41 74.5 42 41.2
          56 - 65 61 0 0.0 2 3.6 59 57.8
Body Mass Index (kg/m2) 0.015
          Mean (±SD) 271 24.85 (± 4.70) 26.09 (± 5.07) 26.70 (± 5.09)
Skin type (Fitzpatrick scale) 0.674
           I-II 98 46 39.0 20 36.4 32 31.7
           III 113 43 36.4 24 43.6 46 45.5
           IV-V-VI 63 29 24.6 11 20.0 23 22.8
Atopic predisposition
          Yes 98 40 33.9 23 41.8 35 36.5 0.618
Skin disease
          Yes 40 24 19.8 2 3.6 14 13.7 0.011
Self-assessed SS 0.921
          SS 126 56 49.1 26 51.0 44 47.3
          NSS 132 58 50.9 25 49.0 49 52.7
n.a.: not applicable (due to expected variation in age during the different hormonal status); NSS: non-
sensitive skin; SS: sensitive skin.
1  Data from Nationaal Kompas Volksgezondheid (www.nationaalkompas.nl). 
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Perceived effect of menstrual cycle and menopause on self-assessed SS 
 A total of 121 premenopausal women were included in the analysis of the perceived 
effect of menstrual cycle on SS, while 157 peri- and postmenopausal women were included 
in the analysis of the perceived effect of menopause on SS. The results are presented in 
Figure 1. A perceived effect on SS was reported by premenopausal women before (35.5%) 
and/or during (28.9%) menstruation. Association analyses are shown in Tables 2 and 3. The 
majority of premenopausal women with high intensity of perimenstrual symptoms stated 
that their skin becomes (more) sensitive during certain phases of the menstrual cycle with 
respect to women with lower symptom intensity (p=0.002). Similarly, the majority of peri- and 
postmenopausal women with high intensity of menopausal symptoms stated that their skin 
became (more) sensitive following the menopause, compared to women with low symptom 
intensity (p=0.018). In this group, in addition, an association with increased sensitive skin 
following the menopause was identified for women with self-assessed SS, women with skin 
diseases, and women currently taking HRT (p=0.000, p=0.042 and p=0.001, respectively).
 With respect to symptoms and stimuli that make women aware that their skin 
may become sensitive or more sensitive due to the menstrual cycle or menopause, for 
premenopausal women, the most commonly reported symptoms were bumps/pimples (85.2%), 
dryness (32.8%), and itching (29.5%), while stimuli were shaving (37.7%), the weather (32.8%), 
emotions (31.1%), and toiletries (29.5%). For peri- and postmenopausal women, the most 
commonly reported symptoms were dryness (54%), itching (46%), and redness (36%), while 
stimuli were weather (42%), emotions (38%), and toiletries (38%). The full list of symptoms and 
stimuli is shown in supplementary Table S1.
Characteristics of facial/body skin and sensitive body parts according to hormonal 
status
 No significant differences in the patterns of facial and body skin were present across 
different hormonal status. Overall, women reported mostly combined dry and oily skin on the 
face (47.8%), while normal and dry skin were mostly reported on the body (37.2% and 44.8%, 
respectively). The characteristics of facial and body skin are reported in supplementary Table 
S2. The list of sensitive body parts is shown in Table 4. Significant differences were present 
for the face (p=0.020) and feet (p=0.044), more frequently reported by premenopausal and 
perimenopausal women, respectively. Overall, the most frequently reported sensitive body 
parts were the face (53.6%), legs (27.7%), and hands (27.3%).
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Table 2. Relationship between the effect of menstrual cycle on self-assessed sensitive skin and 
sociodemographic, lifestyle, and health characteristics (n=121).
Effect of menstrual cycle on SS
Yes No/Rare
n n % n % p value 
Age group (years) 0.246
20 - 35 58 28 60.9 30 49.2
36 - 45 49 18 39.1 31 50.8
Use of hormones as contraceptives 0.195
Yes (currently) 58 21 41.2 37 54.4
No (in the past or never) 61 30 58.8 31 45.6
Self-assessed sensitive skin 0.256
SS 56 27 56.2 29 44.6
NSS 57 21 43.8 36 55.4
Intensity of MC symptoms 0.002
Low (absent or mild) 53 14 27.5 39 56.5
High (moderate or severe) 67 37 72.5 30 43.5
Atopic predisposition 0.846
Yes 40 18 35.3 22 33.3
No 77 33 64.7 44 66.7
Skin disease 1
Yes 23 10 19.6 13 18.8
No 97 41 80.4 56 81.2
Body Mass Index (kg/m2) 0.542
Mean (± SD) 116 24.59 (± 4.54) 25.12 (± 4.83)
MC: menstrual cycle; NSS: non-sensitive skin; SS: sensitive skin.
SENSITIVE SKIN AND FEMALE HORMONES 
133
4.1
Table 3. Relationships between the effect of menopause on self-assessed sensitive skin and 
sociodemographic, lifestyle, and health characteristics (n=157).
Increased SS after menopause
Yes No
n n % n % p value 
Age group (years) 0.190
46 - 55 67 29 63.0 38 49.4
56 - 65 56 17 37.0 39 50.6
Use of hormones as HRT 0.001
Yes (currently) 10 9 18.4 1 1.2
No (in the past or never) 120 40 81.6 80 98.8
Self-assessed sensitive skin 0.000
SS 63 34 72.3 29 37.7
NSS 61 13 27.7 48 62.3
Intensity of M symptoms 0.018
Low (absent or mild) 58 15 30.6 43 53.1
High (moderate or severe) 72 34 69.4 38 46.9
Atopic predisposition 0.442
Yes 44 19 39.6 25 31.6
No 83 29 60.4 54 68.4
Skin disease 0.042
Yes 14 9 18.0 5 6.1
No 118 41 82.0 77 93.9
Body Mass Index (kg/m2) 0.839
Mean (± SD) 130 26.75 (± 5.61) 26.37 (± 5.08)
HRT: hormonal replacement therapy; M: menopause; NSS: non-sensitive skin; SS: sensitive skin.
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Figure 1. Perceived effects of the menstrual cycle and menopause on self-assessed sensitive skin (SS). a) 
Premenopausal women (n=121) answered the question: “Do you notice that your skin becomes sensitive or 
more sensitive during certain phases of the menstrual cycle?”. Women answering “No” (48.8%) and “Yes, 
rarely” (8.3%) were included in the group “No or rare perceived effect of menstrual cycle on SS”, while 
women answering “Yes, sometimes” (28.9%) and “Yes, often” (13.2%) were included in the group “Perceived 
effect of menstrual cycle on SS”. b) Peri- and postmenopausal women (n=157) answered the question: “Do 
you notice that your skin has become sensitive or more sensitive since menopause?”. Women answering 
“No, my skin has become less sensitive” (8.9%) and “No, my skin sensitivity has not changed” (43.3%) were 
included in the group “No perception of increased SS after menopause”, while women answering “Yes” 
(31.8%) were included in the group “Perception of increased SS after menopause”.
Table 4. Sensitive body parts according to hormonal status (n=278). Respondents were allowed to choose 
multiple body parts.
Premenopausal Perimenopausal Postmenopausal
n % n % n % p value 
Equally sensitive 25 20.7 10 18.2 23 22.5 0.841
Face 75 62.0 30 54.5 44 43.1 0.020
Hands 28 23.1 16 29.1 32 31.4 0.358
Neck 10 8.3 4 7.3 5 4.9 0.612
Chest 16 13.2 14 25.5 17 16.7 0.136
Back 12 9.9 6 10.9 9 8.8 0.867
Genitals 10 8.3 7 12.7 13 12.7 0.468
Legs 28 23.1 15 27.3 34 33.3 0.244
Feet 14 11.6 14 25.5 21 20.6 0.044
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DISCUSSION
 The primary objective of this cross-sectional study was to investigate the perceived 
influence of fluctuating hormone levels during the menstrual cycle and menopause on self-
assessed SS. A high percentage of premenopausal women reported (stronger) perceptions 
of symptoms associated with SS just before and during menstruation (42.1%). A lower, but 
still important, percentage of peri- and postmenopausal women perceived this following 
menopause (31.8%). Women with a higher intensity of (non-skin-related) perimenstrual and 
menopausal symptoms were more likely to perceive these effects. The onset or exacerbation 
of SS due to the menstrual cycle seems to be independent of normal self-assessed skin 
sensitivity, atopic predisposition, and affection by skin diseases, as demonstrated by the lack 
of associations found in this study. Atopic predisposition and skin diseases have been included 
among the risk factors leading to a greater likelihood of reporting SS. It could be speculated 
that their reported exacerbation during the menstrual cycle [7, 18] has an indirect influence 
on SS, for example, through a worsening of the skin barrier function or through an alteration 
of the skin inflammatory mechanisms; however, we could not observe such an effect in our 
study. In contrast, menopausal women with skin diseases more frequently perceived increased 
SS following menopause, compared with women without skin diseases. Psoriasis and other 
autoimmune (skin) diseases are known to occur or be exacerbated during menopause [19, 
20], and this could possibly mediate indirect effects on SS. In addition, the lack of a significant 
difference in prevalence of SS across different hormonal status suggests that the effect of 
menopause might be perceived primarily by women who had SS already before menopause. 
Oestrogen depletion during menopause could exacerbate a clinical status already affected by 
the  pathomechanisms involved in SS, while having no major impact on NSS. The association 
between increased SS following menopause and the use of HRT could be mediated by the 
intensity of menopausal symptoms, since women taking HRT were also characterised by a 
higher symptom intensity (p=0.020). Given the low number of women taking HRT in this study, 
its effects on SS should be evaluated in a larger population.
 As a second objective, we investigated self-assessed characteristics of facial and body 
skin and sensitive body parts according to hormonal status. No significant differences in skin 
assessment were identified between different hormonal status for either facial or body skin, 
despite the fact that oestrogen depletion in menopause has been linked to decreased sebum 
production and skin hydration [8, 21]. One study showed that the lowest levels of skin surface 
lipids could be measured in women older than 70 years [22]. Less combined oily and dry or 
only oily skin, due to decreased sebum secretion, could thus be perceived by women older 
than the participants included in this study. With respect to skin hydration, a high percentage 
(54%) of peri- and postmenopausal women reported skin dryness as one of the symptoms 
responsible for increased SS following the menopause. This result is in line with the effects of 
oestrogen decline occurring during the menopause [8, 17, 21, 23]. The lack of any difference 
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in the percentage of dryness of facial or body skin between different hormonal status might 
be explained by the effect of cold weather at the time when the questionnaire was distributed, 
prompting an overall higher percentage of women to report dry skin [24]. The lower percentages 
of peri- and postmenopausal women who reported SS of the face could be related to a lower 
sensory perception due to age-related decrease in epidermal nerve fibre density [25]. Another 
mechanism could be the age-related increase in corneocyte size, due to a slower epidermal 
cell proliferation rate [26], which could improve skin barrier function and lead to decreased 
skin sensitivity. However, while some studies reported improved skin barrier function in aged 
facial skin, measured as decreased TEWL, others could not detect differences [22, 27]. The 
feet, reported by a higher percentage of peri- and postmenopausal women, are described to 
undergo loss of fat distribution and sensitivity to touch with age, and a cold sensation to the feet 
was included as a menopausal symptom [28-30]. Whether these factors could have prompted 
more women to report the feet as a sensitive body part, or whether other skin changes could 
have played a role, remains to be investigated. 
 In conclusion, based on the results of our study, we confirm the importance of taking 
into consideration the fluctuating hormone levels during the menstrual cycle and menopause 
in the evaluation of patients’ symptoms in clinical practice, in the assessment of skin responses 
to dermato-cosmetic treatments, as well as in the selection of personal care routine [18]. This 
holds true particularly for women with a higher intensity of perimenstrual and menopausal 
symptoms, as well as for menopausal women with skin diseases. Subjective assessments of 
skin dryness during the menstrual cycle and menopause might be linked to quantitative and 
direct measurement of skin water content by confocal Raman microspectroscopy, a technique 
for in vivo analysis of skin molecular composition [31]. Given the magnitude of influence of 
oestrogen on female physiology [20], we underline the importance of performing further 
research in order to unravel the mechanisms by which oestrogen exerts its influence on 
normal and aging skin, as well as on autoimmune diseases such as psoriasis.
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SUPPLEMENTARY MATERIAL
Table S1. Symptoms and stimuli which make women realize that their skin becomes (more) sensitive 
during certain phases of the menstrual cycle or in menopause. Respondents were allowed to choose 
multiple answers.
MC (n=61) M (n=50)
Symptoms n % n %
Bumps/pimples 52 85.2 17 34.0
Stinging 2 3.3 2 4.0
Dryness 20 32.8 27 54.0
Redness 7 11.5 18 36.0
Itching 18 29.5 23 46.0
Burning 7 11.5 6 12.0
Tightness 6 9.8 12 24.0
General skin discomfort 5 8.2 12 24.0
Other 2 3.3 4 8.0
I do not know 3 4.9 2 4.0
Stimuli n % n %
Weather 20 32.8 21 42.0
Sun exposure 11 18.0 12 24.0
Shaving 23 37.7 10 20.0
Emotions 19 31.1 19 38.0
Toiletries/cosmetics 18 29.5 18 36.0
Clothes 5 8.2 10 20.0
Other 4 6.6 5 10.0
I do not know 17 27.9 9 18.0
MC: menstrual cycle; M: menopause.
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Definitions of symptoms used in the questionnaire:
Bumps/pimples = bumps or papules with or without white top 
Stinging = sensation like having needles prickling the skin, or having alcohol dabbed on a 
wound
Dryness = the skin is dry and scales
Redness = presence of red spots and stripes, sometimes extended, on the skin
Itching = sensation that causes the desire to scratch
Burning = the skin feels warm, like if a warm object is put on the skin
Tightness = the skin feels tense and less flexible
No description provided for general skin discomfort
Table S2. Characteristics of facial and body skin according to hormonal status (n=278). Respondents 
were allowed to choose only one skin type.
Premenopausal Perimenopausal Postmenopausal
n % n % n % p value 
Facial skin type 0.714
           Normal 32 26.7 14 25.9 32 31.4
           Dry 27 22.5 7 13.0 18 17.6
           Oily 7 5.8 3 5.6 4 3.9
          Combined* 54 45.0 30 55.6 48 47.1
Body skin type 0.160
           Normal 39 32.2 22 40.7 42 41.2
           Dry 55 45.5 20 37.0 49 48.0
           Oily 2 1.7 0 0 0 0
          Combined* 25 20.7 12 22.2 11 10.8
*Combined: concomitant presence of dry and oily parts.
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ABBREVIATIONS 
AUC  Area under the curve
CI  Confidence interval
OR  Odds ratio
SS  Sensitive skin
NSS  Non-sensitive skin
ROC  Receiver operating characteristic
SC  Stratum corneum
4.2
Risk factors associated with sensitive skin and 
potential role of lifestyle habits: a cross-sectional 
study
Falcone D1
Richters RJ1
Uzunbajakava NE2
van Erp PE1
van de Kerkhof PC1
Clin Exp Dermatol, 2017. 42(6): 656-658.
1 Department of Dermatology, Radboud University Medical Center,  
Nijmegen, the Netherlands.
2 Philips Research, Eindhoven, the Netherlands.
CHAPTER 4.2
144
ABSTRACT
Sensitive skin (SS) is a widespread condition, but still not completely understood. To identify 
risk factors that increase the likelihood of SS, 258 women aged between 20 and 65 years old 
and resident in the Netherlands were surveyed by questionnaire, which included questions on 
sociodemographic characteristics (age group, Fitzpatrick skin type, hormonal status), health 
state (atopic predisposition, skin diseases), and lifestyle habits (history of smoking and of sun 
exposure, frequency of physical exercise). Analysis of the responses confirmed that atopic 
predisposition, presence of skin diseases and Fitzpatrick skin types I and II are risk factors 
significantly associated with SS. In addition, as current or past smoking and a history of low 
sun exposure showed a trend to increase the likelihood of reporting SS, we suggest that the 
potential role of lifestyle factors in the onset or exacerbation of SS should be investigated 
further.
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 In the industrialized world, 50–61% of women and 30–44% of men report having sensitive 
skin (SS), a condition characterized by the presence of subjective perceptions (e.g. stinging, 
itching, burning) to mild stimuli of different nature [1]. However, clear characterization of SS 
remains elusive because of the variability of the reported stimuli, symptoms and severity, 
and the frequent absence of objective signs of skin irritation [1]. An important step towards 
unraveling the pathomechanisms involved in SS is to perform survey-based studies to evaluate 
which factors are particularly related to this condition [2, 3]. Knowledge of such risk factors 
would be instrumental in better understanding these symptoms in clinical practice, and in 
better selecting individuals who are prone to experience SS and who could be included in 
clinical studies to evaluate the potential pathomechanisms involved in SS. The objective of 
this study was therefore to identify risk factors associated with the likelihood of reporting SS. 
For this purpose, we distributed a digital questionnaire to a sample population of women. 
Following an exploratory approach, several factors were considered: age, Fitzpatrick skin type, 
hormonal status, presence of atopic predisposition and presence of skin diseases. In addition, 
we explored the possible role of lifestyle habits, including smoking, history of sun exposure 
and frequency of physical exercise. Although an association between SS and fair skin type, 
atopic predisposition and skin diseases has already emerged in previous studies [2, 3], to our 
knowledge no survey-based study has as yet evaluated the role of lifestyle habits.
REPORT
 Informed consent was obtained from all individual participants included in the study. 
The recruiting procedure and the design of the questionnaire have been described in detail 
previously [4]. Briefly, the digital questionnaire was distributed, in December 2014, to women 
aged between 20 and 65 years old and resident in the Netherlands. In total, 301 women 
responded to the questionnaire. After exclusion of women who did not specify their age group 
or hormonal status (n=23), who did not know how to classify the sensitivity of their skin (n=19) 
or did not answer the question on skin sensitivity (n=1), 258 women were included in the 
analysis. Of these, the percentage of women with SS was 45.3% (n=126), while the percentage of 
women with non-sensitive skin (NSS) was 47.4% (n=132). Statistical analyses were performed 
using SPSS Statistics version 20 for Windows (IBM SPSS Inc., USA) and SAS version 8.2 for 
Windows (SAS Institute, USA). Significance level was set at p value <0.05. In the first step, 
univariate logistic regression was used to explore factors related to SS. The crude odds ratios 
(ORs) for the likelihood of reporting SS using univariate logistic regression are shown in Table 
1. Significant factors related to a higher likelihood of reporting SS were presence of atopic 
predisposition (OR=1.75, 95% CI 1.04–2.95) and presence of skin disease (OR=2.60, 95% CI 
1.25–5.42). Significant factors related to a lower likelihood of reporting SS were Fitzpatrick 
skin type III, IV, V and VI (OR=0.53, 95% CI 0.32–0.90) and history of moderate to high sun 
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exposure (OR=0.41, 95% CI 0.18–0.91). A positive history of smoking (current or past) increased 
the risk of SS with respect to having never smoked (p=0.13). In the second step, factors with a 
significance level lower than a predefined cut-off value (p=0.20) were included in a multivariate 
logistic regression model with forward selection procedure. The aim was to identify which 
factors contributed independently to the risk of SS. The adjusted ORs of the final model are 
presented in Table 2. Factors significantly (p=0.001) associated with the likelihood of reporting 
SS were presence of skin disease (OR=2.41, 95% CI 1.13–5.14), atopic predisposition (OR=1.77, 
95% CI 1.03–3.03) and Fitzpatrick skin type III, IV, V and VI (OR=0.54, 95% CI 0.31–0.92). This 
indicated that women with skin diseases or atopic predisposition were, respectively, 2.41 and 
1.77 times more likely to report SS than women without these conditions, after controlling 
for other factors in the model. In addition, women with fair skin types (I and II) were 1.85 
times (reciprocal of 0.54) more likely to report SS than women with darker skin types (III, IV, V 
and VI). The model explained 8.16% (pseudo-R2) of the variance in SS, and its discriminatory 
power, expressed as area under the curve (AUC) of the receiver operating characteristic curve 
(ROC), was 63.2%. Our data confirm that atopic predisposition, presence of skin diseases 
and Fitzpatrick skin types I and II are independent risk factors that increase the likelihood 
of reporting SS, as reported by previous survey-based studies [2,3]. Of note, current or past 
smoking and a history of low sun exposure showed a trend to make a significant contribution 
to the model, although this was not significant (p=0.06). As both of these factors increased the 
risk of SS, this raises the question as to the role that these lifestyle habits might have on SS. 
Smoking is already associated with the clinical severity of psoriasis [5]. A previous study found 
that the thickness of the stratum corneum (SC) correlates negatively with years of smoking 
but not with the smoking status [6], and this might play a role in SS, as a thinner SC could lead 
to a higher susceptibility to irritants. Controlled, repetitive ultraviolet light exposure improves 
the barrier function of patients with skin diseases such as atopic dermatitis and psoriasis, and 
has been shown to decrease the responses to irritants [7]. A history of moderate to high sun 
exposure might bring similar benefits to SS. Although it is reasonable to believe that skin type 
and sun exposure are to a certain extent correlated, with people with fairer skin types more 
likely to avoid sun exposure than those with darker skin types because of the stronger side 
effects, we believe that the additional independent contribution of sun exposure to SS should 
be evaluated in further studies. The same holds true for smoking and other lifestyle factors 
with potential effects on SS, such as dietary habits, urban or rural place of living (with more or 
less pollution) and stressful (working) environment [8–10]. 
 In conclusion, our study confirms that atopic predisposition, presence of skin diseases 
and Fitzpatrick skin types I and II are risk factors significantly associated with SS. It also 
appears that current or past smoking and a history of low sun exposure may also affect SS, and 
we suggest that the potential role of lifestyle factors in the onset or exacerbation of SS should 
be investigated further.
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Table 1. The (crude) ORs to predict the likelihood of reporting sensitive skin, along with the 95% CI, using 
univariate logistic regression analysis (n = 258).
n OR (95% CI) p value
Age group
     20-35y 59 1.00 (reference) 0.133
     36-45y 57 2.16 (1.03; 4.55)
     46-55y 87 1.33 (0.68; 2.59)
     56-65y 55 0.98 (0.46; 2.06)
Hormonal status
     Premenopausal 114 1.00 (reference) 0.912
     Perimenopausal 51 1.08 (0.56; 2.09)
     Postmenopausal 93 0.93 (0.54; 1.61)
Physical exercise*
     Low 35 1.00 (reference) 0.448
     Moderate , High 219 0.75 (0.64; 2.71)
Fitzpatrick skin type*
     I, II 90 1.00 (reference) 0.018
     III, IV, V, VI 164 0.53 (0.32; 0.90)
Sun exposure*
     Low 31 1.00 (reference) 0.028
     Moderate,  High 223 0.41 (0.18; 0.91)
Smoking*
     Never 109 1.00 (reference) 0.129
     Currently , In the past 144 1.47 (0.89; 2.43)
Atopic predisposition#
     No 158 1.00 (reference) 0.034
     Yes 92 1.75 (1.04; 2.95)
Skin disease^
     No 220 1.00 (reference) 0.011
     Yes 38 2.60 (1.25; 5.42)
*Categories were grouped because of similar risk values compared with sensitive skin.
#Defined as history of atopic dermatitis, asthma or hay fever.
^Most often reported skin diseases were psoriasis (n=9), contact dermatitis (n=8) and acne (n=7).
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Table 2. The (adjusted) ORs to predict the  likelihood of reporting sensitive skin, along with the 95% CI, 
using multivariate logistic regression analysis with forward selection procedure (n = 258).
OR (95% CI)
Fitzpatrick skin type
     I, II 1.00 (reference)
     II, IV, V, VI 0.54 (0.31; 0.92)
Atopic predisposition
     No 1.00 (reference)
     Yes 1.77 (1.03; 3.03)
Skin disease
     No 1.00 (reference)
     Yes 2.41 (1.13; 5.14)
AUC = 63.2%, pseudo R2 = 8.16%.
LEARNING POINTS
 •  Sensitive skin (SS) is defined as the presence of heightened sensory perceptions to 
mild stimuli, often in the absence of objective signs of skin irritation.
 •  SS is a widespread condition in the industrialized world; however, general consensus 
on its pathomechanisms is still pending.
 •  Identifying risk factors that increase the likelihood of reporting SS would be an 
important step towards a better understanding of this condition in clinical practice 
and better selection of subjects in clinical studies.
 •  Fair skin type, presence of skin diseases and atopic predisposition are confirmed to 
be risk factors that increase the likelihood of reporting SS.
 •  Past or current smoking and a low history of sun exposure showed a trend to increase 
the likelihood of reporting SS.
 •  The effects of these and other lifestyle factors with possible effects on the skin 
(e.g. dietary habits, stress) on the onset or exacerbation of SS should be further 
investigated.
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ABSTRACT
Interleukin-1α (IL-1α) and its receptor antagonist IL-1RA play a pivotal role in skin homeostasis 
and disease. Although the use of biopsies to sample these cytokines from human skin is widely 
employed in dermatological practice, knowledge about less invasive, in vivo sampling methods 
is scarce. The aim of this study was to provide an overview of such methods by systematically 
reviewing studies in Medline, EMBASE, Web of Science and the Cochrane Library using 
combinations of the terms “IL-1α”, IL-1RA”, “skin”, “human”, including all possible synonyms. 
Quality was assessed using the STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) checklist. The search, performed on 14 October 2016, revealed 
ten different sampling methods, with varying degrees of invasiveness and wide application 
spectrum, including assessment of both normal and diseased skin, from several body sites. 
The possibility to sample quantifiable amounts of cytokines from human skin with no or 
minimal discomfort holds promise for linking clinical outcomes to molecular profiles of skin 
inflammation.
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INTRODUCTION
 The primary function of the skin is to provide a physical barrier between the internal 
milieu and the external environment [1, 2]. In addition, the skin was more recently recognized to 
have a strong immunological role [3]. Keratinocytes and resident skin cells, such as fibroblasts, 
mast cells, Langerhans cells and other dermal dendritic cells, have been shown to release a 
wide variety of mediators, both in the maintenance of tissue homeostasis (immune-surveillance) 
as well as in case of injury or pathogen invasion [4]. Among the most characterized mediators are 
interleukins (IL) belonging to the IL-1 family, namely IL-1α, IL-1β and their receptor antagonist 
IL-1RA [5]. These cytokines are among the first mediators to be released in acute or chronic 
skin inflammation and are involved in a wide spectrum of (skin) diseases [4, 5]. In this respect, 
blocking IL-1 activity for therapeutic purposes has entered clinical practice [6]. Of note, unlike 
IL-1β, IL-1α and IL-1RA have also been shown to be detectable in normal skin [4].
 Evidence for the presence of biologically active IL-1 in normal epidermis and stratum 
corneum (SC) emerged in the mid 1980s by means of bioassays, which measured the ability 
of IL-1 to augment proliferation of specific cell lines (e.g. murine thymocytes in the thymocyte 
co-stimulation assay) or to stimulate release of collagenase or prostaglandin from human 
dermal fibroblasts [7, 8]. Bioassays were limited by the impossibility of discriminating between 
IL-1α and IL-1β as well as between IL-1 and other cytokines [9], prompting some authors 
to cautiously refer to their findings as IL-1 or IL-1α “like” material [10]. In the late 1980s 
these obstacles were overcome by the advent of monoclonal antibodies against IL-1α and IL-
1β, allowing the two isoforms to  be determined and distinguished with high sensitivity and 
specificity [9]. Since then, enzyme immunoassays (EIA) and enzyme-linked immunosorbent 
assays (ELISA) have become widely used for the evaluation of soluble analytes in biological 
samples [11, 12]. The major shortcomings of ELISA are that it allows the measurement of only 
one analyte at a time in a given sample and that it requires relatively large sample amounts 
(typically 100 µL) [13]. Building on the principles of ELISA, in the late 1990s multiplex arrays 
were introduced with the purpose of measuring multiple analytes in the same sample at the 
same time [13, 14]. An example is constituted by multiplex bead-based assays, in which sets 
of microscopic color-coded beads (microspheres) coated with capture antibodies for specific 
analytes are simultaneously used [13, 14]. By flow cytometric analysis, the signal coming from 
the different bead sets can be distinguished and the binding events between the detection 
antibodies and the analyte-capture antibody complex on each bead set can be quantified [13, 
14]. Comparability analyses between ELISA and multiplex bead-based assays yielded positive 
results [15]. 
 Given the relevance of IL-1 in skin homeostasis and disease, different sampling 
methods, followed by the above-mentioned immunoassay quantifications, have been reported 
to analyze it. While taking skin biopsies remains the most widely used approach in clinical 
practice, successful attempts using less invasive sampling methods have been reported. 
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The aim of this study was to provide an overview of such minimally invasive methods by 
systematically reviewing studies in which IL-1α and/or IL-1RA were sampled from the skin of 
human volunteers in vivo. The choice was restricted to these two mediators because of their 
constitutive presence both in normal and diseased skin and their clinical relevance [4-6]. For 
each method, applications as well as advantages and shortcomings were highlighted. We hope 
that this review will increase awareness of the additional insights offered by analysis of local 
skin inflammation at the molecular level and will foster research towards implementation of 
minimally-invasive biomarker analysis in dermatological practice.  
METHODS
 An extensive literature search was performed on 14 October 2016 in four computerized 
bibliographical databases: Medline, EMBASE, Web of Science and the Cochrane Library. 
Medical subject heading and free text searches embracing the following terms were used: 
“interleukin 1 alpha”, “interleukin 1 receptor antagonist”, “skin”, “human”, including all possible 
abbreviations and synonyms. The complete search strategy is shown in supplementary Table 
S1. The literature search was limited to publications in English. No date restrictions applied.  
The article selection process followed three steps. In step one, a first screening was performed 
by one reviewer (DF) in which titles and abstracts, and materials and methods when the 
abstract was not available, were reviewed for relevance, taking into account a list of exclusion 
criteria. In case of uncertainty or if none of the exclusion criteria were met, in step two a 
second screening was performed in which the full text was retrieved and inclusion judged by 
two independent reviewers (DF and PvE) on the basis of a list of inclusion criteria. Consensus 
on inclusion was reached by discussion. In step three, the reference lists of the eligible studies 
were additionally screened to ensure that all relevant studies were included. The schematic 
representation of the article selection process and the list of exclusion and inclusion criteria is 
shown in supplementary Figure S1. 
 The methodological quality of the included studies was assessed by the STrengthening 
the Reporting of OBservational studies in Epidemiology (STROBE) criteria: each study received, 
independently by the two reviewers (DF and PvE), a score ranging from 0 to 22, which was then 
expressed as a percentage of the maximum score [16]. Depending of the level of fulfillment of 
the criteria stated in STROBE, articles were categorized as A (>80%), B (60%-80%) or C (<60%). 
When scores differed by more than 1.5, consensus was reached by discussion. 
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RESULTS
Article selection and quality
 The search in the four bibliographical databases revealed a total of 6598 hits. After 
exclusion of duplicates and of articles meeting any of the exclusion criteria in the first screening, 
535 articles remained for full-text evaluation. For most articles, the exclusion criteria from 
the first screening applied following full-text evaluation. Four articles for which the inclusion 
criteria applied were excluded because of the lack of description of the human volunteers from 
which the skin material was taken or of the method used to obtain the skin material. Manual 
screening of the reference lists resulted in the inclusion of one more article. In total, 63 articles 
were included in this review. The number of articles at each step of the selection process is 
shown in supplementary Figure S2. 
 Article quality was, on average, good: eight articles were classified as a category C 
(score <60%), 47 articles were classified as a category B (score 60-80%) and the remaining 
eight articles were classified as a category A (score >80%). Shortcomings were mainly related 
to the lack of description of potential confounders and effect modifiers concerning the study 
participants (e.g. age, skin type) or the sampling procedure (e.g. season and experimental 
conditions in which the sampling was performed). In addition, only a few studies specified the 
number of participants included at each stage. 
 Each sampling technique is presented in the following paragraphs. An overview of each 
technique, including collection time, applications, advantages and shortcomings is shown in 
Table 1. A detailed summary of each study included in this review can be requested from the 
first author.  
Tape stripping
 The majority of articles (n=24) sampled IL-1α and/or IL-1RA using tape stripping. This 
technique was characterized by a high heterogeneity in the sampling procedure. Unfortunately, 
only a few articles thoroughly described the sampling procedure by specifying the type, area 
and number of adhesive tapes used, the application time of each tape on the skin, and whether 
constant pressure was applied, all variables known to influence the procedure [17]. For the 
quantification of the protein levels of IL-1α and/or IL-1RA, the majority used EIA/ELISA (n=16) 
[18-33] and the remaining used multiplex arrays [34-41]. Concomitantly to the analysis of IL-1α 
and/or IL-1RA, nine articles used tape stripping to sample additional cytokines and chemokines 
[20-23, 34, 36-38, 40]. The additional measurement of the total protein content on the tapes 
was used as a biomarker of the cohesiveness of the SC [20, 27, 36, 40, 41] . 
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 Among the advantages of tape stripping, the minimal invasiveness and the short duration 
of the procedure were mentioned [19, 20], suggesting that the cytokine amounts are hardly 
influenced by the sampling process [20]. Among the drawbacks, the fact that in normal SC only 
IL-1α and IL-1RA are present in sufficient amounts for routine cytokine determination [19]. In 
agreement with this, some articles reported that other cytokines and chemokines were not or 
rarely detected [21-23, 34]. Moreover, a study of de Jongh et al. [20] evaluated the distribution 
of IL-1α and IL-1RA in the SC, showing that, while in normal SC the distribution does not 
change with depth, after perturbation with chemical substances it changes significantly. The 
authors concluded that, in the study of irritated or diseased skin, it would be better to sample 
the whole SC. Observations about the variability of amounts across the SC were also reported 
in other studies [32, 40].
Skin suction blistering
 The second most widespread method to sample IL-1α and/or IL-1RA was based on skin 
suction blistering (n=15). In this technique, introduced by Kiistala et al. [42] in the 1960s, the 
viable epidermis is separated from the dermis by application of negative pressure, resulting in 
the generation of artificial blisters. In the articles included in this review, the negative pressure 
was between 200 and 400 mmHg, the suction cups ranged in size from 5 to 15 mm and the time 
needed for the formation of the blisters was mostly 2-3 hours. Warming was sometimes added 
to aid blister formation. For the quantification of the protein levels of IL-1α and/or IL-1RA, the 
majority used EIA/ELISA (n=10) [43-52] and the remaining used multiplex arrays [53-57]. All 
studies but two analyzed additional cytokines and chemokines, albeit many reported that not 
all could be detected [43-45, 51, 52, 54, 55]. 
 The advantage offered by the assessment of the local inflammatory profile in the suction 
blister fluid [54, 55] was counterbalanced by the suggestion that the local trauma caused by 
the suction process might induce cytokines release and formation, thereby influencing the 
measured amounts [46-48, 50]. Other reported issues included the cumbersomeness of the 
technique [56], the possibility of pain during the procedure [57] and the possibility of blood 
contamination of the blister [52]. 
Adsorption by Sebutape
 The third most common method consisted in the adsorption of IL-1α and/or IL-1RA 
from the skin surface by means of a lipophilic tape, Sebutape (CuDerm, Dallas, TX, USA) (n=9). 
Sebutape, originally developed for the extraction of sebum from the skin, was demonstrated 
by Perkins et al. [58] to be able to recover quantifiable levels of inflammatory proteins from 
normal skin. All articles used ELISA to quantify the protein levels of IL-1α and/or IL-1RA [58-
65], except one which used a multiplex array [66]. In addition to the measurement of IL-1α and/
or IL-1RA, four articles sampled additional cytokines and chemokines [58, 63, 64, 66]. However, 
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authors reported that some of these additional biomarkers were frequently extremely low or 
not detected. 
 The minimal-invasiveness of the method was demonstrated by Perkins et al. [58] by 
analyzing the impact of 30 sequential applications of Sebutape on the skin and finding no 
upregulation of IL-1α nor IL-8, another inflammatory cytokine, up to 24 hours after stimulation. 
However, the same author warned about the problem of sebum deposition on the tape, which 
could compete with IL-1α for adsorption. As a consequence, all articles employing this method 
used short (1-2 minutes) collection times. 
Skin chamber technique
 Four articles sampled IL-1α and/or IL-1RA using a skin chamber technique. This 
technique, developed from the skin suction blistering method, was used as in vivo model 
to study the cutaneous inflammatory response in humans and, specifically, the dynamics 
of leukocyte migration [67]. In this procedure, after removal of the blister roof obtained by 
application of negative pressure, the denuded dermis (“skin window”) is covered by a chamber 
containing a medium capable to induce a chemotactic response (mostly autologous serum) 
[67]. All articles included in this review collected the skin chamber fluid between 3 and 24 
hours after removal of the blister roofs and, besides IL-1α and/or IL-1RA, used ELISA to 
analyze additional cytokines and chemokines [68-71]. 
Microporation
 Three articles used microporation to sample IL-1α and/or IL-1RA. In this technique, an 
infrared laser is used to generate micropores (approximately 100-µm wide) up to the first tens 
of µm in the epidermis. Transdermal fluid (TDF) is then collected by application of negative 
pressure similarly to the skin suction blistering technique (around 300 mmHg for 3-4 hours). 
One article analyzed IL-1α with ELISA and IL-1RA with a multiplex array [72], whereas the 
others used only multiplex arrays [73, 74]. All studies also assessed additional cytokines and 
chemokines but reported that some were extremely low or not detected. 
 While being less invasive than the skin blistering technique, as the impact on the 
integrity  of the tissue is relatively minor [74], concerns arise about the collection efficiency of 
TDF, since in one out of nine volunteers [72], seven out of 28 volunteers [73] and six out of 16 
volunteers [74] collection of TDF failed or was too low. The possible impact of the procedure 
on the measured amounts of cytokines should be considered and additional data on the 
reproducibility of the depth of the laser-generated micropores would be needed. 
Swabbing
 Three articles sampled IL-1α and/or IL-1RA by swabbing the skin with cotton-tipped 
swabs or cotton buds impregnated with a solution of saline and Triton to lyse cells and extract 
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proteins. All articles used ELISA to analyze IL-1α and/or IL-1RA together with other cytokines 
and chemokines [75-77]. 
Skin surface wash sampling
 Two articles sampled IL-1α and IL-1RA by means of skin surface wash. In this technique, 
proposed by Portugal-Cohen et al. [78], a small well is attached to the skin by an adhesive pad 
and is filled with 0.5-1 mL extraction buffer consisting of phosphate buffered saline (PBS) 
with pH around 7. After sealing, the well is left on the skin for a 30-minute incubation time. 
Collected samples were analyzed with ELISA in the study of Portugal-Cohen et al. [78] and with 
multiplex arrays with varying detectability levels in a more recent study [79]. 
 The advantage of the method relies on its minimal invasiveness, whereas its drawback 
is the relatively long incubation time [80]. Moreover, the extraction buffer is only suitable to 
extract hydrophilic compounds; lipophilic compounds could be sampled using a more suitable 
extraction buffer containing surfactants [80]. 
 Of note, a similar version of this method (though defined as a “skin chamber technique”) 
was used by Reilly et al. [48] to sample biomarkers from tape-stripped skin. Yields of IL-1α 
increased by increasing the incubation time and the number of tape strips. 
Microdialysis
 One study used microdialysis to sample IL-1α and other biomarkers and quantified 
them by multiplex array [81]. Two linear semi-permeable membranes were inserted into the 
volar forearm of healthy volunteers at a depth of 0.7 mm for a length of 20 mm. Upon onset 
of probe perfusion with buffer, extracellular molecules would diffuse through the membranes 
into the probe lumen to be collected in the exiting fluid (dialysate). Dialysate collection lasted 
for 30 minutes and was performed at baseline and at several time points following intradermal 
injection of allergen. 
 Although almost all biomarkers could be detected following allergen injection, the use 
of microdialysis for sampling large proteins, such as cytokines, is challenging [82]. In order 
to increase relative recovery, an in-house membrane with molecular mass cut-off of 3000 
kDa was used, much higher than the molecular mass cut-off of 100 kDa usually employed 
in commercially available membranes for cytokine sampling [82, 83]. This can expose the 
membranes to ultrafiltration, possibly causing significant loss of dialysate [82, 83]. Other 
effects potentially hampering the recovery rate of cytokines in microdialysis include low analyte 
concentration in the extracellular milieu and the adsorption onto the polymeric materials used 
to construct the membranes and the outlet probe [82, 83]. Finally, commonly to skin suction 
blistering and microporation, the trauma to the skin due to probe insertion and the possible 
effect on the measured amounts of biomarkers should be considered. 
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Scraping
 In one article, delicate scraping with a surgical blade was used to obtain extracts of SC 
from healthy volunteers and scales from plaques of patients with psoriasis [84]. Samples of 10 
mg were homogenized in PBS and levels of IL-1RA and other biomarkers were subsequently 
analyzed with a multiplex array. 
Transdermal analyses patch
 A novel method to sample IL-1α and IL-1RA from the skin surface was introduced by 
Orro et al. [85]. In this method, a transdermal analyses patch (TAP) is attached to the skin by 
means of a dermal adhesive plaster. On the side in contact with the skin, the patch contains a 
circular nitrocellulose micro-array (5 mm in diameter) coated with antibodies for four different 
protein biomarkers. On the upper side, covering the micro-array, a reservoir allows addition 
of a standardized amount of buffer (PBS at pH 7.3) for biomarker extraction and ensures 
close contact between the micro-array and the skin. In the study of Orro et al. [85], following 
optimization of the protein capture and detection protocols, 20 minutes resulted a suitable 
incubation time for biomarkers extraction. After removal of TAP, biomarkers were analyzed 
using ELISA. 
 In the same study, authors compared the biomarkers yield of TAP and of the skin surface 
wash sampling method, showing higher yield of proteins for the former. They suggested that 
the higher sensitivity of TAP might be due to higher concentration of proteins in the buffer, or 
to possible degradation of analytes in skin surface wash. Also Reilly et al. [48], using a similar 
version of skin surface wash, suggested that the reason why some mediators could not be 
detected could be dilution of the small amount of inflammatory exudates in a large volume of 
PBS. 
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DISCUSSION
 The primary objective of this study was to systematically review minimally-invasive 
methods whereby the pro-inflammatory cytokine IL-1α and its receptor antagonist IL-1RA 
were sampled from the skin of human volunteers in vivo, and subsequently analyzed at the 
protein level by means of immunoassays. Ten different methods were found. Common to all 
methods was the possibility to assess, in addition to IL-1α and/or IL-1RA, other biomarkers 
including pro-inflammatory cytokines, anti-inflammatory cytokines, chemokines, and various 
growth factors. Since not every article explicitly mentioned if IL-1α, IL-1RA or the other 
biomarkers were measurable in all samples, a comparison of the different methods based 
on the detectability level of the collected biomarkers was not possible. As a general trend, 
IL-1α and IL-1RA were often or consistently measurable, whereas the other biomarkers were 
sometimes rarely or not detectable. Possible reasons could be absence in the epidermis, low 
production or production in different time courses, rapid uptake by target cells, and insufficient 
sensitivity of the assay [21, 48, 55, 58, 74, 81]. Another frequently reported aspect was the large 
inter-subject variability in the biomarkers amounts [21, 32, 36, 43, 45-47, 56, 58, 63, 64, 72, 73, 
81], for which authors resorted to non-parametric statistical analyses or to log-transformation 
of the data. 
 The balance between the expression levels of cytokines of the IL-1 family is decisive 
in the generation of pro-inflammatory and homeostatic functions [5]. In particular, the ratio 
between IL-1RA and IL-1α can be used to assess skin inflammation [4]. Compared to healthy 
volunteers, an increase in the IL-1RA/IL-1α ratio was observed in patients with inflammatory 
skin diseases including psoriasis, atopic dermatitis (AD), dandruff, seborrhoeic dermatitis and 
rosacea [32, 36, 63, 64, 75]. This indicates that the increased ratio could be considered a non-
specific hallmark of various kinds of inflammation [32, 36, 63], and might reflect an attempt 
to downregulate the inflammatory response [64]. This is supported by a decrease in the levels 
of IL-1α and in the IL-1RA/IL-1α ratio observed after topical treatments [18, 25, 27, 32, 35, 
36, 39, 75, 77] and by a decreased IL-1α expression found in full-thickness biopsy specimens 
of psoriatic skin [86]. The ratio might also highlight differential expression of inflammatory 
markers following different modalities of skin irritation, since an increased ratio compared to 
normal skin was observed after repeated exposure to sodium lauryl sulfate (SLS) [21, 72] and a 
lower ratio was reported after single exposure to SLS [58] or after tandem exposure to SLS and 
another irritant [34]. Interestingly, an increased ratio could also distinguish non-lesional skin 
in patients with AD, psoriasis and rosacea from skin of healthy volunteers [32, 64], as well as 
sun-exposed skin on the face compared to unexposed skin [23, 32, 58, 85]. This suggests that 
inflammatory changes might be present even in normal-appearing skin and supports what 
Professor Kligman called “invisible dermatoses” [87].
 Among the extrinsic factors possibly affecting the recovered amounts of IL-1α and IL-
1RA figure season, since a lower IL-1RA/IL-1α ratio was found in summer compared to winter 
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[41], and ultraviolet (UV) exposure, since release of IL-1α and/or IL-1RA was observed following 
UV irradiation [23, 43, 56, 73]. These factors indicate that data collection and skin phototype 
(e.g. Fitzpatrick skin type) should be specified, as they might constitute potential confounders. 
In addition, the presence of IL-1α in sweat [22] and the increased expression of IL-1α at low 
humidity [88] suggest that the temperature and relative humidity of the experimental room 
should be standardized, as for measurements with bioengineering techniques [89-91]. Among 
the intrinsic factors, conflicting results emerged for gender, since differences were found in 
one study [19] and not in others [28, 35], as well as for age, since an effect was observed in 
some studies [23, 79] and not in others [31, 34]. In the particular case of infant skin, higher 
IL-1α levels without concomitant signs of inflammation were found in neonates compared to 
adults [38] and at one month post-partum compared to birth [62], suggesting that, for this 
specific age group, IL-1α might be used as a biomarker of skin barrier maturation [62].
 The limitation of this study is that the restriction of the search strategy to IL-1α and 
IL-1RA could have excluded minimally-invasive methods used to sample other biomarkers. 
The addition of relevant cytokines and chemokines such as IL-1β, IL-6 and IL-8 [4] would have 
strengthened and, possibly, broadened the overview of minimally-invasive sampling methods; 
on the other hand, it would have also complicated the search strategy and prolonged the article 
selection process. Despite this obvious limitation, we believe that the relevance of the chosen 
biomarkers and the systematic article selection process maintain the validity of the overview of 
minimally-invasive methods presented in this review. 
 In conclusion, this review showed that several methods are available to collect 
quantifiable amounts of IL-1α, IL-1RA and other biomarkers from the skin, causing no or 
minimal discomfort. This is relevant on both practical and ethical grounds. Whereas it might 
be possible to argue that the levels of biomarkers measured in the fluid extracted by skin 
suction blistering, microporation and microdialysis are more representative of the overall 
levels present in the skin, the long collection time and the relative invasiveness make them less 
practical for use in routine testing. Tape stripping, adsorption with Sebutape, swabbing, skin 
surface wash sampling, scraping and TAP, characterized by shorter collection time and lower 
invasiveness, would be more fit for that purpose. However, it needs to be realized that these 
methods sample biomarkers at the skin surface, and that surface levels do not necessarily 
correspond to the ones in deeper skin layers. Independently of the method used, assessing the 
individual cytokine profile locally in the skin would bring additional insights than assessing it only 
systemically in blood [54, 55, 69, 81]. We strongly encourage performing clinical investigations 
to gain further insights into the relationship between clinical responses and biomarkers at the 
molecular level. This will hopefully lead to  implementation these minimally-invasive methods 
in clinical practice to target and monitor therapies, predict disease progression and response 
to treatment.
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5.1Figure S2. Results of the article selection process.
ABBREVIATIONS 
a*  CIE spectrum (Commission Internationale de l’Éclairage): a*, b* and L* values
CCL  (C-C motif) ligand 
CRP  C-reactive protein 
CXCL  (C-X-C motif) ligand 
ELISA  Enzyme-linked immunosorbent assay
hBD  Human beta defensin
IL  Interleukin
PBS  Phosphate buffered saline
RCM  Reflectance confocal microscopy
SC  Stratum corneum
TAP  Transdermal analyses patch
TEWL  Transepidermal water loss
TL-1A  TNF-like ligand 1A
TNF  Tumor necrosis factor
TSLP  Thymic stromal lymphopoietin
VEGF  Vascular endothelial growth factor
5.2
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Transdermal Analyses Patch following different  
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Spee P2
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van de Kerkhof PC1
van Erp PE1
Skin Res Technol, 2017. 23(3): 336-345.
1 Department of Dermatology, Radboud University Medical Center,  
Nijmegen, the Netherlands.
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ABSTRACT
Background/aims: FibroTx transdermal analyses patch (TAP) is a novel technology for non-
invasive measurements of protein biomarkers on the skin surface, in vivo.  The aim of this 
study was to explore the potential of TAP in detecting skin surface biomarkers following mild 
perturbations, in vivo, using two experimental models: tape stripping, mimicking acute barrier 
disruption, and histamine iontophoresis, mimicking acute and local inflammation at minimal 
skin barrier insult.
Methods: Tape stripping and histamine iontophoresis were performed in two separate 
experiments on the volar forearm of healthy volunteers (n=27 and n=10, respectively). 
Biomarker levels were assessed with TAP at baseline and up to 72 hours after stimulation. 
Functional (transepidermal water loss – TEWL – and a* value) and morphological (reflectance 
confocal microscopy – RCM) assessments were added in the tape stripping and histamine 
iontophoresis experiments, respectively. 
Results: Cytokines IL-1α and IL-1RA and the antimicrobial peptide hBD-1 showed distinct 
dynamics, despite substantial inter-individual variation in levels, with an increase following 
tape stripping and a decrease following histamine iontophoresis. These dynamics could 
be related to the assessments made by TEWL and RCM. In the tape stripping experiment, 
additional biomarkers could be detected. 
Conclusion: TAP measurements, especially IL-1α, IL-1RA and hBD-1, from the skin surface 
were sensitive enough for monitoring dynamic changes in the skin in the two models of skin 
perturbation. We conclude that TAP holds promise for non-invasively unraveling the dynamics 
of processes related to skin perturbation and repair.
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5.2
INTRODUCTION
 The barrier function of the skin is mainly fulfilled by the stratum corneum (SC), 
consisting of a compact structure of dead, flattened cornified cells (corneocytes) embedded 
in a lipid matrix [1]. Corneocytes derive from differentiation of keratinocytes in the underlying 
epidermis, a process initiated at the stratum basale, the boundary between the epidermis 
and dermis. Upon disruption of the skin barrier, a cascade of events occurs, leading to the 
onset of an inflammatory response that triggers the repairing mechanisms that ultimately 
restore the barrier integrity. Present evidence shows that this process involves different 
cytokines and intercellular interactions [2]. The release of a pre-formed pool of interleukin 
(IL)-1α, which is constitutively present in keratinocytes and the SC, is considered to be the 
first step in the inflammatory cascade [3]. IL-1α stimulates keratinocytes and fibroblasts to 
produce early pro-inflammatory cytokines and chemokines, e.g. IL-1β, IL-6, IL-8, and tumour 
necrosis factor (TNF)-α [3]. One of the effects of these secondary pro-inflammatory cytokines 
and chemokines is to stimulate and attract a variety of immune cells, e.g. T- and B-cells, 
neutrophils, and immature dendritic cells [2]. To counteract these inflammatory processes, 
keratinocytes also release anti-inflammatory mediators, such as IL-1 receptor antagonist (IL-
1RA), which is also constitutively present in keratinocytes and the SC and functions by blocking 
the IL-1 receptors [3, 4]. The balance between IL-1RA and IL-1α plays an important role in 
the regulation of the inflammatory response in skin and in skin homeostasis in general [2, 5]. 
In addition to cytokines and chemokines, keratinocytes release lamellar bodies in the upper 
epidermis upon disruption of the skin barrier [6-8]. These organelles release lipids and anti-
microbial peptides (e.g. human beta defensin (hBD)-1 and hBD-2) in the extracellular space, 
thus forming a chemical barrier against invasion of pathogens during the repairing process [8]. 
Several studies have shown co-regulation between processes regulating skin permeability and 
microbial defense during skin repair, indicating that these distinct barrier functions of the skin 
are inter-dependent rather than independent [6, 7].                 
 Given their essential role in orchestrating skin defense and repair, several in vivo 
approaches have been developed to sample proteins that regulate these processes. Among 
the invasive methods figure skin punch biopsies, in which both inflammatory mediators and 
antimicrobial peptides can be detected [9-11]. Minimally invasive methods are based on 
harvesting material from the superficial layers of the skin; examples include removal of SC 
by sequential application of adhesive tape (tape stripping) [3-5, 12-14], extraction of interstitial 
fluid by microporation of the SC and epidermis followed by vacuum application [15, 16], and 
adsorption of skin surface mediators by a lipophilic tape (Sebutape, CuDerm, Dallas, TX, USA) 
[17-19]. A non-invasive method based on skin surface wash sampling of mediators secreted 
from the skin has also been described [20, 21]. Despite their undeniable value for skin research, 
these methods affect skin and/or have technical restrictions which limit their potential for 
measuring subtle changes in skin at different time-points over a condensed period of time. 
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 Recently, a novel and non-invasive technique based on enzyme-linked immunosorbent 
assay (ELISA) has been developed for simultaneous measurements of proteins directly from 
the skin surface [22]. The so-called transdermal analyses patch (TAP) is applied directly to the 
skin surface, where it captures proteins of interest by immune-recognition. With this method, 
IL-1α, IL-1RA, and hBD-1, skin mediators that are constitutively present in the skin [3, 7], could 
be detected on healthy, intact skin [22]. However, it has as yet not been addressed whether TAP 
can measure qualitative and/or quantitative changes of skin regulatory proteins during, for 
instance, skin irritation, inflammation, infections, skin ageing or skin repair. 
 The aim of this study was to explore whether TAP is able to detect dynamic changes 
in skin responding to irritants in vivo by measuring, on the skin surface, a panel of proteins 
expressed in the skin at various time-points. For this, two well-established in vivo models of 
skin irritation were employed on healthy volunteers. In a first experiment, tape stripping was 
used as a model of acute barrier disruption. In addition to TAP measurements, transepidermal 
water loss (TEWL) and redness (a* value) were measured in order to characterize the irritant 
reaction by traditional biophysical methods. In a second experiment, histamine iontophoresis 
was used as a model of acute and local skin inflammation with minimal barrier impairment. 
Morphological changes induced by the irritant reaction were characterized by reflectance 
confocal microscopy (RCM). In both experiments, levels of biomarkers were measured at 
baseline and at different time points following skin irritation. In addition to IL-1α, IL-1RA and 
hBD-1, TAPs for detection of several other constituent and inducible mediators were included. 
PATIENTS AND METHODS
Study participants
 Twenty-seven (25 females, 2 males) healthy volunteers were included in the first study, 
carried out between September and November 2015, and 10 (7 females, 3 males) healthy 
volunteers were included in the second study, carried out between May and July 2016. Mean 
age was 27 (18-62) years old in the first study and 34.6 (19-62) years old in the second study. 
Criteria for inclusion were Fitzpatrick skin type I-II-III and willingness to give a written informed 
consent. Pregnant or breastfeeding women and volunteers with a history of skin diseases, 
atopic or allergic predisposition (i.e. atopic dermatitis, asthma, allergic rhinoconjuctivitis), use 
of immunosuppressive drugs and compromised skin at the experimental sites (volar forearms) 
were excluded from participation. For the second study, presence of implanted electrical 
devices (e.g. cardiac pacemakers) was an additional exclusion criterium. In both studies, 
volunteers were asked not to apply toiletries (e.g. shower gels, moisturizers) on their forearms 
from 24 hours before the experiments and not to sunbathe or use a tanning bed from two weeks 
before the experiments. To comply with the guidelines of biophysical measurements, the first 
experiment was performed under controlled temperature and relative humidity conditions (20-
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22 °C, 40-60% relative humidity). Both studies were performed at the dermatology department 
of the Radboud University Medical Center in Nijmegen, the Netherlands, and were approved by 
the ethics committee Regio Arnhem-Nijmegen. 
Detection of skin surface biomarkers by TAP
 Four different TAPs were used, each containing a micro-array coated with antibodies for 
the measurement of protein biomarkers: TAP1, containing antibodies for IL-1α, IL-1RA, hBD-1, 
and chemokine (C-X-C motif) ligand 2 (CXCL-2); TAP2, containing antibodies for IL-8 (or CXCL-
8), TNF-α, thymic stromal lymphopoietin (TSLP), and vascular endothelial growth factor-A 
(VEGF-A); TAP3, containing antibodies for CXCL-3, TNF-like ligand 1A (TL-1A), hBD-2, and 
hBD-4; TAP4, containing antibodies for IL-4, C-reactive protein (CRP), CXCL-1, and chemokine 
(C-C motif) ligand 2 (CCL-2). Each TAP was attached to the skin via the provided adhesive 
bandage and, after addition of a standardized amount of buffer on the reservoir covering the 
micro-array (phosphate buffered saline – PBS – at pH 7.3), it remained in contact with the skin 
for 20 minutes; during this time, the antibodies printed on the micro-array captured biomarkers 
through immune-recognition. After removal, TAPs were stored at 4 °C until analysis using 
spot-ELISA, as previously described [22]. 
Study 1: tape stripping and biophysical measurements
 Tape stripping was performed on four sites (Site 1, Site 2, Site 3 and Site 4) on the non-
dominant mid volar forearm using a metal oblong plate with an oval aperture (13 mm x 22 
mm, 2.9 cm2) covered by adhesive tape (6890 PVC Tape, Scotch, 3M, Maplewood, MN, USA) to 
standardize extension of the skin and the velocity and angle of removal [23]. Tape application, 
performed by the same investigator, was stopped when the skin became homogeneously 
refulgent and the tape did not stick anymore, indicative of the removal of the whole SC. The 
number of strips necessary to remove the SC was counted in each site and averaged. 
 Volunteers were divided in four groups and in each group the same type of TAP (either 
TAP1, TAP2, TAP3, or TAP4) and study protocol (summarized schematically in supplementary 
Figure S1) were applied. Immediately after tape stripping (0-20 minutes), TAP was applied 
on Site 1. At 20-40 minutes after tape stripping, TAP was applied on Site 1 and Site 2; at 24 
hours, on Site 2 and Site 3; at 72 hours, on Site 2, Site 3 and Site 4. The rationale for the 
application of TAP on different sites was to evaluate whether the previous application affected 
the successive measurement. The overall dynamics of biomarkers levels was obtained by 
taking the measurement performed on the site in which TAP was applied for the first time (i.e. 
0-20 minutes: Site 1; 20-40 minutes: Site 2; 24 hours: Site 3; 72 hours: Site 4). In addition, TEWL 
(Aquaflux AF200, Biox, UK) and a* value (Spectrophotometer 2600d, Konica Minolta, Japan) 
were measured on Site 4 at 10 minutes, 30 minutes, 24 hours and 72 hours after tape stripping, 
in order to exclude possible effects of previous TAP application. Three and two measurements, 
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respectively, were performed and the average value was calculated. Baseline measurements 
with TAP, TEWL and a* value were performed on the contra lateral mid volar forearm. 
Study 2: histamine iontophoresis and RCM measurement
 Histamine iontophoresis was performed on the non-dominant mid volar forearm 
using 1.5 mL of a solution of 0.5% histamine dihydrochloride (Allergopharma B.V., Zeist, 
the Netherlands) in 1% hypromellose gel prepared by the local pharmacy. Stimulation was 
performed at 0.4 mA for 2.5 minutes using a iontophoresis sytem (Chattanooga Group, Hixson, 
TN, USA) and a couple of silver-silver chloride electrodes with an active area of 7.2 cm2 
(Iomed Iogel Iontophoresis Electrode Small; Chattanooga Group, Hixson, TN, USA). Prior to 
stimulation, the skin areas where the electrodes needed to be applied were gently rubbed with 
a 5 cm x 5 cm tissue (Cutisoft, BSN medical GmbH, Hamburg, Germany) soaked in 1.5 mL 
demineralized water in order to remove sebum and other impurities. 
 All four TAP types were applied on the area stimulated by histamine iontophoresis at 
the following time points: immediately after stimulation, at 1 hour after stimulation, and at 
72 hours after stimulation. In addition, imaging with RCM (VivaScope 1500 system, Lucid Inc., 
USA) was performed at 30 minutes, 90 minutes, and 72 hours according to a standardized 
protocol. Two horizontal maps of 4 mm x 4 mm (Vivablock) were made at the level of the 
SC/granulosum and at the stratum spinosum, while two vertical mappings (Vivastack) were 
performed by capturing a series of images of 0.5 mm x 0.5 mm starting from the skin surface 
up to 150 µm in depth with steps of 3 µm. Of note, for the RCM measurement at 30 minutes, 
only two Vivastacks were taken, in order to minimize the contact time of the device with the 
skin, possibily influencing the subsequent measurement at 1 hour with TAP. The thicknesses 
of the SC and living epidermis were measured as previously described [24] by two observers 
(DF and MP), and averaged. Baseline measurements with TAP and RCM were performed on the 
contra lateral mid volar forearm.
Statistical analysis
 Results are presented as median (minimum-maximum). Differences in the 
measurement of the same biomarker between different sites in study 1, as well as differences 
in the measurement of the same biomarker between baseline and post stimulus time points in 
study 1 and 2, were evaluated with the Wilcoxon signed rank test for matched pairs. Statistical 
analyses were performed with GraphPad Prism version 5.03 for Windows (GraphPad Software 
Inc., USA). A p value ≤0.05 was considered statistically significant. Missing values were excluded 
from the analyses. Due to the exploratory nature of this study, no corrections for multiple 
comparisons were applied.
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RESULTS
Study 1: levels of biomarkers following tape stripping
 A total of n=7 volunteers per TAP type were included, with exception for the TAP2 group 
in which n=6 volunteers were included. No differences with respect to age, gender, Fitzpatrick 
skin type and mean number of strips needed to remove the SC (n=25.7, range 14.3-40.3) were 
present between the four groups. 
 We were able to detect 15 out of 16 biomarkers. In two subjects, TAP3 biomarkers at 
0-20 minutes and 20-40 minutes after tape stripping could not be measured, possibly because 
of a damage to the patches. The results of the 7 most consistently measurable biomarkers 
are shown in Figure 1. The levels of biomarkers showed large inter-individual differences. 
However, despite this variation, some showed a clear upregulation following stimulation: IL-
1RA, IL-1α, and hBD-1. The median level of IL-1RA increased 4.6- to 6.9-fold in the first 24 
hours after tape stripping, while at 72 hours it was back at baseline (0.9-fold increase). The 
median level of IL-1α showed a similar trend, albeit the increase was less pronounced in the 
first 24 hours (2.7- to 3.5-fold increase) and at 72 hours it was lower than baseline (0.3-fold 
increase). The median level of the ratio between IL-1RA and IL-1α was higher at 24 and 72 
hours when compared to baseline (1.8 at 24 hours and 0.9 at 72 hours versus 0.5 at baseline), 
albeit the differences were not significant (supplementary Figure S2). The median level of hBD-
1 increased 2- to 3.2-fold following tape stripping and, differently from IL-1RA and IL-1α, was 
still higher than baseline at 72 hours (1.9-fold increase). The median level of hBD-2 seemed 
to show a delayed upregulation similar to hBD-1, with the highest increase at 24 hours (2.2-
fold), but at 72 hours it was back at baseline (0.9-fold increase). Other biomarkers, despite 
being measurable, either did not show a clear trend toward upregulation (CXCL-3 and CRP), or 
were too close to the detection limit of the assay (hBD-4), to be able to define their dynamics 
following tape stripping. 
 When a comparison between different sites was made for the previously mentioned 
biomarkers, differences were found for IL-1RA, IL-1α and hBD-1: all showed decreased levels 
on Site 1 compared to Site 2 at 20-40 minutes after tape stripping. For IL-1α, levels were also 
lower on Site 2 compared to Site 3 at 24 hours after tape stripping. At other time points, and 
for the other biomarkers (hBD-2, CXCL-3, CRP and hBD-4), no differences emerged between 
different sites (supplementary Figure S3). 
 Eight mediators were rarely detected, preventing an assessment of the dynamics after 
tape stripping: IL-8, TNF-α, TSLP, VEGF, TL-1A, CXCL-1, CCL-2 and IL-4. CXCL-2 was never 
detected in any of the samples.
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Figure 1. Results of the 7 most consistently detectable biomarkers measured at baseline and at several 
time points after tape stripping (n=7/biomarker; horizontal bar represents median). * = p ≤0.05; # = 0.05<p< 
0.08.
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Study 1: biophysical measurements
 TEWL and a* value measured at baseline and after tape stripping are shown in Figure 2. 
Both measurements increased significantly immediately after tape stripping; at 24 hours they 
started to recover, but were still higher than baseline after 72 hours (p<0.001). 
Figure 2. TEWL and a*value measured at baseline and at several time points after tape stripping (n=27; 
median and range). * = p ≤0.05.
Study 2: levels of biomarkers following histamine iontophoresis
 No differences with respect to age and Fitzpatrick skin type were present between 
the volunteers included in this study and the volunteers included in each group of the tape 
stripping study. 
 We were able to detect 6 out of 16 biomarkers. Of these, IL-1RA, IL-1α, and hBD-1 
were the most consistently measurable and their dynamics after histamine iontophoresis is 
shown in Figure 3. The median levels of IL-1RA and of hBD-1 had a similar dynamics, as both 
decreased in the first 80 minutes after histamine iontophoresis (1.6- and 2.2-fold decrease for 
IL-1RA, and 2.4- and 4.1-fold decrease for hBD-1), and both were back at baseline at 72 hours 
(1.1- and 1.4-fold decrease for IL-1RA and hBD-1, respectively). Compared to baseline, the 
median level of IL-1α increased slighlty immediately after histamine iontophoresis (1.6-fold 
increase), then decreased at 60 minutes after stimulation (1.7-fold decrease). At 72 hours, the 
median level of IL-1α was back at baseline (1.2-fold increase). The median level of the ratio 
between IL-1RA and IL-1α was lower immediately after histamine iontophoresis compared to 
baseline (0.3 at 20 minutes versus 0.4 at baseline), while no differences were present at later 
time points (supplementary Figure S2).
 CXCL-2, CXCL-3 and TNF-α were rarely detected, preventing an assessment of their 
dynamics after histamine iontophoresis. All other biomarkers were never detected in any of the 
samples.
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Figure 3. Results of the 3 most consistently detectable biomarkers measured at baseline and at several 
time points after histamine iontophoresis (n=10/biomarker; horizontal bar represents median). 
* = p ≤0.05; # = 0.05<p<0.08.
Study 2: SC and epidermal thickness measured with RCM
 SC and living epidermis thicknesses measured at baseline and after histamine 
iontophoresis are shown in Figure 4. The thickness of the SC increased markedly at 30 minutes 
after stimulation (p=0.006) and, despite a recovery, was still higher than baseline at 90 minutes 
(p=0.036). No significant changes in the thickness of the living epidermis were detected. Of 
note, in most volunteers an increase in the reflectance of the SC was visible at 30 and 90 
minutes, often accompanied by a decrease in the contrast of the first nucleated cells at the 
boundary between the SC and stratum granulosum, as shown in Figure 5.
Figure 4. Stratum corneum (SC) and living epidermis thicknesses measured by reflectance confocal 
microscopy (RCM) at baseline and at several time points after histamine iontophoresis (n=10; median and 
range). * = p ≤0.05; # = 0.05<p<0.08.
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Figure 5. Representative RCM images at the boundary between the stratum corneum (SC) and stratum 
granulosum at baseline (a), at 30 minutes after histamine iontophresis (b), and at 90 minutes after 
histamine iontophoresis (c). a) The first nucleated cells delimitating the border between the SC and the 
stratum granulosum are well-defined. The surrounding areas present a low reflectance level typical of 
normal skin. b) At 30 minutes, the boundaries between the first nucleated cells are ill-defined, possibly 
because of the presence of intracellular fluid. The surrounding areas are higly reflective, possibly indicating 
an hydration effect of the active electrode or of the underlying edema. c) At 90 minutes, the boundaries of 
the first nucleated cells are better defined and the reflectance is lower compared to the stituation at 30 
minutes, indicating the decrease of the effects of histamine iontophoresis on the SC.
DISCUSSION
 The aim of this pilot study was to explore the feasibility of using TAP to objectively detect 
subtle changes in skin surface mediators in two well-established in vivo models of skin irritation, 
tape stripping and histamine iontophoresis. In both models, IL-1α, IL-1RA and hBD-1 could be 
consistently measured, as reported previously [22], albeit with very different dynamics. In the 
first hour after tape stripping, a higher amount of IL-1α, IL-1RA and hBD-1 was detected, while 
in the first 80 minutes after histamine iontophoresis, lower amounts were detected. This likely 
reflects the different nature of the two models. In tape stripping, the removal of SC disrupts 
the skin barrier completely, thus making the pool of IL-1α, IL-1RA and hBD-1 more accessible 
for TAP measurements. In histamine iontophoresis, the SC remains intact while its thickness 
increases due to hydration from the active electrode and, possibly, from the underlying edema, 
originated as part of the triple response to histamine, with the consequent “dilution” of the 
biomarkers [15], resulting in less amount detected by TAP. A “wiping” effect of the superficial 
biomarkers due to the application of the active electrode cannot be excluded either. However, 
despite the influence of the nature of the two models, we believe that the measurements with 
TAP reflect the underlying dynamics of these mediators following irritation. This hypothesis 
is supported by the following observations. Firstly, it was shown that the release of a pre-
formed pool of IL-1α is one of the first steps in the inflammatory cascade following skin barrier 
disruption by tape stripping [9]; accordingly, in our study, IL-1α was upregulated in the first 24 
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hours after tape stripping, but it was back at baseline at 72 hours, a time point in which the 
skin barrier was not fully recovered as demonstrated by TEWL measurement in this study and 
by immunohistochemistry in previous studies [23, 24], possibly reflecting a downregulation of 
the inflammatory response at later time points. Secondly, the trend to higher IL-1RA/IL-1α 
ratio at 24 and 72 hours after tape stripping is in agreement with the notion that this ratio is 
increased in cutaneous inflammatory processes both in irritated and diseased skin [14, 17, 
18]. Third, the somewhat delayed upregulation of hBD-1 and, to a lesser extent, of hBD-2, is in 
line with previous findings in which upregulation of the microbial barrier of the skin was found 
from 24 hours after barrier disruption [11, 25]. Fourth, iontophoresis was shown to trigger the 
release of IL-1α as a consequence of the loss of the epidermal calcium gradient [26, 27]: the 
release of IL-1α might explain why this mediator was slighly increased in the first 20 minutes 
after stimulation, in contrast to the lower levels of IL-1RA and hBD-1 measured becaused of 
the dilution effect of the edema.  
 The additional mediators currently available with TAP were rarely detected in the tape 
stripping study and, quite surprisingly, mostly not detectable in the histamine iontophoresis 
study. The reason for this discrepancy might be two-fold. Firstly, experiments were performed 
in the summer time in the second study and in autumn in the first study. Secondly, experiments 
in the second study were performed under less strictly-controlled ambient conditions, allowing 
temperature to be around two degrees higher than during experiments in the first study in 
which biophysical measurements were used. A higher moisture or sweat/sebum production on 
the surface of the skin, caused either by the seasonal and/or ambient room conditions, might 
have prevented the detection of other mediators already present at lower concentrations in the 
skin. It is therefore advisable that future studies with TAP are performed in controlled ambient 
temperature and humidity, similar to the conditions required for biophysical measurements. 
The influence of seasonal effects should nevertheless be further investigated, also considering 
that greater protein recovery in summer than in winter with the Sebutape adsorption method 
has been previously reported [18]. 
 Based on the literature data on in vivo tape stripping, we had expected to detect 
upregulation of TNF-α, IL-8, and TSLP [9, 10, 28, 29]. Low or undetectable levels of TNF-α 
and IL-8, in contrast to the availability of IL-1α and IL-1RA, have been reported with several 
minimally and non-invasive approaches [3, 4, 12, 15, 18-20]. TSLP was also not detected in the 
interstitial fluid extracted by microporation [16]. The difficulty in sampling IL-8 and TNF-α, as 
well as the other biomarkers available with TAP, might be due to a variety of reasons, including 
wrong time point of sampling, in which the levels might have already decreased below the limit 
of detection; rapid uptake by target cells; or absence within the upper skin layers [15, 16]. With 
respect to CXCL-3, and other inflammatory mediators sporadically measured at baseline, their 
presence in non-irritated skin has been proposed to be caused by a process called “immune-
surveillance”, consisting in the continuous attraction of inflammatory cells to guard against 
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pathogens and tumors [15]. CRP has been recently shown to be present in the basal layer, 
possibly due to extrusion from the underlying dermal vasculature [30].
 The high variability in biomarkers levels measured with TAP is common to other 
approaches of cytokine sampling [3, 4, 14, 15, 17-19]. The advantage of TAP with respect to a 
tape stripping approach lies in the reproducible method of cytokine sampling and extraction, 
not depending on sources of variation such as tape adhesiveness, application and removal 
force, angle and speed [31], making TAP measurements comparable between experiments 
performed in different laboratories. In addition, TAP does not damage the SC, unlike tape 
stripping, and as such does not affect the experimental model for skin irritation. Also, multiple 
markers can be simultaneously assessed and, in particular, the possibility to measure 
antimicrobial peptides (hBD-1, hDB-2) opens opportunities to evaluate both the recovery of the 
microbial and permeability barriers following perturbation, concomitantly and non-invasively, 
possibly allowing to gain new insights into their interdependence [6, 7]. However, it is necessary 
to consider that TAP, as other minimally and non-invasive methods, allows extraction of 
biomarkers mostly from the upper surface of the skin, and that biomarkers level there might 
not always be representative of the level in the whole skin [3]. In addition, our preliminary 
results on the use of TAP in skin irritation suggest that the immediate re-sampling from the 
same skin spot following irritation might lead to lower amounts of extracted biomarkers 
(supplementary Figure S3): future studies should thus consider to sample a slightly different 
location, or leave more time between successive samplings.
 In conclusion, this pilot study confirmed that TAP can measure IL-1α, IL-1RA and hBD-
1 consistently from the skin surface in both normal and irritated skin, and that it is sensitive 
enough to differentiate between different modalities of skin irritation and to show dynamics of 
skin irritation. Other biomarkers available with TAP could be more consistenly detected using 
other sampling time points, modalities of skin irritation or diseased skin. Further studies will 
need to take into account the control of ambient conditions, the avoidance of immediate re-
sampling at the same location and the inclusion of a sufficient number of volunteers to manage 
inter-subject variability [19]. The further characterization of the role of cytokines, chemokines 
and antimicrobial peptides by TAP in healthy and diseased skin might constitute a potential 
novel and non-invasive tool in several applications, such as in the assessment of sensory 
irritation, characterized by the development of sensations in absence of objective clinical 
signs of inflammation [2], in the quantitifation and monitoring of therapeutic treatments [17], 
and, ultimately, in the definition of a refined personalized diagnostic method and customized 
treatment [32]. 
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SUPPLEMENTARY FIGURES
Figure S1. Scheme of the study protocol of the tape stripping experiment.
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Figure S2. Ratio between IL-1RA and IL-1α at baseline and at several time points after (a) tape stripping 
(n=7; median and range), and (b) histamine iontophoresis (n=10; median and range). * = p ≤0.05.
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Figure S3. Differences between biomarkers measured on different sites on the volar forearm at baseline 
and at several time points after tape stripping (n=7/biomarker; median and range). * = p ≤0.05; # = 
0.05<p<0.08.
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 ABBREVIATIONS 
AD   Atopic dermatitis
CI  Confidence interval
CIE  Commission Internationale de l’Éclairage
CW  Continuous irradiation mode
DRS  Diffuse reflectance spectroscopy
DT  Delayed tanning
Hb  Hemoglobin
hBD  Human beta defensin
IL  Interleukin
IPD  Immediate pigment darkening
ITA  Individual tipology angle
LED  Light emitting diode
NIR  Near-infrared
NO  Nitric oxide
OPN  Opsin
oxy-Hb  Oxigenated hemoglobin
PV  Psoriasis vulgaris
PW  Pulsed irradiation mode
RCM  Reflectance confocal microscopy
ROS  Reactive oxygen species
SC  Stratum corneum
TAP  Transdermal analyses patch
TEWL  Transepidermal water loss
UV  Ultraviolet
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ABSTRACT
Background/aims: While growing evidence supports the therapeutic effect of 453-nm blue 
light in chronic inflammatory skin diseases, data on its effects on acutely-perturbed human 
skin are scarce. In this study we investigated the impact of 453-nm, narrow-band LED light on 
healthy skin following acute perturbation. 
Methods: Tape stripping and histamine iontophoresis were performed on the forearm of 22 
healthy volunteers over two consecutive weeks. In one week, challenges were followed by 
irradiation for 30 minutes. In the other week (control), no light was administered. Reactions 
were evaluated up to 72 hours thereafter by transepidermal water loss (TEWL), diffuse 
reflectance spectroscopy, and skin surface biomarkers. 
Results: At 24 hours after tape stripping, upregulation of interleukin-1α (IL-1α) emerged in the 
non-irradiated control (p=0.029). This was not the case in the irradiated location (p>0.05), which 
also displayed higher TEWL versus non-irradiated control (p=0.034). The b* value was higher at 
72 hours post light exposure compared to control (p=0.018). At 30 minutes following histamine 
iontophoresis and light treatment, a trend towards a higher a* value was observed (p=0.051). 
Conclusion: We provide the first, in vivo evidence that blue light at 453 nm exerts biological 
effects on acutely-perturbed healthy human skin. 
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INTRODUCTION
 Light and optical techniques have made a profound impact on photodermatology, 
where therapeutic applications span aesthetic and medical domains [1, 2]. Depending on 
wavelength, power density, exposure time, and optical properties of the skin compartments, the 
therapeutic action of light can be based on photomechanical, photothermal, photochemical, 
and photobiological interactions [3]. In particular, the therapeutic effects of ultraviolet (UV)-
free visible and near-infrared (NIR) optical radiation relying on non-thermal photochemical 
and photobiological interactions [4] have been the object of increasing consideration. Since the 
first pioneering studies using low-photon-density, red-laser light sources in the late 1960s [5], 
this field has expanded to embrace the more recently developed light emitting diodes (LEDs) 
with optical output covering the whole visible and NIR spectrum [4]. 
 While perhaps the vast majority of applications focuses on red and NIR wavelengths, 
UV-free blue light, corresponding to the spectral range of both violet (400-450 nm) and blue 
(450-495 nm), has been attracting increasing attention. A solid body of scientific data has been 
accumulated in the last decade, stemming from in vitro experiments on human cutaneous 
cells performed using well-defined irradiation parameters [6-13]. The current evidence 
attributes the high therapeutic potential of UV-free, 453-nm blue light to its anti-proliferative 
capacity on human endothelial cells, keratynocytes and fibroblasts [9, 13], often ascribed to 
initiation of cell differentiation triggered by the release of nitric oxide (NO) from nitrosated 
proteins. Interestingly, while fluences up to 500 J/cm2 were non-cytotoxic when applied to in 
vitro cell cultures of human endothelial cells and keratynocytes, a dose-dependent depletion 
of T-lymphocytes was observed [9], providing initial evidence for an anti-inflammatory effect 
of blue light. Additional evidence in this respect came from in vitro studies using HaCaT cells, 
where gene expression analysis showed downregulated pathways implicated in inflammatory 
responses [6], and using dendritic cells, where a reduced ability to release pro-inflammatory 
cytokines was shown [8, 11]. At the clinical level, the recently reported positive impact of blue 
light on aleviating symptoms of psoriasis vulgaris (PV) and atopic dermatitis (AD), chronic 
inflammatory skin diseases characterized by hyperproliferation and inflammatory infiltrates, 
holds promise for its therapeutic potential [14-17].
 In parallel with this in vitro and clinical works focusing on combating PV and AD, ex 
vivo studies on human hair follicles and in vitro studies on outer root sheath keratinocytes 
demonstrated positive effects of low-fluence (<5 J/cm2) blue light on the prolongation of the 
anagen phase and on the proliferation of hair follicle matrix keratinocytes [7]. Low-fluence 
blue light was also reported to have a stimulatory effect on the metabolism of human dermal 
fibroblasts, leading to increased production of collagen, whereas higher levels had an 
inhibitory effect on cell metabolism and protein synthesis [18]. These emerging data show the 
importance of dose selection and could possibly pave the path for therapies adressing hair loss 
and different stages of wound healing. 
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 Intriguingly, however, the same dose of blue light was shown to have differential effects 
on distinct lineages of human dermal fibroblasts [10]. In addition to differential biological 
responses elicited by different cell lineages and irradiation parameters [10, 18], identifying 
effective therapeutic parameters for blue light-based therapies is further complicated by the 
still incomplete knowledge of the photoacceptors in the skin [19]. Besides nitrosated proteins 
[9, 12], the effects of blue light could be mediated by photoacceptors in mitochondria, including 
cytochrome c oxydase, but also by cryptochromes and other flavoproteins, and all could lead to 
the generation of NO and reactive oxigen species (ROS) [10, 20] or to the activation of G-protein 
coupled receptors [7]. The latter, and, more specifically, the opsin (OPN) protein family, were 
recently reported to be present in the skin and its appendages, and to be potential mediators of 
the effects of blue light [7]. All these different mechanisms could activate several downstream 
pathways and, ultimately, impact cellular responses. As a consequence, the entry into the 
mainstream of therapies of blue light requires additional fundamental and clinical research, 
identifying photoacceptors and molecular pathways, linking irradiation parameters to cellular 
events and proving therapeutic effects based on clinical outcomes.
 Setting the focus on the latter,  the primary objective of this study was to investigate 
the impact of UV-free blue light at 453 nm on the recovery of the skin barrier and on the 
cutaneous inflammatory response elicited by acute perturbation of the skin of healthy human 
volunteers. Whilst blue light has already proven effective in clinical studies on diseased skin 
[2, 14-17], data on its biological effects on perturbed but otherwise healthy skin are scarce. 
Skin reactions were evaluated up to 72 hours after stimulation using several non-invasive 
biophysical measurements. As a seconday objective, we aimed to investigate whether skin 
reactions differed significantly if irradiation was delivered in continuous or pulsed mode [21]. 
By underpinning the study with well-defined irradiation parameters, in vivo skin models and 
a combination of read-outs, we aimed to obtain novel insights into the effects of UV-free blue 
light on acutely pertubed healthy human skin.   
PATIENTS AND METHODS
Study participants
 Twenty-two healthy volunteers were included and randomized in two groups, where 
irradiation with blue light was delivered in continuous (CW) or pulsed (PW) mode. The mean 
age was 21.9 (± 1.9) years old in the CW group (10 females, 1 male) and 22.5 (± 3.6) years old in 
the PW group (10 females, 1 male). Criteria for inclusion were: age between 18 and 40 years, 
Fitzpatrick skin type I, II or III, and willingness to give a written informed consent. Exclusion 
criteria were: pregnancy or breastfeeding; presence of implanted electrical devices (e.g. 
cardiac pacemakers); history of skin diseases, including conditions causing photosensitivity; 
atopic or allergic predisposition (i.e. atopic dermatitis, asthma, allergic rhinoconjuctivitis); 
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use of immunosuppressive drugs and compromised skin at the experimental sites (both volar 
forearms). Volunteers were asked not to apply toiletries on their forearms starting from 24 
hours before the experiments and not to sunbathe or use a tanning bed starting from two weeks 
before the experiments and during the study. Experiments were performed at the dermatology 
department of the Radboud University Medical Center in Nijmegen, the Netherlands, in a room 
with controlled temperature and relative humidity conditions. The study, approved by the ethics 
committee Regio Arnhem-Nijmegen (protocol ID: NL56421.091.16), was performed according 
to the Declaration of Helsinki and was carried out between November 2016 and April 2017. 
 Acute skin perturbation 
 Skin perturbation was performed on two different locations of the volar forearm by 
means of tape stripping and histamine iontophoresis, as previously described [22]. Tape 
stripping (area: 2.9 cm2) was performed approximately 4 cm apart from the electrode for 
iontophoretic histamine delivery (active area: 7.2 cm2), in distal direction, so that both stimuli 
would cover a length of less than 15 cm on the volar forearm. Skin perturbation with both 
stimuli was completed within 15 minutes. 
Irradiation with blue light
 Irradiation of the volar forearm was delivered with a proprietary investigational medical 
device of Class IIa. The device comprised a lamp unit containing 84 high-power LEDs (LUXEON 
Rebel LXML-PR02, Lumileds Holding B.V., the Netherlands) with quasimonochromatic 
emission centered at 453 nm (bandwidth: 19 nm). Lenses in front of the LEDs collimated 
light beams, minimizing the dependence of the irradiance at the skin surface from the exact 
distance from the lamp unit. The LEDs panel was positioned approximately 7 cm above the 
forearm. The irradiation window allowed uniform irradiation of a 15 cm-long section of the 
volar forearm. Two pre-defined, calibrated irradiation settings were used, both delivering a 
fluence of 18 J/cm2 at 10 mW/cm2 average irradiance during a 30-minute treatment time. The 
difference between the settings was that one delivered the fluence in CW mode, and the other 
in PW mode with 200 mW/cm2 peak irradiance, 5% duty cycle and 100 Hz repetition frequency. 
A similar dose of blue light was demonstrated to be safe in human subjects [23]. Moreover, the 
200 mW/cm2 peak irradiance had already been successfully applied in clinical studies on PV and 
AD [14, 16]. Skin surface temperature was measured throughout irradiation by means of two 
thermocouples (Omega Engineering, USA) connected to a data logger (TC-08, Pico Technology, 
UK). The thermocouples were attached to the skin in between the sites stimulated with tape 
stripping and histamine iontophoresis. Data from the two thermocouples were averaged to 
obtain a single  30-minute reading of skin surface temperature during irradiation. Throughout 
irradiation, participants wore safety glasses eliminating the risk of potential retinal damage. 
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Table 1. Summary of the study protocol and measurements. Acute perturbation with tape stripping and 
histamine iontophoresis was performed during the first visit of each week. At 30 and 60 minutes after 
histamine iontophoresis, and at 60 minutes after tape stripping, DRS was used to measure the L*a*b* 
values, ITA and the complete reflectance spectra. At 60 minutes after tape stripping, TEWL was additionally 
measured. TEWL, L*a*b* values, ITA and the reflectance spectra were measured also at 24 and 72 hours only 
on this site, as the reaction to histamine iontophoresis faded within a few hours, leaving no clinically visible 
signs. At 24 hours, measurement of IL-1α, IL-1RA, hBD-1 and hBD-2 by means of TAP was performed. At 72 
hours, skin morphology was assessed by RCM. The difference between the two eeks was that, in one of the 
two, skin perturbation was immediately followed by irradiation with blue light, thus assuring an “irradiation” 
and a “control” week. The irradiation week (first or second) and the irradiation forearm (left or right) were 
randomized between volunteers. In both weeks, baseline TEWL, L*a*b* values, ITA and the reflectance 
spectra were measured on intact skin during the first visit, on the forearm contra lateral to the one on which 
the perturbation methods were applied. Baseline TAP and RCM assessments were performed only once, 
during the “control” week. The “control” week was planned one week apart from the “irradiation” week in 
order to avoid possible systemic effects elicited by irradiation, a possibility which could not be excluded at 
this stage. In this respect, an additional “control” was added during the “irradiation” week by performing tape 
stripping also on the contra lateral, non-irradiated forearm. Skin surface biomarkers were not measured on 
this additional control. In total, each volunteer underwent stimulation with histamine iontophoresis twice (in 
the “control” and “irradiation” week) and stimulation with tape stripping three times (two in the “irradiation” 
week – irradiated and non-irradiated – and one in the “control” week). 
IRRADIATION WEEK CONTROL WEEK
Tape 
Stripping*
Histamine 
iontophoresis
Tape 
Stripping
Histamine 
iontophoresis
VISIT 1
Acute perturbation
Irradiation with blue light
TEWL Baseline**
Post stimulus 1 h
DRS Baseline**
Post stimulus 0.5 h
Post stimulus 1 h
VISIT 2
(24 h 
after 
VISIT 1)
TEWL Post stimulus 24 h
DRS Post stimulus 24 h
TAP Baseline**
Post stimulus 24 h
VISIT 3
(72 h 
after 
VISIT 1)
TEWL Post stimulus 72 h
DRS Post stimulus 72 h
RCM Baseline**
Post stimulus 72 h
DRS: diffuse reflectance spectroscopy; hBD: human beta defensin; IL: interleukin; ITA: individual typology 
angle; TAP: transdermal analyses patch; TEWL: transepidermal water loss; RCM: reflectance confocal 
microscopy. 
* In the control tape stripping performed in the irradiation week, the same measurements were made as 
for the other tape stripping spots except for TAP.
**Baseline measurements were performed in the forearm contra lateral to the one where acute 
perturbation was applied. 
EFFECTS OF BLUE LIGHT ON SKIN BARRIER RECOVERY
201
5.3
Study protocol and skin measurements
 The study protocol was repeated over two consecutive weeks, accomodating a total of 
six visits. Tape stripping and histamine iontophoresis were performed during the first visit of 
each week. Skin reaction were evaluated by transepidermal water loss (TEWL) (Aquaflux AF200, 
Biox, UK), diffuse reflectance spectroscopy (DRS) (Spectrophotometer 2600d, Konica Minolta, 
Japan), skin surface biomarkers, and reflectance confocal microscopy (RCM). DRS included 
measurement of the Commission Internationale de l’Éclairage (CIE) L*a*b* values and the 
complete reflectance spectrum in the range 360-740 nm. The individual typology angle (ITA) 
was additionally computed [24]. Skin surface biomarkers consisted in interleukin (IL)-1α, IL-
1RA, human beta defensin (hBD)-1 and hBD-2, and were measured by means of transdermal 
analyses patch (TAP) (FibroTx LLC, Estonia) [22]. RCM (VivaScope 1500 system, Lucid Inc., USA) 
was employed to assess the thickness of the stratum corneum (SC) and living epidermis, as 
described previously [22]. The study protocol is schematically described in Table 1. 
Statistical analysis
 The primary objective (i.e. to investigate whether effects of blue light on skin barrier 
recovery and/or inflammation were detectable) was tested by comparing repeated measures 
in the irradiation and control weeks with the paired-samples t-test. The normality of these 
differences was checked with the Kolmogorov-Smirnov test. The second objective (i.e. to 
investigate whether differential effects by irradiating in CW or PW mode were detectable) was 
tested by the independent-samples t-test. TEWL measurements in the irradiation and control 
week were compared at 1, 24 and 72 hours, after subtracting the baselines measured in the 
respective weeks (ΔTEWL). For the L*a*b* values and ITA, the respective baselines were not 
subtracted, as these differed between the control and irradiation week in the PW group (see 
Results). No subtraction of the baseline was made for the thickness of SC and living epidermis 
either. Given the non-normal distribution of skin surface biomakers, the Wilcoxon signed rank 
test for matched pairs was used to analyse differences between baseline and 24 hours after 
tape stripping in both the irradiation and control week, as well as between the post-stimulus 
values. The reflectance spectra were converted to absorbance spectra [25] and qualitatively 
compared. Statistical analyses were performed with SPSS Statistics version 20 for Windows 
(IBM SPSS Inc., USA). A p value ≤0.05 was considered statistically significant. Due to the 
exploratory nature of this study, no corrections for multiple comparisons were applied.
RESULTS
Randomization and irradiation with blue light
 The radomization in irradiation group (CW or PW), irradiation week (first or second) and 
irradiation forearm (left or right) is schematically summarized in supplementary Figure S1. No 
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differences between the CW and PW groups were present with respect to age, Fitzpatrick skin 
type (five type II and six type III in both groups) and skin temperature during irradiation with blue 
light. The average skin temperature during the 30-minute irradiation was 32.2 (± 1.3) °C in the 
CW group and 31.9 (± 1.2) °C in the PW group ([-0.8; 1.3] 95% CI, p=0.643). The average increase 
in skin temperature between the last five minutes and the first five minutes of irradiation was 0.9 
(± 0.7) °C in the CW group and 0.8 (± 0.5) °C in the PW group ([-0.5; 0.6] 95% CI, p=0.887). 
Baseline measurements: TEWL,  L*a*b* values and ITA
 On the first visit in the irradiation and control week, baseline TEWL, L*a*b* values 
and ITA were measured on intact skin, on the forearm contra lateral to the one where acute 
perturbation was performed. Baseline TEWL did not differ between the irradiation and control 
week in either group. In the CW group, no differences were present for the L*a*b* values and 
the ITA. In the PW group, higher a* and b*, and lower ITA, emerged in the control compared to 
the irradiation week. Values are presented in Table 2.
Table 2. Measurements on intact skin (baseline) in the irradiation and control week in the two groups of 
healthy volunteers included in the study (n=11 in CW, n=11 in PW). 
Irradiation week Control week
Mean SD Mean SD 95% CI p value
CW group
TEWL [g/m2h] 10.5 2.6 10.6 2.0 (-0.8; 0.7) 0.865
a* value [a.u.] 5.1 0.6 5.0 1.3 (-0.5; 0.6) 0.856
b* value [a.u.] 14.9 1.5 15.2 1.8 (-0.8; 0.3) 0.299
L* value [a.u.] 69.2 2.2 68.9 2.2 (-0.6; 1.2) 0.461
ITA [°] 52.1 5.3 51.2 5.8 (-1.2; 3.0) 0.361
PW group
TEWL [g/m2h] 9.8 2.0 10.7 1.8 (-2.5; 0.8) 0.273
a* value [a.u.] 5.4 0.8 5.9 0.9 (-0.8; -0.2) 0.009
b* value [a.u.] 14.7 2.4 15.5 2.4 (-1.0; -0.2) 0.010
L* value [a.u.] 67.8 2.3 67.2 2.1 (-0.1; 1.3) 0.095
ITA [°] 50.0 7.5 48.0 7.5 (0.7; 3.3) 0.007
a.u.: arbitrary units; CI: confidence interval of the difference between irradiation and control week; CW: 
continuos irradiation; ITA: individual typology angle; PW: pulsed irradiation; TEWL: transepidermal water 
loss.
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Figure 1. Difference between the absorbance spectra measured in the irradiated and control forearm in 
the control week at 30 minutes (a, c) and 60 minutes (b, d) after histamine iontophoresis in the CW group 
(a, b) and PW group (c, d). The positive absorption peak of oxy-hemoglobin (oxy-Hb) between 540 and 580 
nm is visible at 30 minutes in about 50% of volunteers (IDs 1, 2, 3, 5, 7, 9, 10, 20, 21, 22). At 60 minutes, 
this effect is starkly decreased. The absorbance spectrum of oxy-Hb is added, rescaled and shifted on the 
y axis for clarity.
Histamine iontophoresis: L*a*b* values, ITA  and reflectance spectra 
 All 22 participants underwent stimulation with histamine iontophoresis. DRS 
measurements were performed at 30 and 60 minutes after histamine iontophoresis, 
corresponding to immediately and 30 minutes after irradiation with blue light, respectively. 
The b* and L* values and the ITA were lower in the irradiated forearm compared to the control 
forearm at 30 minutes after histamine iontophoresis, whereas an opposite trend was present 
for the a* value. No differences emerged at 60 minutes after histamine iontophoresis. Values 
are presented in Table 3. Albeit the effect at 60 minutes was higher in the PW than in the CW 
group with respect to the a* and L* values and the ITA, the difference did not reach statistical 
significance. The values for the comparison between CW and PW groups are presented in 
supplementary Table S1.  
 The difference between the absorbance spectra measured in the irradiation and control 
week is shown in Figure 1. 
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Table 3. Measurements at 30 minutes and 60 minutes after histamine iontophoresis in the irradiation and 
control week (n=22; n=11 in CW, n=11 in PW).
Histamine 
iontophoresis
Irradiation week Control week
Mean SD Mean SD 95% CI p value
30 minutes
a* value [a.u.] 11.0 1.6 10.2 2.3 (-0.003; 1.5) 0.051
b* value [a.u.] 17.1 1.9 17.7 2.3 (-1.2; -0.05) 0.034
L* value [a.u.] 62.9 2.6 64.1 2.3 (-1.7; -0.7) 0.000
ITA [°] 37.1 7.9 38.8 7.5 (-3.3; -0.1) 0.035
60 minutes
a* value [a.u.] 10.4 1.5 10.3 1.5 (-0.5; 0.8) 0.724
b* value [a.u.] 16.9 2.1 17.1 2.3 (-0.7; 0.2) 0.215
L* value [a.u.] 63.9 2.6 64.3 2.2 (-1.0; 0.2) 0.167
ITA [°] 39.4 8.1 39.9 7.1 (-2.1; 1.1) 0.490
a.u.: arbitrary units; CI: confidence interval of the difference between irradiation and control week; CW: 
continuos irradiation; ITA: individual typology angle; PW: pulsed irradiation.
Tape stripping: TEWL, L*a*b* values, ITA and reflectance spectra
 In 3 out of 22 volunteers, tape stripping could not be performed until complete removal 
of the SC and these volunteers were therefore excluded from the analysis. In the remaining 
volunteers, ΔTEWL measured 24 hours after tape stripping was higher in the irradiated forearm 
than in the non-irradiated forearm in the control week, whereas no differences emerged at 1 
and 72 hours. Values are presented in Table 4. Albeit the effect at 24 hours was higher in the PW 
compared to the CW group, the difference did not reach statistical significance (supplementary 
Table S1). No differences were present between ΔTEWL measured in the irradiated and non-
irradiated forearm in the irradiation week, nor between the ΔTEWL measured in the non-
irradiated forearm in the irradiation and control week (data not shown). 
 In the irradiated forearm compared to the non-irradiated forearm in the control week, 
L* value and ITA were lower at 1 hour after tape stripping, b* value was higher at 24 hours 
and 72 hours and ITA was lower at 72 hours. Values are presented in Table 4. No significant 
differences emerged between the two groups (supplementary Table S1). Similarly to the data 
in Table 4, in the irradiated forearm compared to the non-irradiated forearm in the irradiation 
week, L* value was lower at 1 hour after tape stripping ([-1.7; -0.04] 95% CI and p=0.042), b* 
value was higher and ITA was lower at 24 hours ([0.2; 1.1] 95% CI and p=0.005 for b* value, 
[-3.1; -0.3] 95% CI and p=0.022 for ITA) as well as at 72 hours ([0.5; 1.5] 95% CI and p=0.000 for 
b* value, [-3.9; -0.3] 95% CI and p=0.023 for ITA). In addition, at 1 hour, a* value was higher in 
the irradiated forearm compared to the non-irradiated forearm ([0.1; 1.3] 95% CI, p=0.034). In 
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the comparison between the non-irradiated forearm in the irradiation and control week, no 
differences were present at any time point (data not shown). 
 The difference between the absorbance spectra measured in the irradiation and control 
forearm in the control week is shown in Figure 2. 
Table 4. Measurements at 1 hour, 24 hours and 72 hours after tape stripping in the irradiation and control 
week (n=19; n=10 in CW, n=9 in PW).
Tape stripping
Irradiation week Control week
Mean SD Mean SD 95% CI p value
1 hour
  ΔTEWL [g/m2h] 62.8 14.2 60.3 16.9 (-2.5; 7.5) 0.308
a* value [a.u.] 9.4 1.5 9.1 1.6 (-0.3; 1.0) 0.340
b* value [a.u.] 15.3 1.9 14.9 1.7 (-0.1; 1.0) 0.099
L* value [a.u.] 65.7 2.9 66.5 2.4 (-1.5; -0.01) 0.047
ITA [°] 45.4 8.3 47.8 6.5 (-4.1; -0.6) 0.011
24 hours
  ΔTEWL [g/m2h] 54.2 15.7 47.8 18.2 (0.6; 12.3) 0.034
a* value [a.u.] 8.9 1.6 9.2 1.3 (-1.0; 0.4) 0.416
b* value [a.u.] 16.6 1.8 15.8 1.9 (0.3; 1.3) 0.003
L* value [a.u.] 66.7 2.3 66.8 2.8 (-0.9; 0.9) 0.958
ITA [°] 45.1 6.2 46.4 6.5 (-2.9; 0.3) 0.107
72 hours
  ΔTEWL [g/m2h] 21.1 10.8 21.3 11.6 (-5.3; 4.9) 0.934
a* value [a.u.] 8.0 1.2 7.9 1.0 (-0.6; 0.8) 0.743
b* value [a.u.] 17.5 2.0 16.9 1.7 (0.1; 1.1) 0.018
L* value [a.u.] 66.0 2.4 66.7 2.4 (-1.5; 0.1) 0.085
ITA [°] 42.4 7.0 44.5 6.0 (-4.0; -0.2) 0.033
a.u.: arbitrary units; CI: confidence interval of the difference between irradiation and control week; CW: 
continuos irradiation; ITA: individual typology angle; PW: pulsed irradiation; TEWL: transepidermal water 
loss. 
TAP: IL-1α, IL-1RA, ratio IL-1RA/IL-1α, hBD-1 and hBD-2
 All biomarkers were upregulated at 24 hours after tape stripping in the control week 
compared to baseline (p<0.05). This was the case also at 24 hours after tape stripping in 
the irradiation week compared to baseline for all biomarkers except IL-1α: in this case, no 
significant difference with respect to baseline emerged. No differences were present between 
the levels of biomarkers measured in the irradiation and control week. Values are shown in 
Figure 3. 
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RCM: SC and living epidermis thickness
 The SC and the living epidermis were thicker at 72 hours after tape stripping compared 
to baseline in all experimental sites. No differences emerged between the irradiated forearm 
and the controls (p>0.05, data not shown). 
DISCUSSION
 The primary objective of this study was to investigate the biological effects of blue light 
at 453 nm on the recovery of the skin barrier and on the cutaneous inflammatory response 
following acute perturbation of healthy skin. This objective was achieved by comparing skin 
reactions to two in vivo skin models, namely tape stripping and histamine iontophoresis, in 
an “irradiation” week (stimuli followed by irradiation with blue light) with skin reactions in a 
“control” week (stimuli not followed by irradiation).   
 In the irradiation week, the overall dermal blood concentration was increased at 30 
minutes after histamine iontophoresis, compared to the same time point in the control week. 
This was underlined by the trend to higher a* value, the lower b* and L* values and by the 
positive peaks between 540 and 580 nm in the difference absorbance spectra, corresponding 
to the absorption of oxygenated hemoglobin (oxy-Hb) [24]. Increased dermal blood flow 
following irradiation with blue light at 453 nm and 30 J/cm2 fluence was already reported in 
vivo and attributed to the vasodilatory effect of NO release [12]. At 60 minutes after histamine 
iontophoresis, the overall dermal blood concentration was not different compared to the control 
stimulation, in line with the previously reported short-lived hemodinamic effects of blue light, 
fading within 15 minutes after irradiation [12]. 
 TEWL was higher at 24 hours after tape stripping in the irradiated forearm compared 
to the control forearm in the control week. A delaying effect of blue light (430-510 nm) on the 
recovery of TEWL following acute barrier perturbation was reported in a study on mice [26]: 
using electron microscopy, the authors showed absence of lipids at the boundary between 
the SC and stratum granulosum, possibly indicating an inhibitory effect of blue light on the 
release of lamellar bodies. In our study, the higher TEWL after tape stripping in the irradiated 
forearm may be linked to the lack of significant increase of IL-1α compared to baseline found 
on this site, in contrast to the control stimulation where there was a significant upregulation 
of IL-1α compared to baseline. As measurements with TAP at baseline and on the irradiated 
tape-stripped site were performed one week apart, we cannot exclude a day-to-day variability 
effect on biomarkers levels; however, this was demonstrated to be low (coefficient of variation: 
20%) on a five-day period in healthy volunteers [27]. In addition, the hypothesis on the impact 
of blue light on lamellar body release is supported by increasing evidence about the influence 
of IL-1α on lipid synthesis and epidermal differentiation [28]. Unfortunately, the difference in 
IL-1α levels did not reach statistical significance between the irradiated and the control tape-
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stripped sites, probably due to the low number of subjects combined with the high variability 
in skin surface biomarkers measured by TAP [22]. At 72 hours, TEWL and the thickness of 
the living epidermis were not different in the irradiated forearm compared to the controls, 
indicating absence of an anti-proliferative response of one single treatment at such relative 
long times scale compared to the irradiation time [9]. More pronounced and long-lasting 
effects on the barrier function might have been obtained with repetitive irradiations instead 
of a single irradiation [14, 16]. Interestingly, no differences in TEWL emerged between the 
irradiated tape-stripped site and the control tape-stripped site in the irradiation week: this may 
indicate a systemic anti-inflammatory effect. Previous clinical studies on PV and AD observed 
amelioration of the control plaques together with the irradiated plaques. While the authors 
were keen to attribute this effect to the use of topical emollients and to a placebo effect [14, 
16], one can also hypothesize that changes in skin surface biomarkers might also lead to 
alterations in their blood plasma levels, thereby introducing a systemic effect of otherwise 
locally administered light therapy. In order to infer systemic anti-inflammatory effects of the 
latter, blood plasma biomarkers should also be carefully inspected [20]. 
 After tape stripping, b* was higher and L* and ITA were lower in the irradiated site 
compared to the controls. It might be tempting to speculate that irradiation with blue light 
generated immediate pigment darkeing (IPD), a phenomenon which has already been reported 
for UVA irradiation (315-400 nm) [29]. Indeed, human epidermal melanocytes are known to 
express OPN2 and OPN4 [30]: while OPN2 mediates UV response leading to melanogenesis, 
OPN4 in blood vessels (mouse aorta) was shown to be responsive to blue light irradiation 
with maximum aborption band in the range 430-460 nm [31]. This finding could potentially 
explain the effect observed in this study. IPD occurs in the first hours after irradiation, and 
recent evidence suggests synthesis of new melanin [32]. IPD might evolve in delayed tanning 
(DT), appearing within 3-5 days after exposure and resulting in neo-melanogenesis [29]. The 
occurrence of this phenomenon is also suggested by the monotonic decrease in the difference 
absorbance spectra of some volunteers, a trend similar to the absorbance spectrum of melanin 
in the skin [24, 25].
 The secondary objective of this study was to investigate whether irradiation in CW or 
PW mode leads to differential biological effects of blue light on skin recovery. Differences in 
biophysical measurements between the irradiated and non-irradiated forearm in the control 
week were more marked in PW group than in the CW group after both stimuli, albeit not reaching 
statistical significance. An enhanced neo-melanogenesis triggered by blue light in PW mode 
could also explan the differences in a*, b*and ITA baseline values between the irradiation and 
control week in the PW group: indeed, when irradiation was performed in the first week, the 
baseline b* value and ITA measured in the control week (i.e. on the forearm where irradiation 
was performed the week before) were significantly higher and lower, respectively (p<0.05; n=6). 
When irradiation took place in the second week, no significant differences emerged (p>0.05; 
n=5). Previous studies have observed a higher biological response when light was delivered in 
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pulsed mode [21, 33]. Using blue light at 453 nm, a peak intensity of 200 mW/cm2 led to better 
clinical outcomes in the treatment of PV compared to a peak intensity of 100 mW/cm2 [16]. 
Blue light in pulsed mode with high peak intensity is therefore suggested to elictit stronger 
biological effects, albeit the mechanistic pathway remains to be unraveled. 
 In conclusion, this pilot study demonstrated that a single irradiation with blue light at 
453 nm exerts biological effects on acutely perturbed skin. These consisted in an enhanced 
but short-lived hemodynamic response after histamine iontophoresis and, following barrier 
disruption, higher TEWL at 24 hours and a subclinical increase in pigmentation. Our results 
suggest a conditioning effect of blue light on skin barrier formation, possibly mediated by 
epidermal cytokines. These findings could be linked to the positive outcomes of the blue 
spectral band on alleviating symptoms of inflammatory skin diseases involving an impaired 
skin barrier [14-17]. In perspective, clinical studies aimed at unraveling the impact of blue 
light would benefit from larger sample populations, the combined use of several biophysical 
techniques and the local as well as systemic analysis of inflammatory biomarkers. This will 
bring us one step further in unlocking the so much aspired therapeutic potential of blue light 
for the treatment of both cutaneous and systemic conditions with a strong inflammatory 
component.  
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SUPPLEMENTARY MATERIAL
Table S1. Comparison between the post-stimulus measurements in the irradiation and control week in 
healthy volunteers irradiated in CW mode and PW mode.
Difference irradiated-control
in control week
CW group PW group
Mean SD Mean SD 95% CI p value
Histamine iontophoresis
30 minutes
a* value [a.u.] 0.7 1.9 0.8 1.5 (-1.6; 1.4) 0.885
b* value [a.u.] -0.7 1.4 -0.5 1.1 (-1.3; 0.9) 0.724
L* value [a.u.] -0.9 1.4 -1.5 0.9 (-0.4; 1.6) 0.246
ITA [°] -0.9 4.5 -2.6 2.2 (-1.5; 4.8) 0.278
60 minutes
a* value [a.u.] -0.3 1.6 0.5 1.3 (-2.1; 0.5) 0.192
b* value [a.u.] -0.4 1.1 -0.1 0.8 (-1.1; 0.6) 0.582
L* value [a.u.] 0.0 1.2 -0.9 1.4 (-0.3; 2.1) 0.122
ITA [°] 0.5 3.6 -1.6 3.4 (-0.9; 5.3) 0.162
Tape stripping
1 hour
ΔTEWL [g/m2h] 1.2 11.2 3.9 9.8 (-13.0; 7.6) 0.587
a* value [a.u.] 0.2 0.9 0.4 1.8 (-1.7; 1.2) 0.697
b* value [a.u.] 0.0 1.1 0.9 1.0 (-1.9; 0.1) 0.070
L* value [a.u.] -0.7 1.5 -0.9 1.8 (-1.4; 1.7) 0.846
ITA [°] -1.4 3.7 -3.4 3.4 (-1.5; 5.5) 0.244
24 hours
ΔTEWL [g/m2h] 2.5 10.6 10.7 12.9 (-19.6; 3.2) 0.146
a* value [a.u.] 0.1 1.0 -0.1 2.5 (-1.8; 2.2) 0.817
b* value [a.u.] 0.5 1.2 1.1 0.8 (-1.5; 0.4) 0.244
L* value [a.u.] 0.1 1.0 -0.1 2.5 (-1.8; 2.2) 0.817
ITA [°] -0.9 2.7 -1.8 4.1 (-2.4; 4.2) 0.567
72 hours
ΔTEWL [g/m2h] 1.1 8.9 -1.7 12.6 (-7.7; 13.3) 0.581
a* value [a.u.] 0.0 1.4 0.2 1.6 (-1.7; 1.2) 0.729
b* value [a.u.] 0.4 0.7 0.8 1.2 (-1.3; 0.6) 0.403
L* value [a.u.] -0.4 1.6 -1.0 1.7 (-0.9; 2.2) 0.393
ITA [°] -1.3 3.4 -2.9 4.4 (-2.1; 5.4) 0.378
a.u.: arbitrary units; CI: confidence interval of the difference between CW and PW groups; CW: continuos 
irradiation; ITA: individual typology angle; PW: pulsed irradiation; TEWL: transepidermal water loss.
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Figure S1. Schematic represenation of the randomization of the 22 volunteers included in the study in 
irradiation group (continous delivery mode - CW - or pulsed delivery mode - PW), irradiation week (first or 
second) and irradiation forearm (left or right).
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ABBREVIATIONS 
a*  CIE spectrum (Commission Internationale de l’Éclairage): a*, b* and L* values
CRS  Confocal Raman microspectroscopy
DRS  Diffuse refl ectance spectroscopy
hBD  Human beta defensin
HE  Hematoxylin and eosin
IL  Interleukin
NIR  Near-infrared
NMF  Natural moisturizing factor
NSS  Non-sensitive skin
RCM  Refl ectance confocal microscopy
SC  Stratum corneum
SDS  Sodium docecyl sulphate
SS  Sensitive skin
TAP  Transdermal analyses patch
TEWL  Transepidermal water loss
ToF-SIMS Time-of-fl ight secondary ion mass spectrometry
TRPV  Transient receptor potential vanilloid
VAS  Visual analogue scale
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 This thesis focused on two research areas, namely sensitive skin and skin irritation, and 
on their evaluation by means of non-invasive bioengineering techniques. Evaluation addressed 
both skin barrier properties as well as cutaneous inflammation and was performed in vivo in 
healthy human volunteers. In this chapter, the results are summarized and discussed for each 
research area, and future perspectives on the use of bioengineering techniques in dermatology 
and in cosmetic sciences are given. 
SENSITIVE SKIN
 The first objective of this thesis was to investigate three possible pathomechanisms 
leading to self-assessed sensitive skin (SS): impairment of the skin barrier function and 
enhanced vascular and sensory reactivities. 
Is the skin barrier function impaired in sensitive skin?
 The possible impairment of the skin barrier was addressed in chapter 2.2, in which 
confocal Raman microspectroscopy (CRS) was used to measure the stratum corneum (SC) 
levels of water, ceramides/fatty acids and natural moisturizing factor (NMF) in subjects with 
self-assessed SS. The indirect assessment of the thickness of the SC was added. These 
measurements were compared to those of subjects claiming their skin as non-sensitive (NSS). 
No differences were found between SS and NSS subjects in either the volar forearm, thenar of 
cheek, except for a trend to lower levels of ceramides/fatty acids in the cheek in SS subjects. 
These results demonstrated that the skin barrier in SS is not impaired in terms of thinner SC 
or lower levels of water, ceramides/fatty acids and NMF. In chapter 2.2, CRS was additionally 
used to track the penetration kinetics of a solution of glycerol in water, applied topically on the 
volar forearm. This test was performed to establish whether topicals penetrate faster in SS due 
to an impaired skin barrier function. Lower levels of glycerol were found in SS compared to NSS 
subjects in the first minutes after application, reaching statistical significance at one minute. In 
chapter 3.1, a solution of histamine dihydrochloride was applied topically on the volar forearm 
and lower back of subjects with SS and NSS. Histamine is a well-known pruritogen substance, 
and the perception of itch following application, indicative of its penetration into the SC, was 
used as further test for the impairment of the skin barrier. In this case, however, only a trend 
to more intense itch perception was reported by SS compared to NSS subjects in the volar 
forearm, and no differences emerged in the lower back. In addition, in the volar forearm, SS 
subjects showed a higher transepidermal water loss (TEWL) than NSS subjects. Overall, these 
findings do not support a major barrier impairment in SS, but the lower glycerol levels in SS 
compared to NSS subjects suggest that subtle alterations of the skin barrier in SS could be 
responsible for faster and/or increased penetration of topicals in the skin.
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 This notion is in line with previous findings of Richters and coworkers. In two clinical 
studies, tape stripping and the surfactant sodium dodecyl sulphate (SDS) were used as in vivo 
models to disrupt the skin barrier of the lower back. In the tape stripping study [1], a lower 
number of tape strips was necessary for the complete removal of the SC in SS compared to 
NSS subjects. In the SDS study [2], the SC thickness, measured in hematoxylin and eosin (HE) 
histologic images, was thinner at 72 hours after SDS application in SS than in NSS subjects. 
These results indicate that the skin barrier in SS is more vulnerable to mechanical and 
chemical stimuli. 
 We suggest that further investigations aimed at unraveling the altered skin barrier 
properties in SS should focus on the intercellular lipids and on the morphological and biochemical 
characteristics of the SC. The intercellular lipids might differ in terms of amount, ratio and 
lateral organization. CRS has been shown to be able to measure the overall amount of lipids as 
the ratio between the Raman signal of lipids to that of protein in the high wavenumber region 
[3]. In addition, features in the Raman spectra providing information on the lateral organization 
of the lipid chains have been identified in both the fingerprint and high wavenumber regions 
[4]. Besides CRS, a recent study demonstrated that information about the morphological and 
biochemical characteristics of the SC in SS subjects can be gained by analyzing the material 
extracted by tape stripping [5]. Material collected from tapes allowed to measure the amount 
of protein (used as marker of SC cohesion), the amount of enzymes responsible for correct 
maturation and desquamation of corneocytes, and the average dimension of corneocytes, 
whose smaller size may lead to a shorter penetration pathway for exogenous substances. 
 Of note, TEWL measured in the volar forearm was higher in SS than in NSS subjects 
in chapter 3.1, whereas an opposite trend was found in chapter 2.2. As the selection method, 
inclusion/exclusion criteria, age range, Fitzpatrick skin type and model device to measure 
TEWL were the same between the two studies, this discrepancy might be ascribed to a seasonal 
effect. The study using histamine iontophoresis (chapter 3.1) was carried out between April 
and November, while the study using CRS (chapter 2.2) between January and mid-March, thus 
within the winter months. It is tempting to speculate that SS might have different compensatory 
or adaptive mechanisms to the seasonal climatic changes than NSS, which in turn influence 
TEWL. Several parameters linked to the status of the skin barrier have been found to change 
across seasons, among which TEWL, SC hydration, sebum secretion, intercellular lipids, NMF 
components and corneocyte number and size [6]. It is generally believed that the low indoor 
humidity and cold outdoor temperature occurring in winter have a negative influence on the 
skin barrier [6]. Yet, an epidemiological study reported higher percentages of self-assessed 
SS in summer than in winter [7]. Other epidemiological as well as clinical studies have 
shown differences in SS prevalence and intensity of skin irritation between subjects living in 
different climatic and latitude regions [8, 9]. Season might thus constitute another confounder 
responsible for causing ambiguity in the understanding of SS [10]. 
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Are vascular and/or sensory reactivities enhanced in sensitive skin?
 The vascular and sensory reactivities in SS were addressed in chapter 3.1 by application 
of histamine iontophoresis on the lower back. The intensity of the erythema resulting from the 
vasodilatory effect of histamine was measured by diffuse reflectance spectroscopy (DRS) and 
expressed as the a* component of the Commission Internationale de l’Éclairage (CIE) Lab color 
space, since erythema induces a significant increase in this component, making it particularly 
suited for its evaluation [11]. To estimate the extent of the flare reaction resulting from the 
neurogenic inflammation induced by histamine, a simple segmentation algorithm based on 
well-established image processing techniques and on a low cost acquisition set-up of skin 
photographs was devised. The sensory reactivity was expressed as the subjects’ self-assessed 
perception of itch on a Visual Analogue Scale (VAS), and was assessed both during histamine 
iontophoresis and up to 60 minutes following its application. No differences emerged with 
respect to the intensity of erythema or the extent of the flare, whilst higher itch perception 
was reported by SS compared with NSS subjects following application of histamine, reaching 
statistical significance at 30 minutes.  
 Enhanced vascular reactivity was shown by Richters and coworkers; specifically, a flare 
response was observed in SS and not in NSS subjects during mechanical stimulation with tape 
stripping [1]. Despite this,  a lower a* value was measured in SS compared to NSS subjects at 
30 minutes after stimulus: the authors attributed this finding to the more intense spongiosis 
in the former, visible in HE histologic images, since edema is known to decrease redness [11]. 
The lack of differences in the vascular reactivity elicited by histamine might have been due 
to the low sample size, of by the fact that the chosen readout parameters were not sensitive 
enough to detect subclinical changes in blood flow, vasodilation and edema; further studies 
using histamine iontophoresis should therefore use more sensitive and specific bioengineering 
techniques. On the other hand, the higher itch perception reported by SS subjects was in 
keeping with the previous findings of Richers and coworkers, in which SS subjects reported 
more intense dryiness, burning and stinging  perceptions in response to stimuli [1, 2, 12]. 
The fewer tryptase-positive mast cells in SS than in NSS subjects, consistently found in these 
studies [1, 2, 12], is also a strong argument in favor of the involvement of immune cells in SS, 
which in turn could explain the occurrence of the altered vascular reactivity and enhanced 
sensory perceptions in subjects with this condition. 
 The involvement of the cutaneous nervous system in SS has been the frequent object of 
evaluation of other authors as well. Stimulation of C and Aδ fibers, the cutaneous nerve endings 
responsible for mediating perceptions of pain, itch, cold, and heat [13], has been targeted by 
application of electric currents at 5 Hz and 250 Hz, respectively [14, 15]. During stimulation, 
a faster onset of sensory perceptions emerged in SS compared to NSS subjects. Further 
evidence on the neuronal basis of SS came from a study which demonstrated a greater cerebral 
activation in SS than in NSS subjects during a skin irritative test, as measured by functional 
magnetic resonance imaging [16]. Currently, research efforts are homing in on the molecular 
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basis, focusing on sensory proteins and inflammatory mediators [17, 18]. Among these, the 
transient receptor potential vanilloid 1 (TRPV1) is thought to play a role [18], given its obiquitous 
expression in human skin [19], its responsiveness to a wide range of stimuli [20] and its role in 
mediating pain, itch, burning, and warmth sensations [18, 20]. Activation of TRPV1 results in 
the release of neuropeptides, such as substance P and calcitonin gene-related peptide, from 
cutaneous sensory nerves [18, 19]. These would, in turn, bind to receptors on dermal blood 
vessels, leading to neurogenic inflammation and resulting in edema and vasodilation [19]. 
Neuropeptides would also activate keratinocytes and recruit other immune cells by inducing 
the release of pro-inflammatory cytokines and chemokines, thereby activating the cutaneous 
immune system [18]. As these neuropeptides are also known mast cells liberators, it would 
be of interest to investigate whether a causative link exists between TRPV1 activation and the 
fewer tryptase-positive mast cells in SS subjects found by Richters and coworkers [1, 2, 12]. 
Mast cells degranulation may also be directly triggered by activation of TRPV1 expressed on 
these cells [19]. Recent clinical studies have started to investigate an over-expression of the 
TRPV1 receptor in SS subjects at the protein level through immunohistochemistry and at the 
mRNA level through quantitative polymerase chain reaction [21, 22]. 
 To complete the discussion over the sensitive skin phenomenon addressed in this 
thesis, the following discussion points are given. 
Is the selection method of study participants appropriate?
 The validity of the clinical studies evaluating differences between SS and NSS subjects 
described in chapter 2.2 and chapter 3.1 relies on the capacity of the multifactorial questionnaire 
to adequately select study participants. The questionnaire can be deemed an appropriate 
selection tool, since the symptoms and stimuli used to calculate the score according to which 
participants were classified into the SS and NSS groups were shown to discriminate between 
the two categories in a large survey-based study [23]. This is strenghtened by the differences 
between SS and NSS subjects at the clinical, biophysical and immunohistochemical level found 
by Richters and coworkers [1, 2, 12]. Other authors consider the use of questionnaires and 
patient-reported scales as an appropriate selection tool for SS studies [18]. A scale assessing 
the severity of SS has also been proposed [24].
 The selection of study participants in chapter 2.2 and chapter 3.1 prevented possible 
confounders by excluding subjects with concomitant atopic diathesis and skin diseases and 
subjects with very fair skin phototypes (Fitzpatrick skin type I), as well as darker skin phototypes 
(Fitzpatrick skin type IV, V and VI). In chapter 4.1 it is shown that another confounder which 
should be considered in SS studies is the possible role of fluctuating hormone levels. In the 
digital survey, distributed to a sample population of 300 women residents in the Netherlands, 
42% of premenopausal women declared to perceive (increased) skin sensitivity just before and 
during the menstrual cycle, citing presence of bumps/pimples, dryness and itching as the 
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mot frequenly occurring symptoms which make them realize an increased SS. Interestingly, 
this effect was perceived also by women who do not normally describe their skin as sensitive. 
Whether oestrogen and, possibly, progesterone and testosterone, lead to objective changes 
in skin barrier properties and cutaneous inflammation during the menstrual cycle, remains 
to be evaluated in clinical studies. The effects of decreased sex steroid hormones levels in 
menopause are worth evaluation as well, since almost 32% of peri- and postmenopausal 
women reported perception of increased SS since the menopause. The digital survey was 
also used to evaluate risk factors leading to an increased likelihood to report SS, reported in 
chapter 4.2. Presence of atopic diathesis, skin diseases and fair skin phototype (Fitzpatrick 
skin type I and II) emerged as the risk factors increasing the likelihood of reporting SS, in line 
with previous findings of Richters and coworkers [23] and of several other authors (Table 2 
in chapter 1.4). Of note, current or past smoking and low history of sun exposure showed a 
trend to make a significant contribution to the final model. As these and other lifestyle factors 
have been shown to influence skin properties, their possible role in SS should be taken into 
account. This is in keeping with the increased awareness of the need to study diseases not just 
on the basis of the genetic background of an individual, but also in terms of the environmental 
exposures occurring throughout one’s life, the so-called exposome [25]. 
Is there a primary pathomechanism involved in sensitive skin?
 As of today, it has not been established whether a primary pathomechanism responsible 
for SS exists, or if several pathomechanisms may occur concomitantly. Should the altered 
skin barrier be the primary pathomechanism, the cutaneous nerve endings would be more 
exposed to penetration of external irritants and lead to the onset of sensory hyper-reactivity 
and cutaneous inflammation (“outside-in” mechanism). On the other hand, an underlying 
dysfunction in cutaneous inflammation may also undermine the skin barrier function (“inside-
out” mechanism). For example, increased release of histamine from mast cells may reduce the 
expression of differentiation-specific proteins, necessary for the correct formation of the skin 
barrier [26]. Some authors have proposed that different primary pathomechanisms might exist, 
which would lead to a classification of SS subjects according to the primary pathomechanism 
involved [17, 27]. Irrespective of classification, the use of in vivo skin models in the clinical 
studies of Richters and coworkers [1, 2, 12] and in chapter 3.1 demonstrated that SS can 
be elicited by stimuli of different nature, confirming the findings of epidemiological studies 
(chapter 1.4). In addition, the lack of differences in SC levels of water, NMF and ceramides/fatty 
acids between subjects with SS and NSS found in chapter 2.2, together with the consistently 
higher sensory perceptions reported by the former, indicate that treatments for SS solely based 
on hydration and ceramides supplementation may not bring sufficient benefits to subjects with 
SS. Accordingly, increased research efforts have been directed towards the addition of anti-
inflammatory active ingredients and inhibitors of sensory hyper-responsiveness (e.g. TRPV1 
antagonists) to cosmetic formulations aimed at soothing SS symptoms [28-30].   
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Is sensitive skin generalized or localized?
 Previously, SS was considered to be limited to the face. However, this view is now subject 
to change. An epidemiological study showed that, abeit sensitive facial skin was claimed by the 
majority of responders (77.3%), a still high percentage claimed to have sensitive body skin 
(60.7%) [31]. Both self-assessments of sensitive facial and body skin were consistent with self-
assessments of a “general” SS. In another epidemiological study, 85% of responders declared 
that they had SS on the face, and 70% had SS in another body area [32]. These findings are in 
agreement with the results in chapter 4.1, where highest percentages of SS were found for 
the face (53.6%), and lower but still fair percentages emerged for the legs (27.7%) and the 
hands (27.3%). Variations in SC structure and biochemical composition, cutaneous nerve fiber 
density, and mast cells number, among other factors, are present between body sites [33, 34]. 
It is reasonable to believe that SS is a generalized condition, whose pathomechanisms are 
influenced by the peculiarities of each body site. In this respect, facial skin, characterized by 
a weaker skin barrier function and a higher density of cutaneous nerve fibers than other body 
sites [27, 33], is likely to be more severely impacted by external insults in SS compared to NSS 
subjects. This view is supported by the trend to lower ceramides/fatty acids in SS than in NSS 
subjects found in the cheeks but not in the volar forearm in chapter 2.2. 
SKIN IRRITATION
 The second objective of this thesis was to provide novel insights into the non-invasive 
and in vivo evaluation of skin irritation at the molecular level.
Step 1: To review the existing methods to sample molecular markers of 
inflammation from human skin in a minimally-invasive fashion.
 A systematic literature review was performed to provide an overview of the existing 
minimally-invasive methods to sample interleukin (IL)-1 alpha and its receptor antagonist IL-
1RA from human skin in vivo, presented in chapter 5.1. Ten different methods were found, with 
varying degrees of invasiveness and collection times; common to each was the possibility to 
sample additional biomarkers besides IL-1α and IL-1RA and the high inter-subject variability 
in the yield of biomarkers. The possibility to sample biomarkers with minimally-invasive 
methods is likely to facilitate the approval of clinical studies by the regulatory authorities and 
the inclusion of larger sample sizes. This would benefit not only research on skin irritation, but 
also research on drug discovery and development. In this case, the retrospective evaluation of 
how well one or more biomarkers predicted clinical benefits or risks related to an intervention 
could lead to their validation as surrogate endpoints, as defined by the Biomarkers Definition 
Working Group [35]. The advantage of biomarkers as surrogate endpoints in clinical trials is 
that they do not require long periods before being achieved, in contrast to clinical outcomes: 
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this could fasten the development of safe and effective therapies [35]. Another advantage is 
that the same biomarkers used as surrogate endpoints in clinical trials could be extended to 
clinical practice to measure disease responses [35]. This would be especially beneficial for 
psoriasis, a chronic inflammatory skin disease for which, up to now, no biomarkers that can 
accurately predict its progression and therapeutic response have been validated [36]. 
Step 2: To explore whether transdermal analyses patch (TAP) is able to detect 
dynamic changes in skin surface biomarkers following skin perturbation.
 In chapter 5.2, a pilot study was carried out to explore the potential of transdermal 
analyses patch (TAP) to detect skin surface biomarkers following tape stripping and 
histamine iontophoresis as in vivo models of skin irritation. The cytokines IL-1α and IL-1RA 
and the antimicrobial peptide human beta defensin (hBD)-1 were consistently measurable 
following perturbation with both models. At the same time, the dynamics showed opposite 
results. Following tape stripping, an upregulation of all biomarkers was observed, which was 
somewhat slower for hBD-1. Immediately after histamine iontophoresis, no changes in IL-1α 
and a downregulation in IL-1RA and hBD-1 emerged. While these findings could be related to 
the increased availability due to a disrupted barrier following tape stripping, and to a dilution 
effect due to a swollen skin barrier following histamine iontophoresis, the different dynamics 
of the three biomarkers within the same model of irritation likely reflect a different release 
pattern, which TAP was sensitive enough to detect.  
 The pilot study also confirmed observations emerged from the literature review 
of chapter 5.1. The high inter-individual variability in the yield of biomarkers found with 
TAP was a common feature of other minimally-invasive methods included in the review. It 
appears thus that high inter-individual variability is a common feature of skin biomakers 
research: further studies should include a suitable number of participants in order to draw 
meaningful conclusions. The fact that additional biomarkers could be measured in the tape 
stripping experiment, performed in autumn, whereas no other biomarkers were detectable in 
the histamine iontophoresis study, performed in summer, suggests a seasonal effect on the 
yield of biomarkers. This aspect emerged in other studies included in the review [37, 38]. The 
effects of temperature and relative humidity should also not be overlooked: control of these 
parameters in the enviroment where biomarkers are collected is advisable, especially when 
minimally-invasive methods sampling biomakers from the skin surface are used.  
Step 3: To explore whether photobiomodulation with blue light at 453 nm affects 
skin recovery following acute perturbation.
 In chapter 5.3, a pilot study is presented in which photobiomodulation with blue light 
centered at 453 nm was used immediately after tape stripping and histamine iontophoresis 
to investigate possible conditioning effects on skin recovery and cutaneous inflammation. 
Experiments were repeated over two consecutive weeks: in one week, irradiation was used to 
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condition skin responses, while in the other week no light was used (control). The cytokines 
IL-1α and IL-1RA and the antimicrobial peptides hBD-1 and hBD-2 were measured with TAP on 
normal skin and at 24 hours after tape stripping in the irradiated and in the control sites. As in the 
pilot study reported in chapter 5.2, these biomarkers were consistently measurable, and in the 
control site they were upregulated with respect to baseline. However, while a similar increase 
was present in the irradiated site for IL-1RA, hBD-1 and hBD-2, no upregulation emerged for 
IL-1α. This finding might be related to the previously reported anti-inflammatory effects of 
blue light, albeit the photoacceptor(s) and the mechanisms responsible for transducing light 
absorption into cellular responses remain to be unraveled. 
 This pilot study fosters the measurement of biomarkers locally in the skin by minimally 
invasive methods. The possibility to detect different dynamics in small scale pilot studies, 
shown in chapter 5.2 and chapter 5.3, holds promise for the use of TAP in clinical studies in 
which the effect of therapies is tested, or a biomarker blueprint of different inflammatory skin 
diseases and subtypes thereof is sought. 
 To complete the discussion over skin irritation, the relationship between its assessment 
at the molecular level and at the macroscopic level by means of bioengineering techniques 
deserves attention. 
 A number of articles in the review of chapter 5.1 added macroscopic assessment of 
skin irritation by bioengineering techniques in addition to the sampling of  IL-1α and/or IL-
1RA. In some studies, lower TEWL and higher SC hydration were in agreement with decreased 
inflammatory biomarkers, indicating improvement of the clinical status of the skin [38-40]. 
On the other hand, the association was not straightforward in other studies. In some cases, 
decreased TEWL and increased SC hydration following topical treatments were not mirrored 
by decreased levels of inflammatory biomarkers [41, 42]. In other cases, increased TEWL and 
erythema, indicators of skin irritation, were accompanied by lower yield of IL-1α compared 
to control [43-45]. Other articles described varying associations between bioengineering 
techniques and inflammatory biomarkers according to the type of irritant used, or to the single 
or repeated application of the same irritant. In this respect, substances causing mild increase 
in TEWL and erythema could determine higher yields of IL-1α and/or IL-1RA than substances 
for which bioenginneering techniques indicated a more pronounced inflammatory reaction 
[46-48]. An inverse relationship between the severity of cutaneous inflammation measured by 
bioengineering techniques and the recovered amounts of IL-1α and/or IL-1RA could be due to 
different kinetics of release, dependent on the type of irritant used and the extent of irritant-
induced keratinocyte injury [46, 48]. 
 In chapter 5.2 and chapter 5.3, bioengineering techniques including TEWL, DRS and 
reflectance confocal microscopy (RCM) were used to further characterize skin irritation following 
the application of tape stripping and histamine iontophoresis. In chapter 5.2, upregulation 
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of IL-1α, IL-1RA, hBD-1 and hBD-2 could be related to increased availability following skin 
barrier disruption; however, at 72 hours after tape stripping, IL-1α and IL-1RA levels were 
back at baseline, whereas this was not the case for TEWL. This indicates that the upregulation 
measured with TAP could not exclusively be related to the disrupted barrier, but also to an 
underlying dynamics of release. Similarly, downregulation of IL-1RA and hBD-1 immediately 
after histamine iontophoresis could be related to increased SC thickness assessed by RCM; 
however, the absence of downregulation of IL-1α might reflect a release of this biomarker. In 
chapter 5.3, higher TEWL in the irradiated tape-stripped site compared to the control tape-
stripped site was found, concomitantly to the absence of upregulation of IL-1α. Both results 
indicate an effect of blue light on the recovery of the skin barrier following acute perturbation: 
in particular, an inhibited inflammatory response could undermine the normal recovery of skin 
homeostasis, thereby explaining the increased TEWL. 
 Chapters 5.1, 5.2 and 5.3 show examples of how the assessment of skin irritation could 
be improved by a synergic combination of measurements: inflammatory biomarkers at the 
molecular level, and skin biophysical properties at the macroscopic level. Together, such in 
vivo and non-invasive assessments could allow a deeper understanding of skin responses not 
only following irritation, but also in diseased conditions and following therapeutic interventions. 
FUTURE PERSPECTIVES ON BIOENGINEERING TECHNIQUES IN 
DERMATOLOGY AND IN COSMETIC SCIENCES
 The sensitivity and specificity of the analysis of cells and tissue morphology offered 
by skin biopies make them the gold standard to assess skin physiology and pathology. Also 
in chapter 3.1, skin biopsies were taken to thoroughly characterize the effects of histamine 
iontophoresis on the epidermal and dermal compartments using immunohistochemistry. 
However, the importance of objective skin assessments offered by bioengineering techniques, 
obtained non-invasively and therefore without discomfort, cannot be underestimated. At times, 
moreover, bioengineering techniques may prove more advantageous that skin biopsies. In 
chapter 5.2, RCM revealed an increased SC thickness following histamine iontophoresis, likely 
indicating an hydrating effect of the active electrode or of the underlying edema. This effect 
was marked at 30 minutes, with a median increase of approximately 4 µm, and halved at 90 
minutes. Yet, in chapter 3.1, the analysis of skin biopsies taken at 60 minutes after stimulation 
did not reveal increased SC thickness. This indicates that minor changes in SC thickness might 
have been made undetectable by the preparatory processing of the tissue prior to staining. 
 Recent developments have increased the specificity and sensitivity of information offered 
by bioengineering techniques. An example is given in chapter 2.1, in which a systematic literature 
review was performed to compare skin barrier assessments with established, macroscopic 
biophysical methods (TEWL and electrical methods for estimating the SC hydration) and with 
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CRS. While the former provide an indirect assessment of the status of the skin barrier, the 
latter can directly measure the biochemical components and their distribution in the SC. In 
the studies included in the review of chapter 2.1, a relationship between the two assessments 
was not always straightforward; accordingly, in chapter 2.2, only weak correlations were found 
between macroscopic biophysical methods and CRS. Besides CRS, successful attempts at 
directly measuring SC components have been reported with other top-notch techniques. A 
novel prototype based on near-infrared (NIR) microspectroscopy has been recently proposed 
for simultaneous and quantitative measurement of water and lipid levels in the skin [49]. 
Another study has demonstrated, for the fist time, the feasibility of time-of-flight secondary ion 
mass spectrometry (ToF-SIMS), a surface analysis technique characterized by high chemical 
sensitivity and specificity, to analyze SC lipids in tape-stripped samples collected in vivo [50]. 
Advances have been made also in the assessment of cutaneous inflammation. For example, it 
is known that, when linearly polarized light is illuminated on the skin, a part is reflected by the 
skin surface, retaining its polarization state, whereas another part undergoes diffuse scattering 
in the underlying dermis, becoming depolarized [51]. By detecting the light re-emitted from the 
skin using a cross-polarization filter, an image is obtained containing information on the skin 
color originating from the microcirculation at a depth of approximately 0.5-1 mm, whereas 
effects from the skin surface are suppressed [51]. Analysis of cross-polarized images was able 
to detect subclinical changes in erythema, not visible with the naked eye, following mild skin 
irritation [52]. Enhanced visualization of erythema and edema in cross-polarized images was 
also achieved by exploiting the characteristic absorption bands of hemoglobin and water in 
narrow-band spectral imaging [53]. At the same time, red blood cells concentration could be 
estimated from cross-polarized, RGB images after a post-processing algorithm [54]. Another 
approach employed NIR femtosecond lasers to excite multiphoton absorption in endogenous 
skin fluorophores: besides obtaining “optical biopsies” with subcellular resolution, in vivo and 
non-invasively, clear changes in the cellular metabolism of inflamed compared to normal skin 
could be detected by concomintant measurement on the lifetime of the autofluorescence [55]. 
Efforts have also been directed at overcoming the limitation of single-point measurements 
given by TEWL and electrical methods for estimating SC hydration. Information on the 
heterogeneity of the status and hydration of the skin barrier was obtained by imaging the skin 
with contact-based capacitance sensors [56] and by interpolating single-point measurements 
to generate continuous color maps [57]. 
 Despite their potential, bioengineering techniques still face some challenges before 
widespread application in clinical dermatological practice. As mentioned in chapter 2.1 for 
CRS, albeit the same applies for other technologies, a potential way forward could be to 
promote collaborations between technology experts, dermatologists and skin scientists. The 
aim would be to determine how to include the information provided by the instrumentation 
in routine clinical or product testing protocols, and how it could affect the decision-making 
processes. This view is shared by other authors [58], who also highlighted the necessity to raise 
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awareness of the existing technologies within the medical community, standardize protocols, 
determine clinically relevant parameters such as sensitivity and specificity in large clinical 
trials, and determine the cost-effectiveness of the technologies. This approach has been 
proved successful for RCM, for which a protocol for the diagnosis of chronic plaque psoriasis 
in dermatological practice has been proposed [59]. The protocol was based on the knowledge 
of disease features recognizable in RCM images, gained through a series of preliminary clinical 
studies in psoriasis expertise centers, and on a sound knowledge of relevant literature. As 
such challenges will be overcome, and more affordable technological implementations will 
be brought forward, chances are high that the widespread application of bioengineering 
techniques in dermatological practice and in cosmetic sciences will prove invaluable in offering 
personalized and non-invasive skin treatment solutions. 
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RGB  Rood-blauw-groen
TAP  Transdermal analyses patch
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TRPV1  Transient receptor potential vanilloid 1
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 De doelstelling van dit proefschrift was om onderzoek te verrichten naar gevoelige huid 
en huidirritatie door middel van niet-invasieve meetmethoden. Zowel traditionele biofysische 
methoden als transepidermaal waterverlies (TEWL) en capaciteit (Corneometer) werden 
gebruikt, als ook nieuwe technieken zoals confocale Raman microspectroscopie. Metingen 
werden uitgevoerd om kenmerken van zowel de huidbarrière als van huidontsteking in gezonde 
proefpersonen te karakteriseren.  
GEVOELIGE HUID
 Het eerste doel van dit proefschrift was om inzicht te krijgen in drie mogelijk 
onderliggende pathomechanismen van gevoelige huid: een verminderde barrièrefunctie en 
een verhoogde sensitiviteit en vasculaire reactiviteit. In een aantal klinische studies werden 
proefpersonen die een subjectief ernstig gevoelige huid en proefpersonen die een niet-
gevoelige huid rapporteerden geselecteerd op basis van een nieuwe vragenlijst [1]. In de 
vragenlijst stonden vragen over sensaties, huidreacties en de ernst hiervan op verschillende 
prikkels, zoals toiletartikelen, kou en stress. Deze sensaties behoorden tot de discriminerende 
factoren voor gevoelige huid, die gevonden werden in een eerdere studie [1]. 
Is er een verminderde huidbarrière in gevoelige huid?
 De barrièrefunctie werd onderzocht in hoofdstuk 2.2 met behulp van een nieuwe 
optische techniek, confocale Raman microspectroscopie (CRS), en in hoofdstuk 3.1 door 
middel van topicale applicatie van een oplossing van histamine. CRS werd gebruikt om de 
dikte van het stratum corneum en de hoeveelheid water, lipiden en natural moisturizing factor 
(NMF) in die laag direct te meten. Deze techniek werd ook gebruikt om de penetratie kinetiek 
van een oplossing van glycerol in het stratum corneum te onderzoeken. Histamine is een stof 
die jeuk, zwelling en roodheid opwekt als het in de huid doordringt. In beide klinische studies 
beschreven in hoofdstuk 2.2 en 3.1 werd tevens gebruik gemaakt van traditionele biofysische 
meetmethoden zoals TEWL en Corneometer om een indirecte schatting van de hydratiestatus 
van de huidbarrière te maken. In hoofdstuk 2.2 vonden wij, behalve een trend naar minder 
lipiden in de wang van proefpersonen met gevoelige huid vergeleken met proefpersonen met 
niet-gevoelige huid,  geen significante verschillen tussen de twee groepen. Dat betekent geen 
verschil in de dikte van het stratum corneum en in de hoeveelheid water, NMF en lipiden in de 
onderarm, wang en handpalm. Het enige significante verschil was een kleinere hoeveelheid 
glycerol in het bovenste deel van het stratum corneum en in de eerste minuten na applicatie in de 
groep met gevoelige huid. In hoofdstuk 3.1 vonden wij een trend naar verhoogde jeuksensaties 
na topicaal histamine in de groep met gevoelige huid in de onderarm maar niet in de onderrug. 
Hieruit concluderen wij dat de barrièrefunctie in mensen met gevoelige huid niet significant 
verminderd is; toch is de kleinere hoeveelheid glycerol in deze groep  waarschijnlijk een bewijs 
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van een sneller doordringen van stoffen in de huid. Eerdere klinische studies die dezelfde 
vragenlijst hebben gebruikt voor de selectie van proefpersonen met en zonder gevoelige huid 
hebben aangetoond dat het stratum corneum gemakkelijker beschadigd wordt bij de gevoelige 
huid [2, 3]. Onze aanbeveling is dat aanvullend onderzoek naar de mate van betrokkenheid 
van de huidbarrière in de gevoelige huid gericht zou moeten zijn op adhesie en grootte van 
corneocyten en op de organisatie van de intracellulaire lipiden [4, 5]. Verder onderzoek naar de 
invloed van seizoen op de gevoelige huid is ook wenselijk, omdat wij een hogere TEWL vonden 
in de onderarm van mensen met gevoelige huid vergeleken met mensen zonder gevoelige huid 
in de lente/zomer (hoofdstuk 3.1) en niet in de winter (hoofdstuk 2.2). De invloed van seizoen 
op kenmerken van de huidbarrière is al bekend in de literatuur [6]. 
Is er verhoogde sensitiviteit en vasculaire reactiviteit in gevoelige huid?
 De verhoogde sensitiviteit en vasculaire reactiviteit werden onderzocht in hoofdstuk 
3.1 met behulp van een in vivo huidmodel, histamine iontoforese. In dit huidmodel wordt 
elektrische geleiding gebruikt om histamine gemakkelijker in de huid te laten doordringen, 
met een minimaal effect op de huidbarrière. Wij vonden geen significante verschillen tussen 
proefpersonen met gevoelige en niet-gevoelige huid wat betreft de mate van roodheid, 
gemeten met behulp van een diffuus reflectie spectrofotometer (DRS) als de a* waarde van 
de Commission Internationale de l’Éclairage (CIE) kleurruimte [7]. Ook de uitbreiding van de 
flare respons, gemeten in macroscopische foto’s met behulp van beeldverwerking en een 
segmentatie algoritme, was niet afwijkend. Wel hadden proefpersonen met gevoelige huid 
een hogere subjectieve perceptie van jeuk, die significant werd op 30 minuten na histamine 
iontoforese. 
 Een flare respons in proefpersonen met gevoelige huid werd ook waargenomen 
in een ander in vivo huidmodel, tapestrippen [3]. Deze huidreactie werd niet opgewekt in 
proefpersonen met niet-gevoelige huid. Bovendien werd een lagere a* waarde in de gevoelige 
huid gemeten op 30 minuten na tapestrippen: dit resultaat zou verklaard kunnen worden 
door de aanwezigheid van een ernstige spongiose in deze groep vergeleken met de niet-
gevoelige huid, omdat bekend is dat zwelling roodheid vermindert [7]. Onze hypothese is dat 
de afwezigheid van significante verschillen in vasculaire reactiviteit na histamine iontoforese 
zou kunnen toegewezen worden aan de lage aantal proefpersonen geïncludeerd in de studie of 
aan de sensitiviteit van de metingen. Meer geavanceerde en sensitieve meetmethoden zouden 
gebruikt moeten worden om subtiele verschillen in vasculaire reactiviteit in gevoelige huid 
vast te stellen. Toch komt de hogere jeuk perceptie na histamine iontoforese in proefpersonen 
met gevoelige huid overeen met de hogere huidpercepties waargenomen in andere studies 
[2, 3, 8]. Deze studies hebben ook een lager aantal tryptase positieve mestcellen per mm 
dermis aangetoond in de gevoelige groep vergeleken met de niet-gevoelige groep, daarmee 
suggererend dat het innate immuunsysteem een rol speelt in het pathomechanisme van 
gevoelige huid. Uitgebreid onderzoek naar de verhoogde sensitiviteit in gevoelige huid werd 
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uitgevoerd in het verleden, bijvoorbeeld met behulp van elektrische geleidingen om bepaalde 
zenuwen in de huid te stimuleren [9], of met behulp van functionele magnetische resonantie 
imaging om de activering van de hersenen na huidirritatie in kaart te brengen [10]. Huidige 
onderzoeken zijn meer gericht op de moleculaire mechanismen van sensitiviteit en vasculaire 
reactiviteit [11, 12]. In het bijzonder wordt verondersteld dat de transient receptor potential 
vanilloid 1 (TRPV1) een rol speelt bij de gevoelige huid, vanwege zijn aanwezigheid in meerdere 
cellen en structuren in de huid en vanwege zijn interactieve rol bij cutane percepties [13]. 
Verder onderzoek naar de betrokkenheid van TRPV1 en mestcellen, en hun betrokkenheid, 
is van belang in de ontrafeling van het fenomeen van gevoelige huid, en het zou mogelijk de 
verhoogde sensitiviteit en vasculaire reactiviteit van deze aandoening verklaren. 
 De volgende opmerkingen zijn relevant om de discussie over gevoelige huid in dit 
proefschrift volledig te maken. 
Is de vragenlijst een passend selectiemiddel in klinische studies?
 De vragenlijst die wij hebben gebruikt om proefpersonen met en zonder gevoelige huid 
te includeren in de klinische studies van hoofdstuk 2.2 en 3.1 is een passend selectiemiddel 
gebleken. Eerdere studies die deze vragenlijst hebben gebruikt hebben verschillen aangetoond 
tussen proefpersonen met en zonder gevoelige huid middels klinische, biofysische en 
immunohistochemische methoden [2, 3, 8]. Verder hebben wij exclusiecriteria toegepast die 
een invloed zou kunnen hebben gehad op de uitslag, zoals atopie, co-existerende huidziekten 
en een zeer licht of donker huidtype (Fitzpatrick schaal I, IV, V en VI) [1]. In hoofdstuk 4.1 
hebben wij gevonden dat ook de verandering van vrouwelijke hormonen ten grondslag aan 
gevoelige huid zou kunnen liggen. In deze studie hebben wij een vragenlijst digitaal toegestuurd 
naar een populatie van 300 vrouwen van verschillende leeftijden en wonende in Nederland. 
Ongeveer 42% van vrouwen in pre-overgang en 32% van vrouwen in overgang of post-overgang 
meldden een (verhoogde) gevoelige huid tijdens de menstruatiecyclus en vanaf de overgang, 
respectievelijk. De invloed van oestrogeen, en in mindere mate progesteron en testosteron, 
op kenmerken van de huidbarrière en van huidontsteking, en indirect op gevoelige huid, zou 
onderzocht moeten worden in klinische studies. Met dezelfde vragenlijst, in hoofdstuk 4.2 
hebben wij ook de onafhankelijke bijdrage van verschillende factoren om het risico op gevoelige 
huid te voorspellen onderzocht. Deze waren atopie, huidziekten en licht huidtype (Fitzpatrick 
schaal I en II); dit was in overeenstemming met de literatuur (zie tabel in hoofdstuk 1.4). 
Opmerkelijk was de trend naar een significante bijdrage van een voorgeschiedenis van lage 
blootstelling aan zonlicht en roken op dit moment of in het verleden. Het is bekend dat deze 
en andere leefstijlfactoren invloed op de huid hebben: het is dus van belang dat toekomstige 
studies rekening houden met deze factoren in het ontrafelen van gevoelige huid. 
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Is er een primair mechanisme dat ten grondslag ligt aan gevoelige huid?
 Het is nog niet bekend dat een verminderde barrièrefunctie indirect zou kunnen zorgen 
voor een verhoogde sensitiviteit en vasculaire reactiviteit, of dat de verhoogde sensitiviteit en 
vasculaire reactiviteit de primaire onderliggende factor zouden kunnen zijn voor de verminderde 
barrièrefunctie, bijvoorbeeld vanwege het vrijkomen van histamine door mestcellen [14]. 
Eerdere studies hebben voorgesteld dat er verschillende primaire mechanismen zouden 
bestaan, en dit zou leiden tot een classificatie van mensen met gevoelige huid volgens het 
primaire pathomechanisme [11]. Onafhankelijk van deze classificatie, heeft het gebruik van 
reproduceerbare in vivo huidmodellen en uitlezingen over tijd, zoals in Richters et al. [2, 3, 8] 
en in hoofdstuk 3.1, aangetoond dat gevoelige huid kan worden opgewekt door verschillende 
factoren. Verder wijzen de hogere huidpercepties in gevoelige huid die gevonden zijn in deze 
studies en het gebrek aan verschillen in de hoeveelheid water, NMF en lipiden in de huidbarrière 
aangetoond in hoofdstuk 2.2 op het feit dat behandelingen exclusief gebaseerd op suppletie en 
herstel van de huidbarrière niet genoeg zijn om gevoelige huid te herstellen. Mede daardoor 
heeft onderzoek naar persoonlijke verzorging in mensen met gevoelige huid zich nu gericht op 
anti-ontstekingsingrediënten en TRPV1-antagonisten [15-17].
Is gevoelige huid gelokaliseerd of diffuus? 
 In het verleden werd gevoelige huid hoofdzakelijk in het gezicht gerapporteerd. Nieuwe 
studies hebben echter aangetoond dat mensen die aangeven gevoelige huid te hebben dit ook 
ervaren op een aantal specifieke andere plaatsen op het lichaam [18, 19]. Ook in hoofdstuk 4.1 
hebben wij gevonden dat, terwijl de meeste vrouwen rapporteerden gevoelige huid te hebben 
in het gezicht (53.6%), een redelijk percentage benen (27.7%) en handen (27.3%) noemden als 
locatie voor gevoelige huid. Het is bekend dat kenmerken van de huid, zoals de barrièrefunctie, 
de densiteit van cutane zenuwen en het aantal mestcellen, variabel zijn in verschillende 
plekken van het lichaam [20, 21]. Onze hypothese is dat gevoelige huid een diffuse aandoening 
is, en dat de specifieke eigenschappen van een willekeurige huidlocatie de pathomechanismen 
zullen beïnvloeden. De huid van het gezicht bijvoorbeeld, die in het algemeen een verminderde 
barrièrefunctie en een grotere densiteit van cutane zenuwen toont vergeleken met andere 
plekken van het lichaam [21], zou meer beschadigd kunnen zijn door externe factoren in 
mensen met gevoelige huid dan in mensen zonder deze aandoening. Deze hypothese wordt 
ondersteund door de trend naar minder lipiden gevonden in proefpersonen met gevoelige huid 
dan in degene zonder gevoelige huid in de wangen en niet in de onderarm in hoofdstuk 2.2. 
HUIDIRRITATIE
 Het tweede doel van dit proefschrift was om meer inzicht te krijgen in de in vivo en 
minimale-invasieve meting van ontstekingseiwitten na huidirritatie. 
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Stap 1: Het verkrijgen van een overzicht van de bestaande methoden om 
ontstekingseiwitten in de menselijke huid te meten op een minimaal-invasieve 
manier. 
 In hoofdstuk 5.1 werd een uitgebreid systematisch literatuuronderzoek uitgevoerd om 
een overzicht te krijgen van de bestaande minimaal-invasieve methoden om interleukine (IL)-1 
alpha (IL-1α) en zijn antagonist IL-1RA te meten in de menselijke huid in vivo. Wij hebben tien 
methoden gevonden, met verschillende mate van invasiviteit en tijd nodig om de meting uit 
te voeren. Algemene eigenschappen waren de mogelijkheid om andere eiwitten samen met 
IL-1α en IL-1RA te meten en de hoge variabiliteit in de hoeveelheid eiwitten tussen mensen. 
Omdat deze minimaal-invasieve meetmethoden geen of minimaal huidongemak geven, zou 
het gebruik in klinische studies makkelijker zijn dan methoden waarvoor het nemen van een 
huidbiopt nodig is. Dat kan een voordeel zijn niet alleen voor onderzoek naar huidirritatie, maar 
ook voor onderzoek naar nieuwe behandelingen en geneesmiddelen. De eiwitten die gemeten 
worden op de huid zouden als biomarkers gebruikt kunnen worden om de respons op bepaalde 
therapieën en behandelingen te voorspellen [22]. Het gebruik van deze biomarkers zou in de 
toekomst kunnen leiden tot volledig op de patiënt toegesneden therapie. 
Stap 2: Het exploreren van de bruikbaarheid van transdermal analyses patch 
(TAP) in het bestuderen van dynamische veranderingen in de hoeveelheid 
ontstekingseiwitten op het oppervlak van de huid na acuut kunstmatige schade. 
 Kennis over de dynamiek van ontstekingseiwitten na huidirritatie kan ons van belangrijke 
informatie voorzien over de ontstekingsprocessen in de huid. De in hoofdstuk 5.2 beschreven 
resultaten tonen aan dat transdermal analyses patch (TAP), een nieuwe methode gebaseerd op een 
pleister gecoat met antilichamen, gebruikt kan worden om de hoeveelheden ontstekingseiwitten 
op het oppervlak van de huid kwalitatief en kwantitatief te meten. In deze studie hebben wij 
gevonden dat IL-1α, IL-1RA en de antimicrobiële peptide humaan beta defensine (hBD)-1 (hBD-
1) consistent gemeten konden worden en verschillende dynamiek lieten zien na kunstmatige 
schade met tapestrippen en histamine iontoforese als in vivo huidmodellen. Bovendien, was 
de dynamiek binnen een huidmodel voor de drie eiwitten verschillend: dat suggereert een 
verschillend expressiepatroon en dat TAP gevoelig genoeg was om dat te meten.  
 De hoeveelheden ontstekingseiwitten gemeten door TAP waren heel variabel tussen 
proefpersonen, wat ook al opgemerkt werd in het systematisch literatuuronderzoek van 
hoofdstuk 5.1 voor de andere meetmethoden. Vervolgstudies die de minimaal-invasieve meting 
van ontstekingseiwitten gaan gebruiken zullen dus genoeg proefpersonen moeten includeren 
om betrouwbare conclusies te trekken. Opmerkelijk was dat in de studie van hoofdstuk 5.2 meer 
typen van ontstekingseiwitten gemeten konden worden in de lente vergeleken met de zomer. Het is 
aantrekkelijk te speculeren dat seizoen een invloed heeft op de hoeveelheid van ontstekingseiwitten 
in de huid, zoals gesuggereerd door andere studies [23, 24]. De temperatuur en vochtigheid van de 
kamer waar experimenten worden gedaan moet ook gestandaardiseerd zijn.   
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Stap 3: Het exploreren van de invloed van blauw lichtgevende diode (LED)-licht 
(453 nm) op het herstel van de huid na acute kunstmatige schade.
 Eerdere klinische studies hebben de positieve effecten van blauw LED-licht (453 nm) 
op de verbetering van de symptomen van plaque psoriasis en atopische eczeem aangetoond 
[25, 26]. Huidige kennis wijst naar het verminderen van de ontsteking van de huid en het 
afremmen van de versnelde aanmaak van huidcellen, beide kenmerken van deze chronische 
inflammatoire huidziekten. In een immunohistochemische studie met gezonde proefpersonen 
werd ook aangetoond dat de bestraling met blauw licht op intacte huid veilig was [27]. Niettemin 
ontbreekt onderzoek naar de invloed van blauw licht op huidirritatie in gezonde proefpersonen 
nog steeds. In hoofdstuk 5.3 hebben wij dus de effecten van blauw LED-licht (453 nm) na 
acuut kunstmatige schade door middel van tapestrippen en histamine iontoforese in gezonde 
proefpersonen onderzocht. De experimenten in deze twee huidmodellen werden uitgevoerd 
op twee opeenvolgende weken: in een week werd blauw licht gebruikt om de huidreacties 
te beïnvloeden, terwijl in de andere week geen licht werd gebruikt (controle). In beide weken 
werd op 24 uur na tapestrippen TAP gebruikt om IL-1α, IL-1RA, hBD-1 and hBD-2 te meten. In 
overeenstemming met hoofdstuk 5.2 vonden wij een toename na tapestrippen in vergelijking 
met intacte huid in alle biomarkers behalve IL-1α. Met betrekking tot deze cytokine werd geen 
significante toename gemeten vergeleken met baseline na bestraling met blauw licht. Dit is 
aanvullend bewijs  voor de invloed van blauwe licht op de ontstekingsprocessen van de huid.
 Hoofdstuk 5.2 en 5.3 geven voorbeelden van de bruikbaarheid van TAP als minimaal-
invasieve methode om de dynamiek van ontstekingseiwitten lokaal in de huid te karakteriseren. 
Naar aanleiding van dit proefschrift, hopen wij dat deze meetmethode toegepast zal worden 
in grotere klinische onderzoeken naar huidziekten zoals psoriasis en atopisch eczeem: dit 
zou nieuwe biomarkers aan het licht kunnen brengen om de klinische respons op topicale 
behandelingen of biologische agentia te voorspellen, en uiteindelijk om per individu te beslissen 
welke behandeling de voorkeur geniet. 
 De volgende opmerking is relevant om de discussie over huidirritatie in dit proefschrift 
volledig te maken.
 In sommige artikelen geïncludeerd in het systematisch literatuuronderzoek van 
hoofdstuk 5.1 werden ook niet-invasieve biofysische methoden voor de indirecte schatting van 
de status en hydratie van de huidbarrière in combinatie met de meting van IL-1α en/of IL-1RA 
gebruikt, zoals TEWL en capaciteit. In enkele artikelen wezen zowel de ontstekingseiwitten als 
de biofysische  metingen op een verbetering van de klinische status van de huid [24, 28, 29]. 
Daar tegenover toonden andere artikelen geen duidelijke associatie: bijvoorbeeld, een lagere 
TEWL en hogere hydratie van de huidbarrière werden niet gevolgd door een vermindering van 
ontstekingseiwitten [30, 31]. In sommige gevallen veranderde bovendien de associatie met het 
type van huidirritant of met het eenmaal of meermaals gebruik van dezelfde huidirritant [32]. 
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Reden voor deze discrepantie zou kunnen zijn  dat er een verschillende dynamiek of mate van 
schade van keratinocyten is [32].
 Ook wij hebben in hoofdstuk 5.2 en 5.3 een combinatie van biofysische methoden 
(TEWL, DRS en reflectie confocale microscopie - RCM) gebruikt, samen met TAP, om 
huidirritatie na tapestrippen en histamine iontoforese te bestuderen. In hoofdstuk 5.2 kon 
de toename van IL-1α, IL-1RA, hBD-1 and hBD-2 verklaard worden door de beschadigde 
huidbarrière na tapestrippen, die aangetoond werd door een hogere TEWL. Niettemin was op 
72 uur na stimulatie TEWL nog hoger dan in normale huid, terwijl  IL-1α en IL-1RA weer op 
baseline waren. Dit suggereert een dynamiek van deze ontstekingseiwitten na kunstmatige 
huidschade, die niet alleen verklaard kan worden door TEWL veranderingen. Op dezelfde 
manier kon de daling van IL-1RA en hBD-1 direct na histamine iontoforese verklaard worden 
door het dikkere stratum corneum, gemeten met behulp van RCM. Tegelijkertijd wijst het feit 
dat de niveaus van IL-1α niet veranderd waren op het verhoogd vrijkomen van deze biomarker 
na iontoforese. In hoofdstuk 5.3, op 24 uur na tapestrippen en in de controle week, was de 
hoeveelheid IL-1α verhoogd vergeleken met baseline, zoals ook gevonden werd in hoofdstuk 
5.2. In tegenstelling werd op hetzelfde tijdstip en na bestraling met blauw licht een gebrek aan 
toename van IL-1α vergeleken met de niveau op baseline (intacte huid) door ons gevonden. Op 
24 uur na tapestrippen was TEWL hoger in de onderarm waar de bestraling had plaatsgevonden 
vergeleken met de controle onderarm. Deze resultaten wijzen op een effect van blauw licht 
op de huidbarrière en op het cutane ontstekingsproces, wat in overeenstemming is met de 
resultaten van klinische studies bij psoriasis en atopische eczeem.
 Aan de hand van de resultaten beschreven in hoofdstuk 5.1, 5.2 en 5.3 kunnen wij 
de combinatie van niet-invasieve biofysische methoden en de minimaal-invasieve meting van 
ontstekingseiwitten aanbevelen om meer inzicht te krijgen in de mechanismen van huidirritatie 
in huidziekten en behandelingen daarvan. 
TOEKOMSTIGE PERSPECTIEVEN MET BETREKKING TOT HET GEBRUIK 
VAN  BIOENGINEERINGSTECHNIEKEN IN DE DERMATOLOGIE EN 
COSMETISCHE WETENSCHAPPEN 
 Huidbiopten bieden de hoogste sensitiviteit en specificiteit voor de analyse van de 
morfologie en bepaalde celtypen in fysiologie en pathologie. Ook wij hebben huidbiopten 
afgenomen in hoofdstuk 3.1 om de effecten van histamine iontoforese op de epidermale en 
dermale compartimenten te bestuderen. Echter, het gebruik van bioengineeringstechnieken 
om de huid op een niet-invasieve manier te onderzoeken, zonder huidschade of huidongemak 
te veroorzaken, moet niet worden onderschat. Soms kunnen bioengineeringstechnieken zelfs 
voordelen hebben boven huidbiopten. Bijvoorbeeld, in hoofdstuk 3.1 hebben wij de dikte van het 
stratum corneum in histologische beelden gemeten en wij hebben geen verschillen in de dikte 
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gevonden na histamine iontoforese. Wanneer wij daarentegen RCM gebruikten voor dezelfde 
meting in hoofdstuk 5.2, bleek het stratum corneum dikker te zijn onmiddellijk na iontoforese. 
Subtiele verschillen in de dikte van het stratum corneum zouden onzichtbaar kunnen worden 
vanwege de chemische procedure die huidbiopten ondergaan moeten. 
 Recente ontwikkelingen hebben de sensitiviteit en specificiteit van 
bioengineeringstechnieken verbeterd. Een voorbeeld daarvan is CRS voor de directe meting 
van stratum corneum componenten. In hoofdstuk 2.1 hebben wij een uitgebreid systematisch 
literatuuronderzoek uitgevoerd om de associatie tussen metingen met CRS en traditionele 
biofysische technieken zoals TEWL en capaciteit te bestuderen. Deze associatie was niet altijd 
duidelijk, zoals ook wij vonden in hoofdstuk 2.2 met de lage correlatie tussen CRS, TEWL en 
capaciteit. Recentelijk kwamen ook andere bruikbare geavanceerde technieken naar voren 
voor het karakteriseren van de huidbarrière, zoals nabij-infrarood spectroscopie [33]. Andere 
ontwikkelingen hebben zich gericht op het vasculaire systeem, bijvoorbeeld om een betere 
schatting van de ernst van het erytheem te maken met behulp van speciale filters bij het 
nemen van foto’s van de huid [34, 35]. Weer andere technieken kunnen een schatting maken 
van de concentratie van bloedcellen uit rood-blauw-groen (RGB) beelden van de huid [36]. 
 Ondanks hun bruikbaarheid in de niet-invasieve analyse van de huid in fysiologie en 
pathologie, zijn bioengineeringstechnieken nog niet algemeen toepasbaar als klinische 
hulpmiddelen binnen de dermatologie. Zoals beschreven in hoofdstuk 2.1 voor CRS (en dit 
geldt ook voor andere technieken), is het belangrijk dat er meer samenwerking komt tussen 
dermatologen, ingenieurs en huidwetenschappers. Door die samenwerking zal er mee 
bewustzijn worden gekweekt om de voordelen van deze technieken in de medische wereld 
te verspreiden, de apparaten in de dagelijkse praktijk bruikbaar te maken, en protocollen te 
ontwikkelen voor de diagnose van huidziekten en het monitoren van therapieën. Deze strategie 
was succesvol voor RCM, voor welke een praktisch protocol voor de diagnose van stabiele en 
instabiele psoriasis plaques recent werd ontwikkeld [37]. Als meer bioengineeringstechnieken 
de transitie van onderzoeksapparaat naar klinische hulpmiddel doormaken, is de kans groot 
dat zij van grote waarde zullen zijn voor meer patiëntvriendelijke en patiënt-toegesneden 
therapieën in de dermatologie en voor toepassing in persoonlijke verzorging.  
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SHORT SUMMARY
This thesis focused on the non-invasive, objective and in vivo evaluation of skin barrier 
properties and cutaneous inflammation in healthy volunteers by means of novel and established 
techniques. This evaluation was applied in two research areas: sensitive skin (SS) and skin 
irritation. 
The first objective of this thesis was to investigate three possible pathomechanisms of SS, 
namely impairment of the skin barrier and enhanced vascular and sensory reactivities. These 
were addressed by (i) measurements with established bioengineering techniques, including 
transepidermal water loss (TEWL), diffuse relfectance spectroscopy (DRS), and electrical 
methods to indirectly measure stratum corneum hydration (chapter 2.2 and chapter 3.1); (ii) 
measurements with confocal Raman microspectroscopy (CRS), a top-notch bioengineering 
technique for the assessment of skin biochemical composition (chapter 2.2); (iii) iontophoretic 
and topical application of histamine, a vasoactive and pruritogen substance (chapter 3.1). 
The results did not show a major barrier impairment in SS, yet from CRS measurements 
evidence supporting a faster penetration of topicals in SS emerged. In SS subjects, histamine 
iontophoresis indicated higher sensory perceptions compared to NSS subjects. From these 
findings and in agreement with previous literature, it was concluded that further clinical 
studies aimed at unraveling pathomechanisms of SS should focus on the morphological and 
biochemical characteristics of the stratum corneum, on sensory proteins and on inflammatory 
mediators. In addition, by performing a cross-sectional digital survey in a population of women, 
it was shown that the role of female hormones and lifestyle factors on the onset or exacerbation 
of SS deserves further attention (chapter 4.1 and chapter 4.2). 
The second objective of this thesis was to provide novel insights into the minimally-invasive and 
in vivo evaluation of skin irritation at the molecular level. This was accomplished in three steps: 
(i) by performing a systematic literature review on the existing minimally-invasive methods to 
sample molecular markers of inflammation (IL-1α and IL-1RA) from human skin (chapter 5.1); 
(ii) by applying one of these methods (transdermal analyses patch – TAP), along with TEWL and 
reflectance confocal microscopy (RCM), to characterize the dynamics of molecular markers 
following two in vivo models of skin irritation (chapter 5.2); (iii) by employing TAP, TEWL, RCM, 
and the same two in vivo models, to evaluate the conditioning effects of photobiomodulation 
with blue light at 453 nm on skin recovery (chapter 5.3). In the review, ten minimally-invasive 
methods for the in vivo evaluation of skin irritation at the molecular level were described, and 
in the clinical studies it was shown that one of these, TAP, was sensitive enough to distinguish 
the dynamics of molecular markers following the two different in vivo models, or following 
photobiomodulation with blue light. It was concluded that further clinical studies aimed at 
unraveling the mechanisms of skin irritation would benefit from the local and minimally-
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invasive sampling of molecular markers. In addition, the combined measurement of molecular 
markers and of skin properties by means of bioengineering techniques was recommended for 
a more thorough assessment of the skin status. 
Together with these objectives, in chapter 2.1 a future perspective for the non-invasive 
assessment of the skin barrier function in dermatology and cosmetic sciences was 
presented. This was done by seeking an association between measurements with established 
bioengineering techniques (TEWL and electrical methods) and CRS, and by showing the 
advantages of the latter compared to the former. 
As a general conclusion, the work presented in this thesis supports the use of novel and 
established techniques in the non-invasive, objective and in vivo evaluation of skin barrier 
properties and cutaneous inflammation. Furthermore, it advocates the widespread application 
of such techniques in dermatological practice and in cosmetic sciences with the aim to offer 
personalized and non-invasive skin treatment solutions.
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RESEARCH DATA MANAGEMENT
The data management of the observational studies included in this thesis followed the 
guidelines for the handling of research data established by the Clinical Research Center 
Nijmegen (CRCN). The guidelines comply with the Dutch Personal Data Protection Act (De Wet 
Bescherming Persoonsgegevens, Wbp) and the Code of Proper Conduct (Code Goed Gedrag 
- FEDERA). 
The data management plan was implemented in the following way:
1.   Case Report Forms (CRFs) for data collection were designed by the investigators and 
approved by the ethics committee Regio Arnhem-Nijmegen (Commissie Mensgebonden 
Onderzoek, CMO). Each CRF contained demographics, code and research data of 
a single volunteer. CRFs were designed in both a paper and electronic version. The 
former was kept in a locked cabinet at the dermatology department of the Radboud 
University Medical Center. The latter was implemented in Castor EDC, a validated data 
management system complying with Good Clinical Practice (GCP) requirements. 
2.   The codelist was created in both a paper and electronic version. The former was kept 
in a locked cabinet at the dermatology department of the Radboud University Medical 
Center, in a location different from the one used for the paper CRFs. The latter was 
saved in a password-protected folder on a server of the dermatology department. 
3.   At the end of the study and after publication, the electronic CRFs were locked with 
the locking module of Castor EDC. The paper CRFs were kept in the locked cabinet 
at the dermatology department. The paper version of the codelist was signed by the 
principal investigator, scanned and saved in a password-protected folder on a server of 
the dermatology department. The electronic codelist was locked.
4.   The paper CRFs and codelist are to be archived at the dermatology department for 
one year. Afterwards, they will be archived in an external paper archive. The locked 
electronic CRFs and codelist will remain in the password-protected folder on the server 
of the dermatology department.
5.   At any time during and after the studies, access to the CRFs and codelist was restricted 
to the investigators, the principal investigator, the research nurse and the study 
monitors. 
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-   Journal club at the dermatology department, Radboudumc, Nijmegen 
-   Radboud New Frontiers at Radboudumc, Nijmegen 
-   Radboud Research Rounds at Radboudumc, Nijmegen
 
2014 
2014-2017 
2014 
2015
 
0.2 
4.0 
0.4 
0.1
b) (Inter)national Symposia & congresses 
-   Annual Science Day of the Nijmegen Institute for Infection,  
    Inflammation and Immunity (N4i), at Radboudumc 
-   Dutch Society for Experimental Dermatology (NVED) in Lunteren,  
     the Netherlands (poster presentation) 
-   British Society for Investigative Dermatology (BSID) in Dundee,  
    UK (poster presentation) 
-   International Society for Biophysics and Imaging of the Skin (ISBS) in 
    Lisbon, Portugal (oral and poster presentation) 
-   European Society for Dermatological Research (ESDR) in Munich, 
    Germany (poster presentation) 
-   European Society for Dermatological Research (ESDR) in Salzburg,  
     Austria (poster presentation)
 
2013 
 
2016 
 
2016 
 
2016 
 
2016 
 
2017
 
0.2 
 
0.5 
 
0.75 
 
1.25 
 
0.75 
 
0.75
c) Other  
-   Operator Training Skin Composition Analyzer gen2-SCA, RiverD  
     International B.V., Rotterdam, the Netherlands (2 days) 
-   Microbiology and biosafety course, Fontys Hogeschool Eindhoven,  
     the Netherlands (3 days) 
-   Intensive course in dermato-cosmetic sciences with focus on efficacy  
     measurements, Vrije Universiteit Brussels, Belgium (5 days) 
-   Peer reviewer of scientific publications 
 
2014 
 
2015 
 
2015 
 
2015-2017
 
0.4 
 
0.6 
 
1.0 
 
0.5
TEACHING ACTIVITIES
d) Lecturing NA NA
e) Other 
-   Supervision of internship of two Master’s students and one Bachelor’s student 
    (6 months) 
-   Supervision of internship of four Bachelor’s students (“Oriënterende  
    onderzoeksstage 5OMB2”) (2 weeks)
 
2014-2017 
 
2015
 
6.0 
 
0.15
TOTAL 29.25
PHD PORTFOLIO
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CURRICULUM VITAE
Denise Falcone was born on February 24th 1988 in Domodossola, a town in Northwest Italy. 
After completing high school in 2007, Denise moved to Milan to study Biomedical Engineering 
at the Politecnico, graduating cum laude in 2012 with a thesis on the analysis of ventricolar 
repolarization using the T wave in electrocardiograms. During her Master's she spent a 
semester at the École Politecnique Fédérale de Lausanne, Switzerland. Willing to pursue a 
career abroad, Denise moved to the Netherlands, where in April 2013 she started a PhD project 
at the dermatology department of Radboud University Medical Center, Nijmegen, under 
supervision of prof. dr. Peter van de Kerkhof and dr. Piet van Erp and in collaboration with dr. ir. 
Natallia Uzunbajakava and dr. Jim Coombs at Philips Research Eindhoven. The results of her 
PhD project are described in this thesis. Denise presented her results at several (inter)national 
conferences, during which she was awarded a travel grant by the British Society for Investigative 
Dermatology (BSID) in Dundee, Scotland and the Albert Kligman Young Investigator Award at 
the International Society for Biophysics and Imaging of the Skin (ISBS) In Lisbon, Portugal. 
During her PhD, Denise was an enthusiastic attender of Radboud in'to Languages, where she 
participated in several courses to learn Dutch. 
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DANKWOORD
It seems hard to believe that more than four years have passed since the April morning when 
I first arrived at the dermatology department of Radboudumc to embark in my PhD adventure! 
Now older and (hopefully) wiser, I would like to thank the many people who helped me along 
the path. 
dr. van Erp, dear Piet, as co-supervisor, your door was always open for discussions, whether 
on study planning, data interpretation or even correction of my creative English-to-Dutch 
translations. Your positive attitude taught me to trust my abilities and to see challenges instead 
of hurdles. Thank you for your staunch support all throughout my PhD.
Prof. dr. dr. van de Kerkhof, dear professor, I could always count on your support, which was 
even more enjoyable when you phrased it in almost flawless Italian. I am grateful for the 
possibility I had of doing my research in your department and under your supervision. 
dr. Uzunbajakava, dear Natallia, thank you for providing support and valuable input throughout 
my PhD, and for sharing your expertise in Raman spectroscopy. Your constructive reviews 
always resulted in the improvement of study manuscripts. 
dr. Coombs, dear Jim, I am grateful for the support that Philips Research Eindhoven provided 
to my PhD project. Thank you for the helpful discussions we had at the High Tech Campus. 
dr. Richters, dear Renée, I have learned from you a great deal about doing clinical research. 
Thank you for that, and for taking skin biopsies in my study. Teaming up with you during our 
sensitive skin project resulted in a productive collaboration, and was many times fun. You have 
all it takes to become an excellent clinical and experimental dermatologist, and I wish you all 
the best in your future career. 
dr. Peppelman, dear Malou, you have been my other reference on how to conduct clinical 
research. Thank you for taking biopsies in my study and for the chats we had in our office. I 
admire your pioneering work of bridging the gap between the medical and technical worlds, 
which should become common practice in patient care. You are an exceptional clinical 
researcher, and I have no doubts you will be successful in your career. 
dr. Spee, dear Pieter, the collaboration we had over the in vivo sampling of skin surface 
biomarkers constitutes an important part of this thesis, which I am proud of. I am happy that 
further clinical studies with TAP will follow at the dermatology department of Radboudumc, 
and I am eager to know what the outcome will be. 
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dr. Varghese, dear Babu, thank you for sharing your expertise in quantitative optical methods 
for skin assessment and for willing to be a co-author in my studies. 
dr. van Abeelen and dr. Oversluizen, dear Frank and Gerrit, your input in the preparation of the 
light-based study was invaluable. Thank you for that, and for willing to be co-authors.
dr. Verkruijsse, dear Wim, thank you for your acute observations and for your supervision in the 
first part of my project.
Dear Marijke, Wilco, Linda, Bianca, Harry, Irene, Charles, Serena, and all other scientists and 
secretaries at the Personal Care and Wellness department at Philips: thank you for sharing 
your deep knowledge on skin and skin measurements and for your kind welcome when I was 
at the High Tech Campus.
Dear ICBE team – Suzanne, Celine, Paul, Gerry, Serge – thank you for revising the 
documentation related to my clinical studies and for your help in dealing with the Instituut voor 
de Gezondheidszorg. 
Dear statisticians – Jam Willem, Ewald and Jan – thank you for your assistance in the statistical 
analysis of my studies.
dr. Zeeuwen, dear Patrick, I was glad to contribute to the microbiome study. Thank you for 
involving me in that project and for your constructive comments during the journal clubs and 
LOTTO presentations.
Dear Hanna and Ivonne, fate elected you my main contact persons for a plethora of 
immunohistochemistry-related questions. You fulfilled this difficult task with remarkable 
patience, and have my endless gratitude! Hanna, congratulations on obtaining your PhD and 
best of luck with carrying out your research.
 
Dear Jos, Gijs, Patrick J, Diana, Ellen, Merel and Danique, whenever Hanna or Ivonne were not 
present, the heavy task of answering my questions fell on your shoulders. Thank you for your 
help and for the gezelligheid in our labuitjes! 
Dear Peter ad Gerwin, thank you for our meetings at RiverD International. Not only could I 
discuss with you about confocal Raman microspectroscopy, but I could also enjoy the beautiful 
view of Rotterdam from the Science Tower.  
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Dear Anželika and Kristiina, your prompt assistance ensured that the TAPs arrived at the 
dermatology department right when I needed them, even when ordered at short notice. Thank 
you!
Dear Lori, thank you for your prompt assistance for any Biox-related matters. I enjoyed coming 
to London for the Skin Characterization Workshop to meet you and skin scientists of high 
caliber as Bob Imhof and Gert Nilsson. Only, the return journey to the Netherlands turned out 
to be quite an Odyssey, Piet can confirm…
Dear Gabriela, Roy and Luuk, thank you for your work during your internships. I hope you had 
a good time at the department, and I wish you good luck with your studies.
Beste Marisol, hartelijk bedankt voor de ondersteuning van mijn studies, zoals voor het 
inschrijven in EPIC en het monitoren. Veel succes met het afronden van jouw promotieonderzoek!
Beste Diny, Manon, Wendy en Eelke, bedankt voor jullie hulp voor het inplannen van afspraken 
en het oplossen van mijn langdurige problemen met de drukker. 
Beste Selma, Juul, Kim, Tessa, Inge, Lieke and Jorre, jullie zijn hardwerkende en zorgvuldige 
klinische onderzoekers. Veel succes met het afronden van jullie promotieonderzoek en met 
jullie opleiding!
Beste verpleegkundigen, artsen en alle medewerkers van de afdeling dermatologie, wij hebben 
niet vele kansen gehad om samen te werken, maar iedere keer dat ik jullie in de gang ontmoet, 
werd ik begroet met een vriendelijke glimlacht. Ook bedankt voor de prettige praatjes tijdens 
de dagjes uit.
 
Beste proefpersonen, zonder jullie medewerking, zou dit proefschrift niet bestaan. Hartelijk 
bedankt voor deelname aan mijn onderzoeken!
Lieve collega’s, ik zou nu graag iets over mijn gezin aan jullie vertellen. 
Mijn ouders behoren tot de “generation Easyjet”: ze zijn altijd bereid om hun koffertjes in te 
pakken, naar Nederland te vliegen en mijn broer en ik te bezoeken. Af en toe, zijn zij met 
de auto gekomen, vol met humanitaire hulp uit Italië zoals olie, pasta en parmezaan. Als zij 
terugkwamen, brachten zij tientallen bloembollen tulpen naar huis. In de lente, lijkt onze tuin 
in Italië op een kleine Nederland, en mensen komen om foto’s te nemen. Mijn ouders hebben 
mij alle kansen gegeven om te studeren, en hebben altijd me gesteund. 
CHAPTER 8
258
Mijn broer Mattia is zeer gewaardeerd door collega’s en vrienden. Hij houdt van reizen, 
literatuur, kunst en architectuur, maar vraag niet aan hem om een klusjesman te worden: 
zeer waarschijnlijk, gaat hij iets kapot maken. Samen hebben wij vele uitjes door Nederland 
gedaan, waarmee ik heb gezien dat jullie land mooi is. 
Cara Tessel, se non ci fossi, bisognerebbe inventarti! Come io sono interessata alla lingua e 
cultura olandesi, tu lo sei della lingua e cultura italiana. I nostri incontri a parlare metà in het 
Nederlands e metà in italiano sono sempre stati spassosi. Grazie per la tua amicizia!
Cara Anna, sono contenta che anche se siamo lontane riusciamo a mantenerci in contatto e ad 
aggiornarci su vari gossip 
Caro Davide, ridendo e scherzando (e a volte litigando!), ci conosciamo da più di dieci anni. 
Voglio dirti grazie, per tante cose. Tu le sai 
Cari mamma e papà, e Mattia, nonostante avermi preso in giro come se fossi Jack lo squartatore 
di Nimega per i miei studi sui volontari, vi meritate comunque l’ultima parola. Grazie per il 
vostro aiuto e sostegno in tutti questi anni!
That’s all Folks! Dear colleagues/lieve collega’s/amici e parenti tutti, an heartfelt/een oprecht/
un sentito
Thank you! Bedankt! Grazie!
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NOVEL AND ESTABLISHED 
TECHNIQUES FOR 
NON-INVASIVE  
SKIN ASSESSMENT
Observational in vivo studies on  
sensitive skin and skin irritation
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DENISE FALCONE
Graag nodig ik u uit voor de 
openbare verdediging van 
mijn proefschrift:
NOVEL AND ESTABLISHED 
TECHNIQUES FOR 
NON-INVASIVE 
SKIN ASSESSMENT
Observational in vivo studies on 
sensitive skin and skin irritation
De verdediging vindt plaats 
op 2 november 2017 
om 12.30 uur 
in de Aula van de 
Radboud Universiteit Nijmegen, 
Comeniuslaan 2 
te Nijmegen
Aansluitend bent u van 
harte welkom op de 
receptie ter plaatse.
Denise Falcone
denise.falcone@radboudumc.nl
Paranimfen:
Mattia Falcone
mattia.falcone@gmail.com
Tessel Galesloot
tesselgalesloot@gmail.com
UITNODIGING
